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1. Mitochondria: more than the energy machinery of the cell 
Mitochondria play an important role in energy metabolism, converting the energy 
released by the oxidation of nutrients into ATP. They also carry out terminal metabolic 
pathways of energy molecules such as ß-oxidation of fatty acids, the Krebs cycle, 
among other functional diversities. In addition to the listed functions these organelles 
also play a major regulatory role in calcium homeostasis, cell proliferation, apoptosis, 
formation of iron-sulfur clusters, among others (Kirichok et al., 2004; Mandal et al., 
2011; Meisinger et al., 2008). Recent investigations have assigned to mitochondria 
functions in the immune response (Angajala et al., 2018). The participation of the 
mitochondria in all these vital functions makes this organelle essential for the survival 
of the cell. 
Mitochondria have their own genetic information, which in humans is a circular 
DNA encoding 13 proteins, 2 ribosomal RNAs (rRNAs) and 22 transfer RNAs 
(tRNAs). However, their functions also depend on the importation of numerous 
proteins coded by the nuclear genome. These imported proteins are involved in the 
maintenance and expression of the mitochondrial genome and in the metabolic 
activities (Figure 1). 
The mitochondrial translation of the genetic information is the essential process for 
the expression of genetic information encoded by the mitochondrial DNA (mt-DNA). 
The genetic code determines the rules for the equivalence codon/amino acid and the 
transfer RNA (tRNA) acts as an interpreter at the ribosome level. It ensures the 
association between the codon of the mRNA and the amino acid fixed on the tRNA by 
codon/anticodon complementarity. Thus, the fidelity of the translation is based on this 
complementarity (named "genetic code") but also on the correct association of each 
amino acid onto the cognate tRNA (named "second genetic code"). This last association 
is called aminoacylation reaction. It consists on covalently fixing an amino acid on the 
3'-end of the corresponding tRNA. This reaction is catalyzed by the aminoacyl-tRNA 
synthetases (aaRS). The specificity of the attachment of each amino acid onto the 
cognate tRNA(s) is ensured by elements present on the aaRS and the tRNA (Giegé and 
Frugier, 2003; Giegé et al., 1998; Hasegawa et al., 1991; Ibba et al., 1999; Saks et al., 
1994).  
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Mitochondrial dysfunctions are involved in a wide and diverse spectrum of human 
disorders as cancer, muscular dystrophies, neurodegenerative and neurodevelopment 
disorders. Mutations in the imported mitochondrial aminoacyl-tRNA synthetases have 
been related with pathologies that mainly target the central nervous system. 
This present introduction will be divided in four main parts: 1) Mitochondria: more 
than the energy machinery of the cell; 2) the mitochondrial translation machinery; 3) 
the import and processing of nuclear-encoded mitochondrial proteins; and 4) the 
mitochondrial translation machinery and human diseases. 
 
Figure 1. Schematic representation of the mitochondrial components and major 
mitochondrial functions. 
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1.1. Origin of mitochondria  
The origin of mitochondria seems well established with the theory of 
endosymbiosis (Gray et al., 2001). An alpha proteobacterium would be the original 
endosymbiote whose evolution would have been accompanied by a massive transfer of 
genes to the nuclear genome of its host (Gray et al., 1999). This hypothesis is supported 
by the existence in the nuclear genome of numerous pseudogenes homologous to 
fragments of human mt-DNA. Analysis of mitochondrial proteomes revealed that only 
part of the proteins would be of alpha proteobacterial origin, another part would have a 
eubacterial origin and the remainder would have no eubacterial homologues. Various 
endosymbiotic models for the origin of mitochondria and chloroplasts from alpha 
Proteobacteria and Cyanobacteria imply transfers of bacterial genes into the nuclear 
genome of the eukaryotic host (reviewed in (Dyall et al., 2004; Gray et al., 1999; 
Kurland and Andersson, 2000)). Horizontal transfer, deletion and gene duplication 
phenomena might explain the remaining proteins with orphanage origin. There are data 
indicating that transfers from mitochondrial to nuclear genomes are an ongoing 
evolutionary process (Kurland and Andersson, 2000). 
Finally, the maintenance of only some genes in the mitochondrial genome, at least 
in mammals, remains an open question and could be due to the extremely hydrophobic 
nature of the corresponding proteins, which would interfere their import through the 
mitochondrial membranes (Anderson et al., 1981). 
1.2. Morphology of mitochondria 
The word “mitochondria” comes from the Greek civilization, mitos meaning 
“filament”, chondros meaning “seed” and was proposed after the observation of their 
appearance by optical and electronic microscopy (Logan, 2006). Mitochondria are 
compartmentalized organelles of approximately less than 10 µm; this size varies 
depending on the cell type (Okie et al., 2016). The number of mitochondria per cell 
varies from few hundreds to several thousands depending as well on the cell type 
(Kuznetsov and Margreiter, 2009). 
Mitochondria are delimited by two lipid membranes creating two separate 
mitochondrial compartments: the internal matrix space and the intermembrane space 
(Figure 1). The matrix contains hundreds of enzymes including those required for the 
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citric acid cycle and b-oxidation. The inner membrane is folded into numerous cristae, 
increasing the surface area (Palade, 1953). The outer membrane is permeable to all 
molecules less than 5 kDa, however most of those molecules cannot pass through the 
inner membrane because of its high selectivity (Vander Heiden et al., 2000). 
1.3. Functions: Metabolic pathways hosted in the 
mitochondria 
Mitochondria are widely known for its main function, the synthesis of cellular 
energy in form of ATP using the ATP synthase. However, another essential function of 
mitochondria is the Iron-sulfur (Fe-S) cluster biogenesis (Lill, 2009). A mitochondria 
reduced to its simplest function will indeed maintain Fe-S metabolism, but not 
necessarily the respiratory chain and ATP synthesis (Beilschmidt and Puccio, 2014). 
Mitochondria participate in addition to other functions necessary for cellular 
homeostasis and maintenance. Mitochondria are critical in the metabolism of lipids, 
carbohydrates and amino acids (Fernie et al., 2004). They are also involved in the 
synthesis of some phospholipids, including phosphatidic acid, cytidine diphosphate 
diacylglycerol, phosphatidyl glycerol and cardiolipin (Voelker, 1991), thus 
autonomously creating lipids necessary for their membrane structure. In addition, 
mitochondria are involved in the synthesis of urea, steroids, heme compounds and Ca2+ 
signalling (Kirichok et al.; Ohta, 2003). Mitochondria also play a role in cell 
differentiation and cell proliferation (Mandal et al., 2011). Mitochondrial function and 
biogenesis is tissue-specific, for example, liver mitochondria contain specific enzymes 
for the detoxification of ammonia (Degli Esposti et al., 2012; Fernandez-Vizarra et al., 
2011). 
1.4. Crosstalk of the mitochondria within the cell 
Mitochondria are far from being an isolated organelle. The relationship between the 
mitochondria and the cell is symbiotic. The nucleus handles much of the machinery 
that replicates and maintains the mitochondrial structure, while the mitochondria 
improve functions that the cell cannot perform efficiently. An example of this is the 32 
molecules of ATP formed from oxidative phosphorylation versus the 2 molecules of 
ATP released from glycolysis. The mitochondria need to work with the rest of the cell 
to maintain cellular and mitochondrial homeostasis (Fosslien, 2001). Mitochondrial 
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homeostasis refers to the maintenance and regulation of mitochondrial morphology and 
function through some events such as: mitochondrial biogenesis, the orchestrated 
process of transcription and translation of proteins in the nucleus and cytoplasm; 
balance of fission and fusion events; proper distribution of mitochondria in the cell 
through transport; and, mitophagia, which is the degradation of damaged mitochondria 
(Suen et al., 2008). 
1.5. Mitochondrial Genome 
The mitochondrial matrix contains several copies of mt-DNA as well as all the 
elements necessary for its replication and expression. While the mitochondrial genome 
of Arabidopsis thaliana is large (125 000 bp) (Initiative, 2000), the human 
mitochondrial genome is a small double-stranded circular DNA of 16 569 bp 
(Anderson et al., 1981). It presents maternal inheritance and is transmitted by 
mitochondria present in the oocytes. The two strands have different densities, 
distinguishing a heavy strand richer in guanine, from a light strand richer in cytosine. 
Each strand has its own origin of replication, which can be bidirectional and 
asynchronous (Clayton, 1991), or unidirectional (Falkenberg et al., 2007). 
Human mt-DNA is highly compact with no introns and contains only one major non-
coding region (NCR) known as the control region (comprising ~900 bp in mammals). 
The control region contains the origin of replication of one DNA strand, the origins of 
transcription for both DNA strands, and the Displacement loop (D-loop), necessary for 
replication and transcription of the genome. Human mt-DNA codes only for 13 proteins 
(all subunits of the respiratory chain), 2 ribosomal RNAs and 22 transfer RNAs, both 
of which are essential for mitochondrial protein synthesis (Clayton, 1991; Falkenberg 
et al., 2007). 
1.6. Respiratory chain at the crossroad 
Mitochondria are known as the "energy powerhouse of the cell" because 
approximately 90% of ATP production takes place in the internal mitochondrial 
membrane. ATP is produced by the respiratory chain complexes (I-V) (Figure 2). 
Complex I (ubiquinone NADH dehydrogenase) is in charged of the oxidation of NADH 
and pumps protons (H+) into the intermembrane space while reducing the ubiquinone. 
Complex II (succinate dehydrogenase) oxidizes the succinate into malate, thus 
 18 
releasing reducing equivalents (electrons) that are transported to complex III through 
the ubiquinone. Complex III (ubiqinol-cytochrome-reductase) receives electrons, 
releasing H+ in this process. Complex IV (cytochrome-C oxidase) reduces O2 to H2O, 
producing H+. As each complex moves electrons along the chain, protons are pumped 
from the matrix into the intermembrane space. The generated proton gradient is used to 
direct the synthesis of ATP by the V Complex (F1F0 ATP synthase), which 
phosphorylates ADP to ATP (Alberts et al., 1989). This proton gradient is commonly 
known as the mitochondrial membrane potential (Dym) and represents the energy 
available to drive changes in the ATP / ADP ratio and reactive oxygen species, as well 
as control the sequestration of mitochondrial calcium (Graier et al., 2007). 
Figure 2. The respiratory chain complexes. Organization of the complexes along the 
mitochondrial inner membrane. Complex I: NADH: Ubiquinine reductase; Complex II: 
Succinate-coenzyme Q reductase; Complex III: Coenzyme Q: cytochrome c oxidoreductase; 
Complex IV: Cytochrome c oxidase; Complex V: ATP synthese. Q: Coenzyme Q; cyt c: 
cytochrome c. 
   
2. Mitochondrial translation machinery 
Among the 37 genes present in the human mitochondrial genome, only 13 code for 
proteins, all components of the respiratory chain. The other subunits of this respiratory 
chain (85 proteins) as well as the other mitochondrial proteins (estimated at ~1500 
(Meisinger et al., 2008)), including the mt-aaRS, are imported from the cytosol (Taylor 
et al., 2003). Mitochondrial translation machinery is intimately associated with the 
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inner mitochondrial membrane where mitochondrial ribosomes are also located (Liu 
and Spremulli, 2000). Its mechanism is similar to eubacterial systems but with some 
particularities. The mitochondrial genetic code presents variations compared to the 
"universal" code. In mammalian mitochondria genomes, the stop codon UGA is 
decoded by the tRNATrp, the isoleucine codons AUA and AUU by the tRNAMet and the 
arginine codons AGA and AGG become stop codons. So, there are four stop codons 
instead of three, and there are only four arginine codons instead of six (Florentz and 
Sissler, 2003). Given the limited number of 22 mt-tRNAs available to decode the sixty 
existing codons (one per amino acid, except two for leucine and two for serine), a 
codon-anticodon interaction limited to two of the three positions could allow greater 
flexibility in mRNA/tRNA recognition. Mitochondrial ribosomes are distinguished by 
their low rRNA content (33% versus 66% in bacterial ribosome and 60% in cytosolic 
ribosome), and by the loss of some structural regions composed of RNA, which seems 
to be compensated by a higher protein content (O'Brien, 2003).  
2.1.  Co-evolutionary events in the mitochondrial 
translation machinery 
The dual genetic origin of the macromolecules constituting the translation 
machinery has raised numerous questions as to their properties, mechanism, and 
specificities of their partnerships, regulation of their expression and mechanisms of co-
evolution. Indeed, the mitochondrial genome evolves 15–20 times more rapidly than 
the nuclear genome (Adrion et al., 2016; Brown et al., 1979; Castellana et al., 2011), 
generating highly variable sequences so that the RNAs coded by the mammalian 
mitochondrial genomes are peculiar. All have lost some information as compared to 
their bacterial homologs. For instance, mRNAs miss 3’ and 5’ untranslated regions, 
ribosomal RNAs are significantly shorter than bacterial counterparts and tRNAs 
present a range of peculiarities, from the absence of a few nucleotide signature motifs 
to the absence of full structural domains (Helm et al., 2000; Willkomm and Hartmann, 
2006). All of these "non-canonical" RNAs are, however, recognized by nuclear 
encoded proteins, requiring accommodation rules of the two sets of macromolecules.   
The evolutionary origin of the different nuclear-encoded mitochondrial proteins 
remains however intriguing. Sequence alignments of the mt-aaRSs have indeed not 
identified sequence stretches or signature motifs that could originate from alpha-
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proteobacterial ancestors, favouring various horizontal gene transfers events along 
evolution (Brindefalk et al., 2007). In general, it has been postulated that the 
conservation of a functional translation in mitochondria requires a continuous 
adaptation of proteins in response to reduced or degenerated RNAs. This is illustrated 
by a gain of plasticity, demonstrated for example when studying the human mt-AspRS 
and compared to the homologue AspRS from E. coli. Even if both proteins share a 
common 3D architecture, the mammalian mt-aaRS showed a gained in plasticity, 
enabling it to handle any tRNAAsp and especially the non-canonical mt-tRNAAsp 
(Neuenfeldt et al., 2013). The enlarged plasticity of the mitochondrial enzymes as 
compared to that of aaRSs from other origins might be the result of an evolutionary 
adaptation of the nuclear-encoded protein to the rapidly evolving mitochondria-
encoded tRNAs (Figure 3). Evolutionary-induced changes in intrinsic properties of 
proteins may represent an alternative to other strategies, such as those reported for the 
mitochondrial ribosome, where the strong restriction in RNA sizes is compensated by 
extension of the number and size of the nuclear encoded proteins (Adrion et al., 2016). 
This particularity will be further discussed below. 
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Figure 3. Atypical structural properties of mitochondrial tRNAs (Figure taken from J.L 
et al., 2014) A) 2D and 3D representation of canonical tRNA. tRNA’s domains are colored and 
named. Conserved and semi-conserved nucleotides are indicated. Long distance interactions 
are shown with dashed lines. B) Mt tRNASer(UCN) from Arabidopsis thaliana, as a representative 
of the three tRNAs accepting serine in plant mitochondria. Of note, this mt-tRNA displays all 
canonical features and a long variable region, which is typical for canonical tRNASer. C and D) 
Mt-tRNASer(UCN) and mt-tRNASer(AGY) in Homo sapiens (as a representation of mammals) and 
Ascaris suum (as a representation of Nematodes), respectively. E) The extreme case of Enoplea 
(group of Nematodes) is illustrated by the T-armless tRNASer(UCN). 
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2.2. The mitoribosome 
The mitochondrial ribosome is the central player in the mitochondrial translation 
machinery. Over the last few years, many studies have been carried out to gain a better 
understanding of its structure (Amunts et al., 2015; Greber et al., 2015). Mammalian 
mitoribosomes, like other ribosomes, are composed of a large and a small subunit, 
mt-LSU and mt-SSU, respectively. The mammalian mt-SSU is composed of a 12S mt-
rRNA and 30 proteins, of which 15 are mt-specific in humans. The mammalian mt-
LSU is composed of 16S mt-rRNA and about 53 proteins, of which 22 are mt-specific 
proteins (Mai et al., 2017). 
Despite its endosymbiotic origin, the size and the composition of the mammalian 
mitoribosome differ from those of the bacterial ancestor. The mitoribosome has a 
smaller fraction of RNAs and a higher amount of proteins. The RNA:protein ratio 
evolved from 2:1 in bacteria to 1:2 in the mammalian mitochondria (Agrawal and 
Sharma, 2012). Interestingly, structural data indicates that some of the new proteins 
will replace the missing RNA content, and additionally others proteins will occupy new 
positions in both subunits of the mt-ribosome (Sharma et al., 2003). Beyond that, it was 
been also shown that certain amino acids from proteins replace nucleotides, directly 
interacting with nucleotides of the ribosome, thus creating amino acid/nucleotide 
interactions to maintain the structure of the RNA (Hosseini et al., 2018). Indeed, recent 
studies focused the attention in deciphering how to fold and protect the mitochondrial 
rRNA, which is drastically reduced in size, but also with significantly fewer G residues 
(Hosseini et al., 2018). The authors show that new mt-proteins physically substitute for 
the truncated RNA helices, maintain mutual spatial orientations of the helices, 
compensate for the lost RNA-RNA interactions, reduce the solvent accessibility of 
bases, and replace guanines conserved in bacteria by forming specific amino acid-RNA 
interactions. They also highlight that G residues (known to be the most sensitive 
nucleotide to oxidation) are primarily lost at positions highly exposed of the 
mitoribosome, indicating that the loss of G nucleotides result from selected evolution 
to the highly oxidizing environment present in the matrix of mammalian mitochondria 
(Hosseini et al., 2018). Altogether, it reveals that the mitoribosome is a nice illustration 
of the transition from an RNA-centric world to a RNA-protein world and of an 
ingenious mechanism of adaptation of nuclear-encoded proteins to mt-DNA encoded 
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RNAs. In this situation, the new mt-proteins contribute directly to the strengthening of 
the rRNA fold. 
In addition, the high-resolution cryoEM structure of mammalian mitoribosomes 
revealed the unexpected incorporation of mitochondrial mt-tRNAPhe (in porcine) and 
mt-tRNAVal (in human) into mt-LSU at the place where 5S rRNA occurs in other 
ribosomes (Amunts et al., 2015; Greber et al., 2015). Strikingly, these two tRNAs are 
present in highly transcribed units of mt-DNA, together with the two mt-DNA-encoded 
rRNAs. The group of Zofia Chrzanowska-Lightowlers has investigated further this 
observation and demonstrate that when steady-state levels of mt-tRNAVal are reduced, 
human mito-ribosome biogenesis displays an adaptive response by switching to the 
incorporation of mt-tRNAPhe (Rorbach et al., 2016). They further suggest that the 
replacement of 5S rRNA (exclusively nuclear-encoded in mammals) by an mt-DNA 
encoded mt-tRNA support the absence of a functional requirement for RNA import into 
mammalian mitochondria (Chrzanowska-Lightowlers et al., 2017; Rorbach et al., 
2016). 
 
2.3. The aminoacylation process 
Before an amino acid can be used for the protein synthesis, it must be transferred 
to a specific (cognate) tRNA molecule, through a reaction named aminoacylation. This 
accurate process is of particular importance as it allows the implementation of the 
genetic code. It is catalyzed by aminoacyl-tRNA synthetases (aaRSs), via a two-steps 
reaction:  
     Mg2+ 
    aa + ATP + aaRS  D aaRS.aa~AMP + PPi 
aaRS.aa ~ AMP  +  tRNA   D aaRS aa-tRNA + AMP 
 
The first step, the activation step, described in 1955 by Hoagland consists of 
forming a transitional reaction with the amino acid and an intermediate ATP molecule 
(Hoagland, 1955), which will then be transferred to the tRNA in a second step. The 
transfer of the activated amino acid takes place on the 2' or 3' OH of the terminal 
adenosine of the tRNA (Hoagland et al., 1958; Hoagland et al., 1957). Some aaRSs 
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require the presence of the tRNA for the amino acid activation step, this is the case for 
the class I aaRS: ArgRS, GluRS, GlnRS and LysRS (Arnez and Moras, 1997). 
2.4. The mitochondrial tRNAs 
The human mitochondrial genome encodes for 22 tRNAs, one per amino acid 
specificities, and two additional ones for leucine and serine, respectively. This set of 
tRNAs is reduced but sufficient to ensure mitochondrial protein synthesis. The genes 
coding for the tRNAs are distributed on the two strands of the mitochondrial genome 
with 14 tRNAs on the “heavy” strand and the other 8 on the “light” strand. “Heavy” 
tRNAs, encoded by the "light" strand, have a higher proportion of G•U base pairs. The 
"light" tRNAs have fewer Gs and have a high proportion of A, U and C, causing a series 
of typical structural characteristics such a biased base-pair content, thus, leading to a 
high ratio of CpA and UpA dinucleotides (Helm et al., 2000). Moreover, due to the 
extreme compaction of the mitochondrial genome, these tRNAs are generally smaller 
than their cytosolic counterparts (from 62 to 78 nucleotides as compared to 75 to 95 to 
"classical" tRNAs). 
The transcription of mtDNA is bidirectional and independent for each strand. It 
is performed by a T3/T7 RNA polymerase and generates three polycistronic transcripts. 
At the end of transcription, mt-tRNAs must undergo maturation phenomena essential 
to their function. Primary transcripts are cleaved by RNase P (at the 5' end of the tRNA) 
and RNase Z (at the 3' end of the tRNA) (reviewed in e.g. (Levinger et al., 2004a)). 
These two cleavages are accompanied by the addition of the 3' CCA trinucleotide 
(essential for aminoacylation) by the CCA-adding enzyme (Mörl and Marchfelder, 
2001) and by several post-transcriptional nucleotide modifications (Suzuki et al., 
2011). The total set of mammalian mt-tRNA with their post-transcriptional 
modifications was published; the authors identified 15 species of modified nucleosides 
at 118 positions in 22 species of mt-tRNAs (Suzuki et al., 2011; Suzuki and Suzuki, 
2014) (Figure 4). Although generally less modified than conventional tRNAs, the 
mt-tRNAs contain three mitochondria-specific modifications: 5-formylcytidine (f5C), 
5-taurinomethyluridine (tm5U), and 5-taurinomethyl-2-thiouridine (tm5s2U) (Suzuki et 
al., 2011). Some of the modifications are present at unusual positions such as adenine 
methylation in position 9 identified for 13 mammalian mt-tRNAs and which, in the case 
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of human tRNALys, has been demonstrated to be essential for classic secondary 
"cloverleaf" folding (Helm et al., 1999). 
Figure 4. Summary of post-
transcriptional modifications in 
bovine mt-tRNAs (Figure taken 
from T. Suzuki and T. Suzuki, 
2014). Species andnumbers of 
post-transcriptional modifications 
identified in 22 bovine mt-tRNAs 
are mapped on the schematic 
secondary structure of tRNA. The 
modified positions are depicted by 
gray circles with a symbol 
indicating each modification. Ae 
each position, the number of 
tRNAs that bear the modification 
are shown in parenthesis. Positions 
27a and 43a, indicated by light 
gray circles, are unique to mt-
tRNASer(UCN). G-1 is specific to mt-
tRNAHis. 
 
 
2.5. Mammalian aminoacyl-tRNA synthetases 
Aminoacyl-tRNA synthetases (aaRS) are housekeeping enzymes, ubiquitously 
expressed. They are modular enzymes, constituted, at least, by the catalytic domain and 
the tRNA anticodon-binding domain. Those are possibly surrounded by additional 
modules for structural or functional purposes (Delarue and Moras, 1993; Guo et al., 
2010). 
In human, cytosolic and mitochondrial aaRSs are encoded by two different sets of 
nuclear genes; except GlyRSs and LysRSs that are encoded by single genes, but are 
generated either from two translation initiation sites or by alternative mRNA splicing, 
respectively (Bonnefond et al., 2005a). So far no gene has been identified for the 
mitochondrial glutaminyl-tRNA synthetase (mt-GlnRS), and it has been demonstrated 
that Gln-tRNAGln is produced by transamidation of Glu-tRNAGln by the GatCAB 
aminoacyl-tRNA amidotransferase (Echevarría et al., 2014). 
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2.6. Two classes of aminoacyl-tRNA synthetases 
The presence of conserved motifs within their catalytic domains, the differences in 
their structures, and the presence of functional properties (face of the recognized tRNA 
and amino acid binding site) made possible to divide aaRSs into two classes (Cusack 
et al., 1990; Eriani et al., 1990) (Table 1). 
2.6.1. Class I aminoacyl-tRNA synthetases 
AaRSs from class I are mainly monomeric, except the TyrRS and the TrpRS, 
which are homodimeric. Their catalytic site includes a Rossmann fold, and two short 
common consensus sequences made of catalytic residues: HIGH (His-Ile-Gly-His) and 
KMSKS (Lys-Met-Ser-Lys-Ser).  It is worth noting that close derivatives of these 
motifs have been described in some systems, like in the case of the ArgRS from yeast, 
where an -MSTR motif was found instead of the “KMSKS” (Delagoutte et al., 2000). 
The Rossmann domain was initially identified as a nucleotide-binding motif (Eriani et 
al., 1990). It is in charge of the ATP binding and it is composed of 5-stranded parallel 
b sheet connected by a helices. Both histidine residues of the HIGH motif are involved 
in the recognition of the amino acid and the ATP. The lysine residues of the KMSKS 
motif are involved in the interaction with the ATP and are located near the accepting 
end of the tRNA. This motif is located on a mobile loop, which is able to change its 
conformation according to the substrates to which the aaRS is bounded. The 
subdivision of class I aaRS into subclasses is based on their sequence homologies 
corresponding to a classification of the amino acids chemical nature. Thus, subclass Ia 
corresponds to hydrophobic amino acids, subclass Ib to long side chain amino acids 
and subclass Ic to aromatic amino acids (Burbaum and Schimmel, 1991). 
2.6.2. Class II aminoacyl-tRNA synthetases 
Class II aaRS have more diverse oligomeric states than class I aaRS, ranging 
from homodimer to heterotetramer (with the exception of monomeric mitochondrial 
PheRS (Sanni et al., 1991)). The separation of the aaRS into two classes was established 
after the resolution of the structure of the SerRS from E. coli in 1990 (Cusack et al., 
1990), and then that of the AspRS from S. cerevisiae, which revealed the presence of a 
new structural motif for ATP recognition (Ruff et al., 1991). Three sequences are 
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present in the catalytic domain, which fold into a 9-strand antiparallel b sheet bounded 
by α helices. Each motif contains a strongly conserved core with an invariant residue 
motif 1 (...P...), motif 2 (...fRXE/D...) and motif 3 (...GXGXGXERfffff...), where f, 
X or bold characters stand respectively for hydrophobic, non-conserved, or strictly-
conserved residues. The motif 1, in addition to its role in the formation of the catalytic 
site, participates in the dimerization of the enzyme. The motifs 2 and 3 also contribute 
to the formation of the active site and each one of them have an arginine residue in a 
particular structural context. Class II aaRS have also been subdivided into subclasses 
according to their sequence homologies. Sub class IIa share the same organization in b 
sheet of their C-terminal domain with the exception of the SerRS. The three aaRSs of 
subclass IIb keep the same organization of their tRNA anticodon-binding domain. 
Finally class IIc is constituted by the aaRS not fulfilling criteria of classes IIa and IIb 
(Arnez and Cavarelli, 1997; Cusack et al., 1990; Eriani et al., 1990). 
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 Class I Class II 
Characteristics 
Motifs HIGH 
KMSKS 
M-1 …P… 
M-2 …(Gx)3ER… 
M-3 …FRxE… 
Active site Parallel b sheet “Rossmann fold” Antiparallel b sheet 
ATP conformation Extent Compact 
tRNA binding Minor groove Major groove 
CCA-3’ conformation Compact Extent 
Aminoacylation site 2’ OH 3’ OH 
Sub-Classes Ia IIa 
 
ValRS       a   
IleRS         a 
MetRS*     a2 
CysRS       a 
ArgRS       a 
SerRS       a2 
ThrRS       a2 
ProRS       a2 
GlyRS*     a2b2  
HisRS       a2 
AlaRS*     a4 
Ib IIb 
AspRS     a2 
AsnRS     a2 
LysRS1    a2 
 
GluRS       a 
GlnRS       a 
LysRS1     a 
 
Ic IIc 
TyrRS     a2 
TrpRS     a2 
PheRS*    a2b2 
Table 1. Principal characteristics and classification of the aminoacyl-tRNA synthetases. 
* aaRS whose oligomeric structure is not preserved in evolution. 
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2.7. Cytosolic versus mitochondrial aaRS. 
Although cytosolic and mitochondrial aminoacyl-tRNA synthetases share the same 
main function, many specific features differentiate them. 
2.7.1. Cytosolic aaRSs: Macromolecular 
organisation and alternative functions. 
 
2.7.1.1. The multisynthetases complexe 
The formation of complexes involving several aaRSs has been observed in 
archaea and eukaryotes (Laporte et al., 2014; Mirande et al., 1982). In mammals 9 of 
the 20 synthetases (AspRS, LysRS, ArgRS, GlnRS, MetRS, LeuRS, IleRS and 
GluProRS) are involved with 3 multifunctional proteins (p43, p38 and p18 renamed 
AIMP 1, 2 and 3) in the formation of a supramolecular complex (Park et al., 2005). All 
three AIMP (ARS-Interacting Multi-Functional Protein) participate in cell regulation 
as "signal" molecules. The multisynthetasic (MARS) complex is known and studied by 
different approaches to discover its network of interactions and structural organization 
(Bandyopadhyay and Deutscher, 1971). The three AIMPs would connect the 
subdomains and stabilize the entire structure. AIMP1 is located in the middle of the 
complex and is associated with ArgRS via its N-terminal. AIMP2 binds to many 
components and its role is critical for the assembly of the complex (Kim et al., 2002) 
(Figure 5). The complex arrangement is organized in two sub-domains depending on 
the affiliation of the proteins to AIMP2 (Kaminska et al., 2009). AIMPs are mutually 
dependent for their cellular stability (Han et al., 2006). 
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Figure 5. Schematic representation of the human cytosolic multi-aaRS complex. (Figure 
adapted from (Kaminska et al., 2009)). Class I aminoacyl-tRNA synthetases are indicated in 
pink, and Class II aminoacyl-tRNA synthetases are shown in brown. The three auxiliary 
proteins AIMP1, AIMP2 and AIMP are showed in green, the linker domain (WHEP domain) 
of multifunctional GluProRS (R) is shown in white.  
 
 
The role of this complex is still poorly understood, but two hypotheses have 
been proposed. First, it was suggested that the complex could improve translation 
efficiency by directing the flow of tRNAs into targeted cellular compartments (Ray et 
al., 2007). Then, it could serve as a molecular reservoir (“depot hypothesis”) where 
anchored proteins display canonical functions and undergone a functional switch 
towards alternative/versatile activity after release (Han et al., 2006; Han et al., 2008; 
Ray et al., 2007) 
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2.7.1.2. Alternative functions  
The aaRSs are a family of enzymes whose participation in protein biosynthesis 
has been clearly established and analyzed from both structural and functional aspects 
(Rajendran et al., 2018; Schimmel, 1987; Sissler et al., 2017). However, in the past few 
years, this functional aspect has been largely extended to new activities that may be 
close to or completely different from the classical aminoacylation reaction (Francklyn 
et al., 2002; Ibba et al., 2005; Martinis et al., 1999; Park et al., 2005).  
Alternative cellular and/or extracellular activities occur by means of 
alternate/moonlighting functions of the cytosolic aaRSs. The functional switch from 
canonical to non-canonical role is achieved either by alteration of the polypeptide fold, 
alteration of surface properties (such as e.g. post-translational modificcation(s)), or by 
atypical cellular organization (different cellular location, relocated to the nucleus or 
secreted, different macromolecular organization, different partnership, ...) (reviewed in 
e.g. (Han et al., 2008; Ray et al., 2007). Although catalytic domains may be involved 
in alternatives functions, most of these are performed by structural domains acquired 
during evolution (Guo et al., 2010). Additionally, some alternative functions are 
performed by splice variants or paralogs rather than by the aaRS implicated in the 
aminoacylation activity (Pang et al., 2014). 
 Examples of alternate functions described for aaRSs are: import to the nucleus 
of some aaRSs in order to control the quality of the tRNAs in the nucleus (Nathanson 
and Deutscher, 2000), the modular structure of ThrRS of E. coli that regulates its own 
gene expression (Caillet et al., 2003; Romby et al., 1996), role of the a C-terminal part 
of the TyrRS as a cytokine, and participation of the N-terminal part of the TyrRS in the 
angiogenesis (Wakasugi et al., 2002a; Wakasugi et al., 2002b), involvement of the 
LysRS in the HIV viral cycle (Duchon et al., 2017), and involvement in some types of 
cancer (Shin et al., 2008), among others. As this field of research is currently 
expanding, many new functions will most certainly be added in the coming years. 
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2.7.2. Mitochondrial aaRSs: structural and 
functional peculiarities. 
 
2.7.2.1. Structure 
 Mt-aaRSs maintain the characteristic motifs that define them as class I or II 
synthetases (Bonnefond et al., 2005b). Striking divergences are, however, observed 
when considering their modular organization. Modular design of the aaRSs is a result 
of a patchwork assembly of different functional modules during evolution. While a very 
large number of aaRSs crystallographic structures are known, less information is 
available regarding the resolution of mammalian mt-aaRSs and especially of the human 
mt-aaRSs structures (Figure 6). Presently, only four mt-aaRSs have been crystalized 
and their structure established. The mt-PheRS shows the largest architectural changes 
with a particular oligomeric organization. While bacterial and cytosolic PheRSs are 
heterotetrameres (a2b2), the mt-PheRS is a monomeric enzyme made of a fusion of a 
and b subunits (Bullard et al., 1999). Crystallographic structures of the mt-PheRS have 
been resolved in the absence and presence of tRNA, showing that the binding of 
tRNAPhe is accompanied by rearrangement involving a ~160° hinge-type rotation from 
a ‘closed’ to an ‘open’ state of PheRS, with global repositioning of the anticodon 
binding domain upon tRNA binding (Klipcan et al., 2008). Other peculiar example is 
the mt-SerRS. Mammals possess two mt-tRNASer isoacceptors, within which one is 
D-armless. mt-SerRS has acquired additional N- and C- terminal extensions (compared 
with its bacterial homolog) so that to be able to recognize and aminoacylate both 
mt-tRNASer isoacceptors (Chimnaronk et al., 2005). The resolution of the mt-AspRS 
crystallographic structure revealed a common 3D structure with the corresponding of 
E. coli AspRS. However, functional differences in thermodynamics and biophysical 
properties, in stability and in substrate selectivity, were detected (Neuenfeldt et al., 
2013). It was also shown that rearrangements between the insertion domain (bacterial 
insertion domain specific to all bacterial-type AspRSs) and the catalytic domain 
improve accessibility and binding of the tRNA end to the catalytic site (Neuenfeldt et 
al., 2013). The structure of TyrRS was shown similar to eubacterial TyrRS, having a 
canonical tyrosine binding domain and adenylate binding residues typical of class I 
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synthetases. However, its electrostatic surface potential distinguishes it from all other 
known TyrRS. On the other hand, human mitochondrial TyrRS has two insertions in 
its structure, absent in eubacterial homologues. The first insertion, is located near the 
recognition site of the mitochondrial tRNATyr accepting end and could be involved in 
the stabilization of the accepting stem. The second insertion, located on the "back" side 
of the synthetase (the side interacting with the tRNA being considered as the "front" 
side) is more important, with about twenty amino acids, and found in sequence in all 
mitochondrial TyrRSs (Bonnefond et al., 2007). 
 
Figure 6. Known crystallographic structures of mammalian mt-aaRSs. (Figure taken 
from H. Schwenzer et al., 2013). A) Bovine mt-SerRS, where the specific “distal helix” and 
“C-tail” are emphasized in green and red, respectively. In addition, the bacterial-type N-
terminal long α-helices hairpin arm is shown in orange. B) Human mt-AspRS, where the 
bacterial insertion domain is highlighted in light green. C) Human mt-TyrRS, where the CP1 
and the α-helical domains are indicated in red and gray, respectively. Note that the S4-like 
domain is missing in this structure. D) Human mt-PheRS in the –closed– state, and in the –
open– state, complexed within Thermus thermophilus tRNAPhe (in white). Binding of tRNA 
engenders a drastic conformational change of mt-PheRS through ~160. 
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2.7.2.2. Functional peculiarities 
 
2.7.2.2.1. Low aminoacylation efficiency 
It has been shown that mt-aaRSs have reduced catalytic activity compared to their 
cytoplasmic or eubacterial counterparts. For the mt-PheRS, mt-TrpRS and mt-LeuRS 
the catalytic efficiency (kcat/KM) for amino acid is 100 times lower than for E. coli 
enzymes, and 250 times lower for ATP (Bullard et al., 1999; Bullard et al., 2000; 
Jørgensen et al., 2000). When using total tRNA extracts from E. coli, mt-LeuRS has a 
specific activity 250 to 400 times lower than its known counterparts, and mt-PheRS 20 
to 30 times lower than other class II synthetases (Bullard et al., 1999). These reduced 
activities could reflect a low efficiency protein synthesis in the mitochondria or suggest 
the intervention of an additional factor that would improve aminoacylation by 
structuring mitochondrial tRNA for example. 
Mt-AspRS is one of the most extensively studied systems in the host laboratory. 
Mt-AspRS shares 43% of identical residues, the same modular organization (including 
the bacterial-type insertion and C-terminal extension domains), and a same architecture 
as E. coli AspRS, a representative bacterial homolog (Neuenfeldt et al., 2013). 
However, and despite the fact that the two enzymes are likely descendants from a 
common ancestor, numerous functional idiosyncrasies/discrepancies were reported, 
including a reduced catalytic efficiency (Bonnefond et al., 2005a; Sissler et al., 2005), 
a reduced identity set for cognate tRNA recognition (see below; (Fender et al., 2006)), 
and an increased sensitivity to inhibitors (adenylate analogues, (Messmer et al., 2009)). 
 
2.7.2.2.2. Broad substrate spectrum 
Another special feature of the mammalian mt-aaRSs is their broad spectrum of 
action. Thus, in addition to aminoacylating human mt-tRNAs, mt-aaRS are able to 
aminoacylate in vitro cytosolic and eubacterial cognate tRNAs (Kumazawa et al., 
1991). Mt-AspRS was found to have a broad charging spectrum including, in addition 
to its cognate tRNA, tRNAAsp from E. coli, T. thermophilus, and S. cerevisiae, which 
all possess the full set of aspartate identity elements and classical structural features 
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(Fender et al., 2006). This unilateral nature of aminoacylation reflects the singularity 
of the mt-tRNAs, which are only recognized by the mt-aaRSs. Nonetheless this in vitro 
condition is an artificial situation extremely unlikely to occur in nature. It is very 
doubtful that a human mt-aaRS face a bacterial tRNA, or an archae tRNA. However, 
this is an important point to make because it illustrates that mt-aaRSs have released 
their specificity (probably to be able to recognize their “bizarre” tRNA). While the other 
aaRSs (which are not mitochondrial) remained "constrained" and as a result, maintain 
strict recognition of the cognate and homologue tRNA substrates. 
2.7.2.2.3. Simplified set of identity elements 
Identity rules were defined as a series of positive (determinants) and negative 
(anti-determinants) elements that respectively trigger specific aminoacylation and 
prevent mischarging (Florentz et al., 2001; Giegé et al., 1998). Studies of the human 
mt-aaRSs have revealed that they recognize a simplified set of identity elements within 
their cognate tRNAs. For instance, it was shown that the human mt-TyrRS does not 
recognizes the first base pair N1-N72 as an element of identity, despite this represent a 
classical identity element of the tRNATyr (Bonnefond et al., 2005b). Indeed, the human 
mt-TyrRS can recognize the G1-C72 base pair typical of eubacterial and mitochondrial 
tRNATyr as well as the C1-G72 reverse base pair present in eukaryotic and archaea 
tRNATyr. As another example, the host laboratory has explored the identity set of the 
human mt-tRNAAsp and confirmed the identity role of the GUC anticodon as in other 
aspartylation systems. The authors have, however, revealed the non-involvement of the 
position 73 (so-called "discriminator base"). While for all aspartate aminoacylation 
systems, G73 is universally conserved and known as a primordial identity element, this 
base is no longer involved in the identity of human mt-tRNAAsp. Mt-AspRS has adapted 
to the "degeneracy" of mt-tRNAAsp and the loss of G73 as an identity element has been 
shown to be compensated within the human mt-AspRS catalytic site by a selected 
mutation of an essential amino acid involved in the recognition of the discriminatory 
base (Fender et al., 2006). 
The unveiling of simplified (reduced) identity sets raises a fundamental 
question concerning the fidelity and quality of protein synthesis within mitochondria. 
This reduction could in fact induce incorrect aminoacylations of tRNA (mischarging), 
as the mt-SerRS, which in vitro incorrectly misacylates the mt-tRNAGln (Shimada et 
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al., 2001). It was shown that the recognition of mt tRNAGln by mt-SerRS in vitro is 
3700 times lower than that of mt tRNASer(UGA), suggesting that kinetic discrimination 
arise from competition between mt-SerRS and mt-GlnRS occurs in the mitochondrion 
to maintain the fidelity of mitochondrial translation (Shimada et al., 2001). Further 
investigations considering this eventuality showed that the EF-Tu elongation factor has 
a lower affinity for Ser-tRNAGln than for Ser-tRNASer and Glu-tRNAGln, suggesting that 
EF-Tu would have a critical role in maintaining translation accuracy by controlling the 
quality of aa-tRNAs (Nagao et al., 2007). 
3. Import and processing of nuclear-encoded mitochondrial 
proteins 
Mitochondria require an efficient system of importation of fully functional proteins. 
Several research teams have investigated this process of protein importation. It has been 
described for a wide range of mitochondrial proteins (Neupert and Herrmann, 2007; 
Pfanner and Geissler, 2001; Wiedemann et al., 2004). Although some mt-aaRS systems 
have been studied in plants (Duchêne et al., 2005; Duchêne et al., 2001) and yeast 
(Rinehart et al., 2005), the data is restricted when regarding the mechanisms of import 
for the human mt-aaRSs. 
3.1. Cytosolic expression of mitochondrial precursor 
proteins 
Nuclear-encoded mitochondrial proteins are translated as precursors in the 
cytosol. Post-translational and co-translational mechanisms for translocation of 
mitochondrial precursors proteins are widely accepted (Schleiff and Becker, 2011; 
Wiedemann et al., 2004). In the case of proteins translocation is post-translational, 
cytosolic chaperones guide the precursor protein, thanks to the presence of a protein 
sorting sequence, to the Tom20, Tom22 and Tom70 receptors of the translocase of the 
outer mitochondrial membrane (TOM) complex (Chacinska et al., 2009). Concerning 
co-translational translocation, it is mRNA that is brought to the mitochondria, instead 
of the protein (Mossmann et al., 2012).  
3.1.1. Mitochondrial targeting sequence 
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Most of the mitochondrial proteins directed to the mitochondrial matrix, the 
inter-membrane space as well as the inner membrane, are first synthesized in the form 
of precursor proteins exhibiting an N-terminal extension, which in most of the cases is 
cleaved after import into the mitochondria (Neupert, 1997). These extensions, named 
mitochondrial targeting sequence (MTS), are usually made of a sequence from twenty 
to fifty amino acids. Although no consensus sequence has been described yet, they all 
form a amphiphilic helices, enriched with basic, hydroxyl and hydrophobic residues 
(Mossmann et al., 2012). On the other hand, most of the mitochondrial proteins located 
in the outer membrane and the transport proteins located in the internal membrane 
present an N- or C- terminal signal or an internal signal that will not be cleaved 
(Rapaport, 2003). 
3.1.2. Translocase machinery of the mitochondrial 
outer membrane 
The nature of the addressing signal together with the chaperone proteins will 
determine the sort of outer membrane translocation complex receptor to be used to the 
importation process. The TOM complex consists of 7 different subunits, which are 
grouped into 3 categories: (i) the receptors Tom20, Tom22 and Tom70, (ii) the tunnel 
of the TOM complex consisting in Tom40 and, (iii) three small proteins Tom5, Tom6 
and Tom7 (Schleiff and Becker, 2011; Van Wilpe et al., 1999). Proteins with an 
N-terminal signal interact with the chaperone Hsp70 and are recognized by the 
Tom20/22 complex. Then, with the assistance of Tom5 they cross the pore of Tom40 
(Dietmeier et al., 1997). Proteins carrying an internal signal (which will not be cleaved) 
are recognized by the chaperone Hsp90, who brings them to the Tom70 receptor 
(Young et al., 2003) (Figure 7). 
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Figure 7 Schematic representation of 
TOM complex. Mitochondrial precursor 
proteins are translated by the cytosolic 
chaperones (Heat shock protein hsp90 and 
hsp70) to the central mitochondrial entry 
gate, the translocase of the outer membrane 
(TOM complex). Internal sorting signal 
(left) and N-terminal MTS (right), made of 
positively charged amino acid (represented 
by the + sign). 
 
 
 
The passage through the outer membrane represents the first import step for the 
majority of mitochondrial proteins. However, for the proteins located within the outer 
membrane and having a simple topology (as a single transmembrane segment), only 
the passage through the TOM complex is required. The other proteins of the outer 
membrane with more complex topology (like Tom40 which presents multiple b 
strands) cross the TOM complex and are carried in the inter-membrane space by the 
SAM (Sorting and Assembly Machinery) complex, which will then allow their 
insertion into the outer membrane (Mossmann et al., 2012). 
 
3.1.3. Translocase machinery of the inner 
mitochondrial membrane 
The Translocator Inner Membrane (TIM) complex consists in the assembly of 
three membrane proteins: (i) the receptor Tim50 exposing a large domain to the inter-
membrane space, (ii) Tim23 constituting the pore of the TIM complex and (iii) Tim17 
being closely associated with Tim23 and which, is supposed to regulate the activity of 
Tim23 (Bolender et al., 2008). The transit of proteins through Tim23 directly depends 
on the membrane potential that exists through the inner mitochondrial membrane. 
Indeed, the latter, in addition to activating the Tim23 pore, exerts an electrophoretic 
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effect on the positively charged pre-sequences and thereby draws the pre-sequence to 
the matrix side (Figure 8). 
It is at this stage that the import of some proteins from the internal member 
ceases. Actually, these proteins have a hydrophobic signal that directly follows the pre-
sequence retaining them in the inner membrane. However, another part of the proteins 
of the inner membrane and of the matrix are drawn by the Presequence 
translocase-Associated Motor (PAM), a ATP dependent motor protein complex 
(Pfanner and Geissler, 2001). 
 
 
Figure 8. Schematic representation of 
TIM complex and some proteolytic 
processes. The N-terminal targeting 
and sorting signals of mitochondrial 
precursor proteins are proteolytically 
removed upon import. This processing 
step is carried out by several proteases 
localized in the mitochondrial matrix 
and inner membrane: The 
mitochondrial processing peptidase 
(MPP), the octapeptidyl 
aminopeptidase 1 (Oct1), the inner 
membrane peptidase (IMP), the 
intermediate cleaving peptidase 55 
(Icp55), and the Aminopeptidase P 3 
(AAP3). 
 
 
3.1.4. Peptidases implicated in the mitochondrial 
targeting sequence processing 
The proteolytic cleavage of N-terminal MTS occurs after the internalization of 
the precursor protein into mitochondria and although some studies have been done, the 
mechanism is still not completely clear. Several peptidases have been identified that 
cleave with different specificity the N-terminal part. The mitochondrial processing 
peptidase (MPP) removes the MTS (Mossmann et al., 2012). Additional cleavages by 
Oct1 (octapeptidyl aminopeptidase 1 (Gakh et al., 2002b)) or Icp55 (intermediated 
cleaving peptidases) can subsequently occur to remove newly exposed residues in the 
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N-terminal (Figure 8). In addition, the membrane bound inner membrane peptidase 
(IMP) removes, after MPP cleavage, the newly exposed hydrophobic sorting signal of 
proteins translocated to inter-membrane space (Mossmann et al., 2012). The second 
known membrane bound peptidase Pcp1 (processing of cytochrome c peroxidase) 
cleaves internal hydrophobic sorting signals. After the cleavage the mature protein is 
then handled by the chaperone proteins mt Hsp70, Hsp60 and Hsp10 to reach its final 
three-dimensional conformation and be functionally active (Bukau and Horwich, 
1998).  
 It turns out that cleavage site selection follows very loose consensus sequences 
making predictions difficult. It is assumed that the precursor proteins are translocated 
through the mitochondrial membrane as unfolded polypeptide chains. This facilitates 
the correct recognition of the MTS and the physical translocation through the narrow 
import machinery. Thus, after processing and sub-mitochondrial sorting, a chaperone 
complex will refold the protein in its active form (Voos, 2013). 
4. Mitochondrial translation machinery and human diseases 
Mitochondrial diseases are a class of heterogeneous disorders produced by 
mutations of either mt-DNA or nuclear DNA. Clinical manifestations can vary from 
mild to profound, from highly tissue selective to multi-systemic, making clinical 
diagnosis a difficult task. One of the remains unresolved issue is why different mt-DNA 
or nuclear mutations result in largely heterogeneous and often tissue-specific clinical 
presentations. Mitochondrial tRNA (mt-tRNA) mutations are frequent causes of 
mitochondrial diseases both in children and adults. However numerous mutations of 
nuclear genes coding for ubiquitously expressed mitochondrial proteins have been 
reported in association with very tissue specific clinical manifestations suggesting the 
existence of yet unknown factors/actors that determine the tissue specificity of the 
mitochondrial translation. 
Several studies have reported mutations in most of the components involved in the 
mitochondrial translation process (Rötig, 2011). However, due to the dual genetic 
origin of these, the inheritance pattern is not the same when it concerns proteins 
encoded by the nuclear genome or when it concerns molecules encoded by the 
mitochondrial genome (Mai et al., 2017). 
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During my PhD, I contributed to an opinion review on the recent advances in the 
pathologies related with mutations in the human mitochondrial aminoacyl-tRNA 
synthetases and in the human mt-tRNAs (Sissler et al., 2017). Some aspects discussed 
in the review will also be considered in other parts of the introduction. 
4.1. Inheritance of mitochondrial diseases caused by 
mutations on the mt-DNA 
There are several unique properties of the mt-DNA that is worth recalling for the 
comprehension of related disorders: (i) there are multiple copies (up to thousands) of 
mt-DNA in each cell; (ii) mt-DNA is maternally inherited; (iii) the phenomenon of 
homoplasmy and heteroplasmy. Homoplasmy implies that all mt-DNA are identical, 
which could be all wild type or all mutated. Heteroplasmy is a mixture of mutated and 
wild type mt-DNA in a single cell. In this last situation, the clinical manifestations 
usually occur above a given threshold of mutated vs wild-type mt-DNA (named 
"threshold effect") and thus can vary between different tissues. In women with 
heteroplasmic mt-DNA mutations, there is a bottleneck in the female germ line, which 
means that the transmission of heteroplasmy level from mother to offspring is often 
random and unpredictable. This explains the heterogeneity in heteroplasmy level, 
clinical phenotype and severity frequently observed within the same pedigree (Alston 
et al., 2017). 
4.2. Inheritance of mitochondrial diseases caused by 
mutations on the nuclear-DNA 
Most of the genes encoding the mitoproteome are in the nuclear genome and follow 
Mendelian inheritance patterns. De novo, X-linked, dominant and recessive inheritance 
cases have been reported in the literature. One representation of the variability in the 
inheritance pattern is POLG gene (Mai et al., 2017). Mutations in the POLG gene have 
been identified as one of the most common causes of inherited mitochondrial diseases 
in children and adults. Mutations in this gene have been reported presenting both 
recessive and dominant genotypes (Tang et al., 2011). 
Homozygosis, heterozygosis, dominant and recessive inheritances are useful 
concepts when it comes to understand the probability of an individual inheriting 
mitochondrial disorders. As a remind, somatic cells contain two alleles for each gene. 
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In the compound heterozygous the two alleles of a gene are not identical at the two 
chromosomal loci, contrary to the homozygous compound where the alleles for a gene 
are identical on both chromosomes (Sissler et al., 2017). A dominant mutation will 
produce a phenotype in individuals who present mutations in one copy of the alleles, 
which can come from just one parent. In the case of recessive mutations, both alleles 
(one from each parent) must be mutated to manifest the disease. 
4.3. Mt-tRNAs and mt-aaRSs in human pathologies 
While over the past 30 years more than 260 pathological mutations have been 
identified within human mt-tRNA, mRNA and rRNA genes, it is only very recently that 
mitochondrial diseases have been associated with mutations in genes encoding other 
macromolecules of mitochondrial translation machinery, including the EF-G1 (Coenen 
et al., 2004), EF-Ts (Smeitink et al., 2006) and EF-Tu (Valente et al., 2009; Valente et 
al., 2007) translation factors and the MRPS 16 ribosomal protein (Miller et al., 2004), 
among others. 
Numerous studies have attempted to unravel the molecular impacts of the mutations 
on the various properties of the affected tRNAs and lead so far to a mosaïcity of 
impacts. The consecutive genotype-phenotype relationship to pathological mutations 
in tRNA genes is very complex. Indeed, if the same mutation can be the cause of 
different pathologies, the same pathology can also be linked to different mutations. This 
can be explained by both a random distribution of mutated mt-DNA among different 
tissues as well as by variable co-existence within the same mitochondria or cell of 
healthy DNA and mutated DNA (heteroplasmy). In most cases, the effects of mutations 
are mild and affect either a single step of the tRNA life cycle or a combination of several 
of them. However, an initial impact is frequently observed on structural properties of 
affected tRNAs, followed by sub-sequent cascade effects on downstream functions 
(Florentz and Sissler, 2003; Levinger et al., 2004b; Wittenhagen and Kelley, 2003). 
The pathological mutations of mt-tRNA and the diseases they cause are listed on the 
webservers "mitomap" (www.mitomap.org) (Brandon et al., 2005) and "mamit" 
(mamit-trna.u-strasbg.fr) (Pütz et al., 2007). Alterations of the mt-DNA are responsible 
of various severe disorders as e.g. encephalomyopathy, lactic acidosis, and stroke-like 
episodes (MELAS) and Leber hereditary optic neuropathy (LHON). Some reviews 
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have compiled the data concerning these pathologies caused by mutations on the 
mt-tRNAs (Boczonadi et al., 2018; Florentz et al., 2003; Rötig, 2011). 
Concerning mutations in the nuclear genes encoding the mitochondrial 
aminoacyl-tRNA synthetases, over the last years they have been increasingly related to 
a variety of mostly paediatric and some adult onset tissue specific disorders. Mutations 
on DARS2, the nuclear gene coding for mt-AspRS, was the first case reported in patients 
with a cerebral white matter disorders called Leukoencephalopathy with Brain stem and 
Spinal cord involvement and Lactate elevation (LBSL) (Scheper et al., 2007). 
Nowadays, mutations in each of the 19 human mt-aaRSs genes have been reported in 
human disease (Sissler et al., 2017). Despite being ubiquitously expressed, mutations 
in these genes show an unexpected variety of phenotypes, including many neurological 
disorders affecting the white matter or causing epileptic encephalopathies (Konovalova 
and Tyynismaa, 2013; Sissler et al., 2017). In an effort to broaden knowledge of 
mutations on the mt-aaRS the hosting laboratory developed a knowledge-based 
repository coupled with a web server (http://misynpat.org) that offers an analysis and 
follow-up tools: to retrieve literature and data related to each mt-aaRS (e.g. references, 
affected genes, related disorders, allelic compositions in patients); to locate the mutated 
amino acid on 3D representation (crystallographic structure or homology model) and/or 
generate a model of the mutant; and finally, to place the mutated position in multiple 
sequence alignments of aaRS sequences, ranging from bacteria up to human, thus 
allowing the evaluation of the conservation of a mutation (Moulinier et al., 2017). 
Furthermore, several investigations have been carried out in order to understand the 
molecular mechanisms underlined to these disorders. Some of the major’s outcomes 
from those studies are that it seems that whatever the mutation in mt aaRSs is, no 
common combination of molecular steps correlates mutations with phenotypic 
expressions. Interestingly, the molecular impact of mutations is not necessarily at the 
level of the aminoacylation function of synthetase. Pathology-related mutations can 
have a direct effect on the mitochondrial translation machinery by impacting one or 
more biogenesis steps and/or the functioning of mt aaRS. Alternatively, they may have 
an indirect effect by affecting the following steps and/or subsequent product activities 
(DNA-coded subunits translation of 13 mt of respiratory chain complexes, respiratory 
chain complex activities and ATP synthesis). In addition, although a dominant effect 
on the brain and neural system is observed, sporadic manifestations also occur in the 
skeletal muscle, kidney, lung and/or heart (Schwenzer et al., 2014b). 
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The strengths of my thesis work were oriented towards the clinical overview of the 
pathologies produced by mutations on the mt-aaRSs. This is in part represented in 
article #1, where one of the major points was the comparison of injuries in the 
anatomical organs systems by pathologies caused on the one hand by tRNAs and on 
the other by aaRSs (Sissler et al., 2017). Additionally, an exhaustive study was 
conducted on the clinical manifestations produced by diseases linked to mutation on 
the mt-aaRSs. The contents of this comprehensive analysis are presented in chapter I 
of this thesis. 
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Opinion
Recent Advances in
Mitochondrial Aminoacyl-tRNA
Synthetases and Disease
Marie Sissler,1,* Ligia Elena González-Serrano,1 and
Eric Westhof1
Dysfunctions in mitochondria – the powerhouses of the cell – lead to several
human pathologies. Because mitochondria integrate nuclear and mitochondrial
genetic systems, they are richly intertwined with cellular activities. The nucleus-
encoded mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs) are key com-
ponents of the mitochondrial translation apparatus. Mutations in these
enzymes predominantly affect the central nervous system (CNS) but also target
other organs. Comparable mutations in mt-aaRSs can lead to vastly diverse
diseases, occurring at different stages in life, and within different tissues; this
represents a confounding issue. With newer information available, we propose
that the pleiotropy and tissue-speciﬁcity of mt-aaRS-associated diseases
result from the molecular integration of mitochondrial translation events within
the cell; namely, through speciﬁc crosstalk between the cellular program and
the energy demands of the cell. We place particular focus on neuronal cells.
Human Mitochondrial Translation: Relevance to Disease
Human mitochondria host numerous essential metabolic pathways, including cellular energy
production in forms of ATP via oxidative phosphorylation (OXPHOS, see Glossary), carried out
by proteins of respiratory chain complexes. Thirteen of these proteins are encoded within
mitochondrial DNA (mt-DNA) and are synthesized via the mitochondrial translation machinery,
while 84 additional proteins are encoded by the nuclear genome [1]. This skewed genomic
distribution also applies to molecules of the mitochondrial translation machinery, given that all
required RNAs (two rRNAs and 22 tRNAs) are encoded by mt-DNA, and all the necessary proteins
(ribosomal proteins, tRNA modifying enzymes, translation factors, aminoacyl-tRNA synthetases,
etc.) are encoded by the nuclear genome, synthesized within the cytosol, and imported into
mitochondria [2,3]. Noteworthy, thenuclear and mitochondrial genomesaccumulatemutations at
different rates [4,5], which can lead to a large-scale reduction or alteration of mt-DNA-encoded
RNAcomponents that still need to be recognized by nucleus-encoded proteins [6]. From the more
than 1000 proteins imported within mitochondria, only some are necessary for translation [1].
Presently, the network of interactions between proteins involved in translation with those involved
in non-translation is poorly characterized.
Pathologies associated with mitochondrial dysfunctions involve a large number of genetic
causes with different inheritance mechanisms – either maternally inherited mutations in RNAs
and proteins encoded by mt-DNA, or Mendelian inherited mutations of proteins encoded by the
nuclear genome [7–9] (Box 1). Mutations in proteins involved in mitochondrial metabolic
processes and directly affecting mitochondrial central functions such as ATP production have
been known and studied for some time [10,11]. However, mitochondrial disorders linked to
Trends
Mutations in nucleus-encoded mt-
aaRSs impact on tissues with high
energy demand, notably the CNS.
Disease-associated mutations occur
at positions rarely conserved in phylo-
geny, but some occur at positions that
are highly conserved in mammals.
These observations point to complex
molecular origins with either direct
and/or indirect effects on the efﬁciency
of mitochondrial translation and/or
alternative functions played by mt-
aaRSs.
We propose that the pleiotropy and
tissue-speciﬁcity of these disease-
associated mutations reﬂect the inte-
gration of mitochondrial translation
processes within cellular homeostasis;
these may occur through speciﬁc
crosstalk between the cellular program
and cellular energy demands, espe-
cially in neuronal cells.
Among the multiple communication
pathways between mitochondria and
the nucleus, the mitochondrial
unfolded protein response may play
a role in the integrated response.
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mutations in various components of the mitochondrial translation machinery potentially affect-
ing ATP production indirectly, are being reported at an increasing rate [12–14]. Mitochondrial
tRNAs (mt-tRNAs) and mt-aaRSs constitute two families of molecules that are raising particular
interest in disease because of their functional connection (one being a substrate of the other in
the aminoacylation reaction) [15,16]. In the following we ﬁrst illustrate the diversity of affected
anatomical systems related to mutations within these two types of molecules. We then focus on
mt-aaRSs as key players in the mitochondrial translation machinery (Figure 1, Key Figure). An
overview of the structure and function of aaRSs is provided in Box 2. The ﬁrst description of a
series of mutations in an mt-aaRS causing a particular leukodystrophy dates back to 2007
[17]. In only 10 years, mutations in each of the nuclear genes coding for the 19 mt-aaRSs have
now been correlated to human diseases, with pleiotropic clinical manifestations [18–20]. Our
stance follows two tracks: ﬁrst, we propose that the effects of mutations on the translation
machinery are subtle and difﬁcult to identify, essentially appearing within a neuronal context in
the CNS; second, that alternative biochemical pathways – some of which are yet to be
discovered – may be involved in differentially modulating mt-aaRS functions. We also attempt
to organize the available data, analyzing reported mt-aaRS mutations in the context of protein
architecture and in terms of evolutionary amino acid conservation of affected positions. We aim
to delineate the boundaries that deﬁne the potential molecular origins of these diseases and
suggest directions for future research along several lines that should be integrated to promote
possible therapeutic strategies.
Diseases Associated with mt-aaRSs and mt-tRNAs
The diversity of pathologies linked to mutations in mt-aaRSs and mt-tRNAs display a marked bias
for the CNS (Figure 2). Indeed, mutations in all mt-tRNAs and in 17/19 mt-aaRSs (the exceptions
being mt-TyrRS and GlyRS) are reported to cause CNS damage [21,22]. This apparent conver-
gence does not, however, hold true when considering the clinical manifestations. For example,
mutations in mt-AspRS and tRNAAsp involve pathologies linked to the CNS; nevertheless,
mutations in mt-AspRS result exclusively in LBSL disease [23], while mutations in mt-tRNAAsp
lead to sporadic bilateral optic neuropathy [21], mitochondrial myopathy [24], myoclonic
epilepsy, and psychomotor regression [25].
Glossary
Aminoacylation: an enzymatic
reaction involving the attachment of
an amino acid to its isoaccepting
tRNA carrying an anticodon
complementary to the codon
specifying that amino acid according
to the genetic code. It is a two-step
reaction involving amino acid
activation and transfer of the
activated amino acid to the cognate
tRNA(s) catalyzed by an aminoacyl-
tRNA synthetase (aaRS).
Catalytic motifs: highly conserved
residues necessary for catalysis
(aminoacylation) to occur. These
motifs are HIGH and KMSKS (or
close derivatives) for class I aaRSs;
and motif 1 ( . . . P . . . ), motif 2
( . . . FRXE/D . . . ) and motif 3
( . . . GXGXGXERFFFFF . . . ) for
class II aaRSs, where F, X, or bold
characters stand for hydrophobic,
non-conserved, or strictly conserved
residues, respectively.
Cardiomyopathy: a group of
diseases affecting the heart muscle,
stemming from multiple causes, for
example mitochondrial
cardiomyopathy is caused by
mitochondrial dysfunction.
Charcot–Marie–Tooth (CMT)
disease: an inherited motor and
sensory peripheral neuropathy
(peripheral nerves in the nervous
system are affected); patients
present with muscle loss, weakness,
and sensory nerve damage in the
hands and feet.
Compound heterozygosity: the
two alleles of a gene are not identical
at the two chromosomal loci.
Early-onset disease: in the case of
mitochondrial dysfunction, a disease
that strikes immediately or a few
hours after birth.
Homozygosity: alleles for a gene
are identical on both chromosomes.
HUPRA syndrome: hyperuricemia,
pulmonary hypertension, renal failure
in infancy, and alkalosis – a severe
mitochondrial autosomal multisystem
disorder with early-onset
presentation. Patients manifest renal
failure leading to metabolic alkalosis
(high pH in serum), pulmonary
hypertension (high blood pressure
that affects the arteries in the lungs
and the right side of the heart),
hypotonia (decrease in muscle tone),
and developmental delay.
Hyperuricemia: excess uric acid
levels in the blood.
Box 1. Genetics of mt-aaRSs and mt-tRNAs Mutations
All mutations reported have been identiﬁed by genomic sequencing. Mutations in mt-tRNA occur in mt-DNA and follow
the maternal inheritance of mitochondria. The copy number of mitochondria in human cells is tightly regulated and varies
enormously depending on the cell type [68]. Mutations in mt-DNA generally affect only a proportion of mt-DNA copies
(termed heteroplasmy, in contrast to homoplasmy where all mt-DNA copies are identical [28,29]). The appearance of
the disease state depends on the proportion of mutated versus wild-type mt-DNAs and on the amount of available
functional gene products (biochemical threshold). The affected organ system(s), in this situation, depend(s) on the
random segregation of mutated mt-DNA during mitotic division (mitotic segregation). By contrast, mt-aaRS mutations
occur in nuclear DNA and present a Mendelian pattern of inheritance. Up to now, the observed mutations exhibit
recessive inheritance. Thus, reported mutations lead to autosomal (i.e., affecting any chromosome other than a sex
chromosome) recessive disorders. Patients are mainly compound heterozygotes, although some have been
reported to be homozygotes.
Clearly, missense mutations in structurally/functionally key regions of the protein (evolutionary conserved positions; Box
4) are lethal and are not available for study. However, in the heterozygous compound state a disease might be observed
when mutations affecting both alleles lead to mild functional defects, or when a ‘strong’ mutation (e.g., a premature
stop) is coupled to a splicing defect in the second allele that leaves some remaining/residual functional activity [30,67]. In
short, the cumulative effects of two mutations should maintain sufﬁcient gene products with some degree of activity. The
overall threshold level for the degree of activity that must remain so as to be observable may depend on the onset of the
disease stage (early-onset vs late-onset disease) and on the cell type. In addition, the window around the threshold
may vary with the mutational effects and the type of mt-aaRS. For example, in LBSL patients, the window starts when
the symptoms become detectable, reaching a level that is still compatible with a life-expectancy of >20 years [30]. By
contrast, for mt-ArgRS mutations, which cause severe early-infantile epileptic encephalopathy, the window is narrow
around the threshold [69].
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Isodecoder: tRNA isodecoders
share the same anticodon triplet but
present sequence differences in
other tRNA regions. tRNA
isodecoders and tRNA isoacceptors
(varying at the anticodon triplet), are
charged with the same amino acid.
In the human nuclear genome there
are more than 270 isodecoder genes
(450 tRNA genes distributed
among 49 isoacceptor families).
Kearns–Sayre syndrome: a
multisystem disorder mainly affecting
the eyes (weakness of the eye
muscle and loss of vision, among
others). Patients can also present
cardiac conduction problems and
ataxia.
Late-onset disease: refers to cases
where symptoms of a disease strike
in childhood or later (early
adulthood).
LBSL disease: leukoencephalopathy
with brainstem and spinal cord
involvement and lactate elevation – a
progressive leukodystrophy disorder
that affects the white matter of the
brain and spinal cord; patients also
present elevated lactate levels. Ataxia
and spastic paresis are primary
clinical symptoms.
Leukodystrophies: a group of
disorders affecting white matter in
the CNS.
Mitochondrial DNA (mt-DNA):
small circular double-stranded DNA;
in humans mt-DNA comprises 16
569 bp, coding on both strands for
only 37 genes: 13 protein subunits of
the respiratory chain complexes, two
ribosomal RNAs (rRNAs), and 22
transfer RNAs (tRNAs). The only non-
coding region is the displacement
loop (D-loop), also called the control
region.
MERRF-like disease: myoclonic
epilepsy with ragged-red ﬁbers – a
mitochondrial disorder with onset in
childhood that affects the CNS and
skeletal muscle. The main feature is
myoclonus, but patients can also
manifest other clinical signs including
muscle weakness, ataxia, seizures,
dementia, degeneration of the optic
nerve, hearing loss, and
cardiomyopathy, among others.
Mitochondrial myopathy:
mitochondrial disorder manifesting in
muscular impairment; primarily
muscle weakness.
Mitochondrial unfolded protein
response (mt-UPR): a signaling
pathway between mitochondria and
the nucleus that responds to
mitochondrial stress in response to
Remarkably, the diversity of pathologies is much wider for mutations in mt-tRNAs than in mt-
aaRSs. In the CNS-related pathologies, eight mt-aaRSs lead to encephalopathies (mt-ArgRS, mt-
AsnRS, mt-CysRS, mt-IleRS, mt-PheRS, mt-ProRS, mt-ThrRS, mt-ValRS), four to leukodys-
trophies (mt-AlaRS, mt-AspRS, mt-GluRS, mt-MetRS), and two to Perrault syndrome (mt-
HisRS, mt-LeuRS).Mutationsalso result in isolated pathological conditionssuchas hearing loss or
deafness (mt-MetRS, mt-AsnRS), and intellectual disability (mt-ArgRS, mt-TrpRS). For patholo-
gies not affecting the CNS, three aaRSs provoke cardiomyopathies (mt-AlaRS, GlyRS, LysRS),
one the MLASA syndrome (mt-TyrRS), and one the HUPRA syndrome (mt-SerRS). By
contrast, mutations in mt-tRNAs are connected with 50 pathological disorders (and about half
are linked to the CNS) displaying a broad clinical spectrum, ranging from mitochondrial myopathy
to neurogastrointestinal syndrome, myoglobinuria, diabetes mellitus, hypertension, and
Kearns–Sayre syndrome (see Table S1 in the supplemental material online).
Another outcome is reﬂected by the contrast between the multiple impacts of mutations in mt-
tRNAs versus the singular impact of mutations in mt-aaRSs. Indeed, not only does every mutated
mt-tRNA have a broad impact in different major organ systems, but each is also linked to more
than two diseases [e.g., mutations in mt-tRNAPro manifest as MERRF-like disease, mitochon-
drial myopathy, or dilated cardiomyopathy) [21]; and, in addition, a mutation in the same tRNA
nucleotide can lead to several disorders (e.g., the mutation A5814G in mt-tRNACys manifests
either as severe encephalopathy or cardiomyopathy) [26,27]. This peculiarity is attributed to the
random distribution of heteroplasmic pools of mt-DNA during mitotic segregation [28,29] (Box 1)
and, by contrast, is not observed for mt-aaRSs. For 13 of the mt-aaRS enzymes, mutations can
lead to a single pathology (e.g., mutations in mt-ProRS lead exclusively to epileptic encephalopa-
thy). There are exceptions where multiple system injuries might be explained by collateral damage,
as in the case of mutations in mt-SerRS that are associated with HUPRA syndrome. In this clinical
scenario, renal failure (primary injury) might be the cause of hyperuricemia and pulmonary
hypertension (secondary injuries). When a single mt-aaRS is associated with two unrelated clinical
Box 2. The Aminoacyl-tRNA Synthetases: From Housekeeping to Moonlighting Function
aaRSs are ancillary/housekeeping proteins whose main recognized function is to perform aminoacylation of cognate
isoaccepting tRNAs. They generally comprise a catalytic domain and a tRNA anticodon-binding domain, but other
functional domains are occasionally added. While the 20 aaRSs differ widely in size and oligomeric state (from monomer
to tetramer), they have been partitioned into two classes based on the fold of the catalytic domains (Rossman fold for
class I, and an antiparallel b-sheet ﬂanked by a-helices for class II), on the signature catalytic motifs, and on the amino
acid mode of linkage with either the 20-hydroxyl or the 30-hydroxyl of the terminal A of tRNA for class I (ValRS, IleRS,
LeuRS, MetRS, CysRS, TyrRS, TrpRS, GluRS, GlnRS, and ArgRS) or class II (SerRS, ThrRS, ProRS, HisRS, AspRS,
LysRS, AsnRS, PheRS, AlaRS, and GlyRS) aaRSs, respectively [70,71]. Most class I aaRSs are monomers and class II
aaRSs dimers (note that class I TyrRS and TrpRS are dimers and the tRNAs straddle each monomer for recognition).
Usually, there is one speciﬁc tRNA synthetase for each of the 20 amino acids. However, as in some bacteria (and most
archaea), Gln-mt-tRNAGln is made in human mitochondria by transamidation of Glu-mt-tRNAGln through the action of an
amidotransferase, in agreement with the fact that no gene for mt-GlnRS has been found [72].
In humans, there are two sets of distinct nuclear genes that code for either the cytosolic aaRSs or the mitochondrial
aaRSs [16]. The only two exceptions concern GlyRSs and LysRSs, for which cytosolic and mitochondrial forms (differing
by the absence or the presence of a mitochondrial targeting sequence, respectively) are encoded by single genes, but
are generated either from two translation initiation sites or by alternative mRNA splicing, respectively [73–75]. Inter-
estingly, human cytosolic aaRSs have been recognized to participate in a diversity of alternative (moonlighting) functions
beyond translation, connecting them to other cellular activities. Examples include enzymes that operate in pathways
linked to, for example, angiogenesis, immune responses, inﬂammation, tumorigenesis, or neuronal development
(reviewed in [43,44]). The functional switch from canonical to non-canonical roles can be achieved by alteration of
the polypeptide fold, alteration of surface properties (post-translational modiﬁcation(s), other), or by atypical cellular
organization (different cellular location, relocated in the nucleus or secreted, different macromolecular complex
organization, different partnership, etc.) (reviewed in [76,77]). Recently, a ﬁrst description of an alternative function
for a mt-aaRS has been identiﬁed: a pro-angiogenic function for rat mt-TrpRS [63]. This suggests that other mt-aaRSs
may also play alternative roles in the cell.
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manifestations (e.g., mt-AlaRS with leukodystrophy or cardiomyopathy, GlyRS with cardiomy-
opathy or peripheral neuropathy, Charcot–Marie–Tooth (CMT) disease, and mt-SerRS with
HUPRA or spastic paresis), it is always due to distinct sets of mutations [22]. This suggests that,
in these cases, organ-speciﬁc variations in disease may originate from different aaRS functions
associated with different sets of mutated residues [22] (Box 3).
Overall, these ﬁndings indicate that, although both mt-aaRSs and mt-tRNAs are involved in
aminoacylation, the pathological consequences of mutations in either system probably arise from
different molecular mechanisms and, consequently, that our understanding and analysis of the
two systems must be dissociated.
unfolded or misfolded proteins or to
an imbalance in mitochondrial
homeostasis.
MLASA syndrome: myopathy, lactic
acidosis, and sideroblastic anemia –
a mitochondrial autosomal recessive
disorder that affects the skeletal
muscle and bone marrow.
Myoglobinuria: presence of
myoglobin in the urine.
Myoclonic epilepsy: an increase in
muscle tone which causes sudden,
brief spasm movements that can
affect the face or limbs.
Organ system: a group of
anatomical structures that together
perform speciﬁc functions in the
body.
Oxidative phosphorylation
(OXPHOS): in mitochondria,
electrons from electron donors are
transferred, in redox reactions, to
electron acceptors such as oxygen,
which then split, take up protons,
and form water. During electron
transport, proton pumps in
complexes I, III, and IV become
activated, leading to the expulsion of
protons from the mitochondrial
matrix to the intramembrane space.
The generated proton gradient
combined with electron movement
lead to the return of protons to the
matrix, thus activating ATP synthase
by a proton-motive force. ATP
synthase links ADP to inorganic
phosphate to generate ATP.
Perrault syndrome: a mitochondrial
disorder characterized by hearing
loss. Affected females also have
ovary abnormalities (abnormal
morphology or missing ovaries). Both
males and females can also present
neurological problems such as ataxia
and/or intellectual disability.
Psychomotor regression:
deterioration of cognitive abilities and
reduction of physical movements.
Respiratory chain complexes:
consist of ﬁve large multiprotein
complexes, located in the inner
mitochondrial membrane, that host
OXPHOS. The complexes are NADH:
ubiquinone oxidoreductase (I),
succinate-coenzyme Q reductase (II),
coenzyme Q-cytochrome c
reductase (III), cytochrome c oxidase
(IV), and ATP synthase (V). The sets
of proteins involved are of dual
genetic origin. A total of 84 subunits
and an additional 28 assembly
factors are encoded by the nuclear
genome while 13 subunits are
encoded by the mitochondrial
genome. Complex II comprises
Box 3. Mutations in the Context of Protein Architecture May Help To Identify the Molecular
Mechanisms of Disease
Structurally, the effects of mutation of a protein residue could be due to its presence at or around any of the binding sites
necessary for function (Figure I) [78–81]. First, mutations in the binding sites for the amino acid, ATP, or the tRNA
terminal -CCA end will lead to an absence of catalysis or impaired catalysis (depending on the level of conservation and
the structural role). Second, for speciﬁcity and tight binding, accessible residues of the aaRSs bind to the cognate tRNAs
at multiple locations on their surface (termed the tRNA identity elements), and residues in the anticodon loop play key
roles in binding. Mutations at the binding interfaces may alter the dynamics and folding of protein residues, leading to
loss of speciﬁcity of binding. In addition, aaRSs frequently form oligomers, and mutations may affect the oligomerization
process, thereby leading to inactive particles or misfolded or aggregated proteins. Third, mutations at positions far from
known key functional regions can still lead to deleterious effects. Indeed, mutation of a buried amino acid may alter
communication between domains (e.g., between the binding of a tRNA identity element and the site of catalysis).
Similarly, a mutation occurring in a region where no known substrate binds might still impact, through molecular
rearrangements and dynamics, on the binding of a substrate or of an alternative molecular partner at a distance. Finally,
the state of oligomerization may vary when residues participating in the oligomerization interface are required for
alternative function(s). In such a case, a mutation may prevent the adoption of alternative conformations or may prevent
an interaction with a new partner, thereby hindering the alternative function.
Acve c atalyc
site  conse rvaon
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Figure I. Putative Functional Regions of an aaRS and Its Substrates: The tRNA, the Activated Amino Acid,
and Other Possible Protein Partners. The cartoon, generated with Pymol [82], is based on the crystallographic
structure of the E. coli GlnRS complexed with its cognate tRNA (PDB code 1QTQ [83]).
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exclusively nucleus-encoded
proteins.
Recessive inheritance: conditions
where both alleles must be affected
to manifest disease.
Selective or evolutionary
pressure: molecular features which
are essential for cell survival are
under selective (or evolutionary)
pressure because their
disappearance or absence of
functionality would lead to either
death or lack of progeny. Molecular
features that are not under selective
pressure can evolve with more
freedom, and are said to be neutral
at the evolutionary level.
Spastic paresis: affected individuals
show an increase in muscle tonus
and in tendon reﬂexes.
Sporadic bilateral optic
neuropathy: damage to and/or
death of neurons in the optic nerve.
The main symptom is loss of vision
and damage can be unilateral
(affecting only one of the two optic
nerves) or bilateral (affecting both
optic nerves)
Thylakoïds: small structures
suspended within the chloroplast that
contain sack membranes where
chlorophyll is localized and
photosynthesis occurs.
Genetics of Disease-associated Mutations in mt-aaRSs
We recently developed a knowledge-based repository coupled with a web server (http://
misynpat.org) that integrates and links clinical, genetic, and structural data on disease-related
mutations of human mt-aaRSs [22]. The MiSynPat repository is one of the sources of the data
discussed below and contains an exhaustive list of reported mutations and related references.
Presently, 208 different disease-related variations have been identiﬁed, either in coding
sequences (153) or in intronic regions (55) of mt-aaRS genes.
For a variety of diseases associated with mt-aaRSs mutations, patients are mainly compound
heterozygotes [22]. Homozygosity is sometimes reported (26 of 153 missense or nonsense
mutations). Although it seems obvious that mutations in essential enzymes would cause
disease, one can also expect that most mutations in such enzymes are lethal. Thus, these
observations have suggested that, to be compatible with survival, homozygous mutations
should not exert too severe an effect on structure and/or on function [20,30] (Box 1). A unique
case is the dimeric mt-TyrRS, for which mutations reported so far are homozygous (with one
patient with two different variations affecting the same position, i.e., G191D associated with
G191V [31]) (Figures 3 and 4) [22]. The only compound heterozygous patient associates a
missense mutation (G191D) with a nonsense mutation (R360X) [32], and only the G191D
variation is present in the expressed dimeric protein. This indicates that the pathogenicity of
mutated mt-TyrRS exclusively relies on homodimeric mutated forms of the enzyme. Although
the relevance to the molecular mechanism is unclear, TyrRS is peculiar because tRNATyr binds
simultaneously to each of the two monomers of the synthetase (the only other case is TrpRS)
[33]. However, the mutated positions are not conserved throughout the global phylogeny and
are spread over the 3D structure. Of note, the mt-TyrRS-related MLASA syndrome stands
apart from other mt-aaRS-associated diseases because it is the only one known to lead to a
musculoskeletal primary defect and no CNS primary injury [34].
For amino acids Gly and Lys, single genes encode both the mitochondrial and the cytosolic
aaRSs (Box 2) [16]. Reported mutations in those two genes show either recessive inheri-
tance or dominant inheritance, and are thus found in both the cytosolic and the mitochondrial
forms of these two enzymes [22]. On the one hand, because the dominant mutations of
cytosolic aaRSs (cytosolic TyrRS, AlaRS, HisRS, and MetRS) are linked to peripheral neuropa-
thy CMT disease, it has been suggested that the CMT-related dominant mutations of GlyRS
and LysRS (both cytosolic and mitochondrial) probably mainly affect the cytosolic function(s) of
these enzymes [35,36]. On the other hand, recessive mutations correlated with cardiomyopa-
thies (for GlyRS and LysRS), or with visual impairment, progressive microcephaly, or hearing
impairment (for LysRS), probably mainly impinge on their mitochondrial function(s), but this has
not been directly tested. The selective impairment of either cytosolic or mitochondrial forms of
these enzymes remains to be carefully investigated experimentally before reaching ﬁrm con-
clusions; indeed, CMT has also been observed to result from mutations in the mitochondrial
fusion protein MFN2 [19].
Collectively, these observations emphasize a confounding issue in the ﬁeld, namely that
seemingly comparable mutations in different mt-aaRSs lead to diseases that are extremely
different, occurring at different stages in life and in different tissues.
Analysis of Mutated Positions in mt-aaRS Architecture and Potential
Functional Implications
Presently, 153 mutations impacting on protein sequences (missense, nonsense, insertion, and
deletion) have been reported, and these are spread over the constitutive functional domains of mt-
aaRSs (Figure 3). Of note, the tRNA-edge binding domain (found in mt-ArgRS, mt-SerRS, and mt-
LeuRS) is the only known functional domain without disease-prone mutations [22], which may
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Key Figure
The Canonical Role of Mitochondrial Aminoacyl-tRNA Synthetases (mt-aaRSs) in Mitochondrial
Translation and the Tissue-Specific Impact of Disease-Associated Mutations
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Figure 1. Human mt-aaRSs are encoded in the nucleus, synthesized in the cytosol, and delivered and imported into mitochondria via a mitochondrial targeting
sequence (MTS) which is cleaved upon entry into mitochondria. mt-aaRSs, key actors in mitochondrial translation, catalyze the speciﬁc attachment of each amino acid
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indicate that this domain, in a mitochondrial context, is either non-essential (or neutral) or so
essential that its mutations are lethal. Interestingly, a loss of selective or evolutionary pressure,
reﬂecting an evolutionary loss of function, has been shown for bacterial insertion domains of
mitochondrial AspRSs [37]. Onlynonsense mutationshavebeen reported in this domainof human
mt-AspRS, and this is interesting because it may be indicative of a lack of speciﬁc role for
constitutive amino acids, supporting the neutral role of this domain.
We now discuss the effects of mutations on the architecture of mt-aaRSs; this analysis allows the
identiﬁcationof functionaldomains (Box 3) and thus facilitates the predictionof thepotential impact
of mutations on these functional domains. Based on an exhaustive list of mutations for these
enzymes, in conjunction with 3D models, all gathered in the repository MiSynPat, it is possible to
onto the cognate tRNA(s). Mitochondrial translation synthesizes 13 proteins that, together with 84 additional nucleus-encoded proteins, form the respiratory chain
complexes. Thus, mt-aaRSs are central to cellular energy production. Mutations in mt-aaRSs have been identiﬁed in diverse human diseases, and the main organs
affected are the central nervous system, as well as the musculoskeletal, cardiovascular, and urinary systems (indicated in the inset). Fully functional mitochondria require
1200 additional nucleus-encoded proteins to guarantee mitochondrial genome maintenance and expression.
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Figure 2. Mitochondrial Aminoacyl-tRNA Synthetase (mt-aaRS) Versus mt-tRNA Mutations and Affected Organ Systems. The diagram shows the total
numbers of known reported mutations and their percentages for mt-aaRSs (left) and mt-tRNAs (right). mt-aaRSs are encoded in the nucleus and mt-tRNAs in the mt-
DNA, and thus mutations segregate in patients following Mendelian or maternal inheritance, respectively (Box 1). The primary impacts of the mutations are classiﬁed
according to ﬁve major organ systems: central nervous system (CNS), cardiovascular, endocrine, musculoskeletal, and urinary. A further category named ‘various’
contains reports of less frequent diseases. Data are extracted from the MiSynPat (http://misynpat.org [22]) and MitoMap (www.mitomap.org/MITOMAP [21]) databases
for mutations in mt-aaRSs and mt-tRNAs, respectively.
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reach some conclusions [22]. Protein architectures can be extracted either from crystal structures
or from models derived by homology (based on crystallographic structures of homologous
proteins). Analysis of these structures has revealed that, for most mt-aaRSs (among those with
a signiﬁcant number of records), mutations occur throughout the known 3D structures, including
surfaces that do not interact with tRNAs and, furthermore, the mutations do not localize spatially
around functional regions that are necessary for aminoacylation (e.g., mt-ArgRS, mt-GluRS, and
mt-TyrRS in Figure 4) [22]. These observations preclude simple mechanistic explanations (Box 3).
Occasionally, however, cases do occur where mutations concentrate in identiﬁed functional
regions. For example, in mt-AspRS, most mutations have been identiﬁed at the dimeric interface
(mt-AspRS in Figure 4; comparewith thevisually randomdistribution of mutations in LysRS, noting
that these two enzymes have similar folds and organizations) [22]. Regarding mt-PheRS, the
pattern ofmutationsonthe free formof theenzyme provides little information. It isknown,however,
that the binding of tRNAPhe is accompanied by rearrangement involving a 160 hinge-type
rotation from a ‘closed’ to an ‘open’ state of PheRS, with global repositioning of the anticodon
bindingdomain upontRNAbinding [38].Whendisplayed in the ‘open’ state, mutationsoccur in the
catalytic core, the anticodon-binding region, and the rearrangement zone, strongly suggesting a
direct impact on aminoacylation function (Mt-PheRS in Figure 4).
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Figure 3. Disease-Associated Mutations of Human Mitochondrial Aminoacyl-tRNA Synthetases (mt-aaRSs). The mt-aaRS mutations are shown to scale;
known functional domains are color-coded. Allelic compositions, as identiﬁed in patients, are linked through black lines for all reported mutations. Amino acid
substitutions due to missense mutations are indicated. The orange X indicates a STOP codon created by a nonsense mutation. The mutation in blue (in LysRS)
corresponds to a dominant mutation. Data were extracted from MiSynPat (http://misynpat.org [22]) which contains all related references. The GlyRS is absent because
most reported mutations are dominant and lead to Charcot–Marie–Tooth disease, suggesting an impact on the cytosolic activity of the enzyme rather than on the
activity of the mitochondrial enzyme. Abbreviation: s.d., splicing defect or defect involving an intronic region.
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Therefore, the distribution of mutated positions on structural models covers almost all regions
of the architecture. However, in some instances only, mutations occur at positions that are
involved in substrate binding, suggesting a putative impairment in the canonical function of
aaRSs) [22].
mt-AspRS LysRS
mt-ArgRS mt-GluRS mt-TyrRS
mt-PheRS 'closed state' mt-PheRS 'open state'
Missense recessive mutaon
Nonsense recessive mutaon
Missense dominant mutaon
- Heterozygous
compound
Missense recessive mutaon   - Homozygous
Figure 4. Selected Human Mitochondrial Aminoacyl-tRNA Synthetase (mt-aaRS) Mutations in 3D Structural Representations. Coordinates for the 3D
models (which include MTSs) of mt-ArgRS, mt-GluRS, mt-TyrRS, mt-AspRS, and LysRS were uploaded from MiSynPat (http://misynpat.org [22]). Human mt-PheRS is
depicted in a ‘closed’ state in the absence of cognate tRNA (PDB: 3CMQ [38]) or in the ‘open’ state when complexed with Thermus thermophilus tRNAPhe (in grey)
(PDB: 2TUP [84]). For all structures, the mitochondrial targeting sequence (MTS) is in yellow, the catalytic domain in red, the anticodon binding domain in green, and the
hinge region in grey, and additional domains are in hues of blue (the color code is the same as in Figure 3). Where appropriate, the second dimer is displayed in light grey.
The color codes for missense and nonsense mutations, in homozygous or compound heterozygous contexts, are indicated in the inset. Cartoons were generated with
Pymol [82].
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Analysis of the Evolutionary Conservation of Mutated Positions in mt-aaRSs
and Potential Functional Implications
The amino acid conservation patterns along the protein sequence can be derived from precise
sequence alignments (Box 4). Such patterns convey crucial functional molecular insights on the
wild-type protein and potentially further our understanding of the molecular mechanisms of
disease (Box 4). An analysis of the amino acid conservation of mutated positions has been
recently conducted based on sequence alignments contained and accessible through MiS-
ynPat [22]. Overall, among the observed mutations in mt-aaRSs, 67% occur at positions that
are not conserved in phylogeny, 13% are conserved based on physicochemical properties, and
only 5% are 100% conserved [22]. For some mt-aaRSs, sufﬁcient data are available to conduct
more detailed analyses.
For only two aaRSs, the observed mutations occur at highly conserved positions: in mt-PheRS
(leading to encephalopathy) and in mt-AlaRS (but only for mutations leading to leukodystrophy)
[22]. For mt-PheRS, in agreement with structural observations (see above), experimental in vitro
aminoacylation measurements reveal a strong impact of these mutations on aminoacylation
levels, potentially leading to impaired translation [39]. Indeed, biochemical characterization of
recombinant mutant mt-PheRS proteins has shown that mutations can affect synthetase
function in different ways, such as by reducing the binding of ATP, phenylalanyl, or tRNA
[39], and/or by affecting synthetase folding and stability [39]. No direct experimental data on
aminoacylation are currently available for mt-AlaRS, and therefore a quantitative evaluation of
the effects of mutations on translation efﬁciency cannot be presently made.
For three mt-aaRSs, mutations have been reported at conserved positions for at least one
allele: mt-ArgRS, associated with encephalopathy, and mt-LeuRS and mt-HisRS, both leading
to Perrault syndrome [22]. In these cases, one can envisage that the canonical structures and
functions might be affected by these mutations, suggesting that the amount of active mt-aaRS
might reside below a minimum biochemical threshold, but this remains to be tested.
For other mt-aaRSs, there is only low or no conservation of mutated positions: mt-GluRS and
mt-AspRS (leukodystrophy), mt-ValRS (encephalopathy), mt-TyrRS (MLASA), and mt-AlaRS
(with mutations in the latter leading to cardiomyopathy only) [22]. The available aminoacylation
Box 4. Mutations in the Evolutionary Context of Protein Sequences
With the advent of genomics, sequences of homologous proteins can be obtained from a large variety of organisms and
organelles. Multiple sequence alignments can help visualize how amino acids are conserved at various positions along
the sequence. Sequence alignments are even more powerful when at least one crystal structure is available for one of
the sequences. That sequence can then serve as a structural template, and the ensuing structural alignments allow key
architectural parameters to be derived for various amino acid positions (e.g., how buried or accessible they are, how
close they are to the active site or to some other binding site, whether they occur in a helix or a loop, etc.). The levels of
conservation derived from sequence alignments at mutated positions are highly informative for the understanding of the
underlying molecular mechanisms. Conservation can be evaluated strictly (always the same type of amino acid) or more
broadly, for example whether the variations occur with the maintenance of similar physicochemical properties (charge,
size, hydrophopathy).
Conservation can also be analyzed within a single phylum or group of phylae. Residues conserved throughout the whole
phylogeny (bacteria, archaea, eukarya, including organelles) are indicative of a selective pressure on that position,
suggesting either a structural or a functional role related to the central function of the protein (in this case aminoacyla-
tion). However, an absence of conservation for an affected position does not call into question the pathogenicity of the
mutation. Most importantly, such differentially conserved residues, in other words those that are conserved in only a
subgroup or phylum of sequences, reveal loss or gain of selective pressure. Consequently, the impact of mutations at
such positions may indicate tissue-speciﬁc modulation of translation or a moonlighting (alternative) function (e.g.,
through the participation in larger molecular complexes). Furthermore, mutation at a non-conserved position (especially
with a change in physicochemical properties) may lead to an unstable or misfolded protein in vivo (aggregation or
degradation) and/or to defective import into mitochondria.
702 Trends in Molecular Medicine, August 2017, Vol. 23, No. 8
data reveal an absence (e.g., mt-AspRS) or only a weak (e.g., mt-TyrRS) effect of the mutations
on the level of aminoacylation [22]. In the case of mt-AspRS, extended investigations on a
subset of LBSL-related mutants revealed an absence of a common impact(s) on the molecular,
cellular, and/or structural properties of mt-AspRS [17,23,30,40,41]. Consequently, the path-
omechanism of LBSL remains unsolved.
Overall, an analysis of the level of conservation leads to the following possibilities. First, there
appears to be no linked segregation between conservation of the affected positions and
disease (e.g., leukodystrophy is found in two of the classes listed above and encephalopathy
in three). Second, there is presumably no correspondence between the level of conservation
and the severity of disease (e.g., ‘mild’ symptoms for mt-AlaRS/leukodystrophy mutated at
positions that are highly conserved, vs ‘drastic’ symptoms for mt-AlaRS/cardiomyopathy
mutated at non-conserved positions). Third, the levels of amino acid conservation might reﬂect
different molecular mechanisms, despite similarities in diseases. As a notable example, leu-
kodystrophies linked to mutations in mt-GluRS or mt-AspRS (at non-conserved positions) are
probably due to a molecular mechanism that is different from the mechanism underlying
leukodystrophy linked to mt-AlaRS mutations (at highly conserved positions) for which amino-
acylation deﬁciencies are strongly suspected. In mt-AspRS, however, it has been shown that,
considering exclusively the subphylum of mammals, all reported mutations affect positions that
are highly conserved ([30]; preliminary data suggest that this may also be the case for mt-
GluRS, but this remains to be validated). This suggests that, for these two enzymes, there may
be a selective pressure, possibly restricted to mammals. Of note, numerous functions beyond
translation (i.e., ‘moonlighting activities’) may have emerged from new selective pressures or
from the generation of new architectural domains, principally in vertebrates, as has been
described for cytosolic aaRSs [42–45] (Box 2). A hypothesis is thus that alternative, albeit
uncharacterized functions may also have emerged for these mt-aaRSs.
In summary, the level of amino acid conservation at the mutated positions ranges from low to
high for the same aaRS and for similar diseases, suggesting that, although the canonical
function of aminoacylation is affected in some cases, other unknown additional functions are
also likely to be affected, and this should provide a future area of research.
Towards a Cellular Integration of Mitochondrial Translation Processes
That mutations in mt-aaRSs generally impact on mitochondrial translation is an inescapable
conclusion from the preceding sections but, at the same time, it is also an insufﬁcient one, in the
sense that we do not know whether, how, why, or when translation is affected. Further, mutations
in mt-aaRSs present striking tissue-speciﬁcity (see Outstanding Questions and Figure 1) that
cannot be rationalized without considering mitochondrial translation as being fully integrated
within the cell and actively participating as an environmental sensor [46]. Douglas C. Wallace has
evoked thecrucialcoupling betweenmitochondriaand the nucleus [46]. Inhis words: ‘The nucleus
must “know” that mitochondria can generate the required energy before proceeding with DNA
replication and transcription’. We suggest that mitochondrial translation plays a pivotal role as an
environmental sensor of the state of the cell. We further suggest that the integration of translation
occurs through speciﬁc modulations and/or connections with other biological processes, which
might be tissue-speciﬁc or tissue-dependent and which might involve some or all mt-aaRSs. In
recent years, several communication and signaling pathways between the nucleus and mito-
chondria have been uncovered [47]. Thus, it is pertinent to examine the effects aaRSs and their
mutations to achieve a better understanding and holistic integration of mitochondrial translation
processes within cells. Indeed, mutations in aaRSs may be able to impact upon many or all
translational events and signaling pathways, with unsuspected biological consequences. We thus
suggest different possibilities for how molecules from the mitochondrial translation machinery
might be integrated within the cellular environment.
Trends in Molecular Medicine, August 2017, Vol. 23, No. 8 703
Integration Through the Unfolded Protein Response
Among the communication pathways between nucleus and mitochondria are the cytoplasmic
and mitochondrial unfolded protein responses (UPRs) that are intimately linked to a fully-
functional translation process. mRNA translation is the result of a wide range of factors and
enzymatic activities that must occur to accurately produce correct polypeptides while simul-
taneously proceeding at the proper speed for native protein folding. The ﬁnal product, protein
folding, is ultimately an error-prone process. In protein synthesis, the types of proteins
synthesized vary widely between cell types and environments and, accordingly, so do the
levels of nutrients, metabolites, and energy requirements for proper protein folding [48]. Any
slowing down or impairment of translation can inﬂuence the folding of a nascent protein, leading
to the accumulation of unfolded or misfolded proteins in the lumen of the endoplasmic reticulum
(ER), leading to ER stress and activation of the UPR [48]. As central cofactors, adequate levels
of functional aaRSs (and fully functional tRNAs) are essential to achieve smooth translation. For
example, a lack of tRNA modiﬁcations in the anticodon triplet has been reported to lead to
protein misfolding with activation of the UPR signaling pathway in various cell types [49].
Similarly, we can envisage that a decrease in the amount of fully functional aaRSs might trigger
the UPR pathway, especially in stringent environments such as those for neuronal cells in the
CNS. For example, it is well known that neuronal cells harbor great morphological diversity and
extremely high energy demands. Functional mitochondria must be efﬁciently transported to
distal regions of neuronal cells where speciﬁc quality-control mechanisms remove dysfunc-
tional mitochondria [50]. Further, as postmitotic cells, neurons are very sensitive to toxic
species such as misfolded proteins [51]. Thus, it cannot be excluded that some mutations
might lead to either misfolded mt-aaRSs or misfolded products of mitochondrial translation,
thereby triggering the mt-UPR pathway. The mt-UPR pathway is linked to the nucleus through
the shuttling of transcription factors that can alter nuclear gene expression [52] upon sensing
mitochondrial stress [53]. Moreover, the links between mitochondrial protein synthesis and ER
occur architecturally through specialized areas – the mitochondria-associated membranes
(MAMs). In terms of tissue-speciﬁc UPR, one study has shown that conditional knockout mice
for heart or skeletal muscle-speciﬁc Dars2 (the gene coding for mt-AspRS) exhibit severe
mitochondrial dysfunction and activation of various stress responses in a tissue-dependent
manner [54]. However, the activated UPR is only observed in cardiomyocytes, which suggests
that this response may be tissue-speciﬁc [54]. In error-prone mutant cytosolic AlaRS (with a
mutation in the editing domain), protein aggregation also led to death of cerebellar Purkinje cells
[55]. Consequently, both sets of observations implicate the mt-UPR and/or misfolded or
aggregated proteins in mt-aaRS-associated pathologies.
Integration Through other Communication and Metabolic Pathways
Several examples lend support to the hypothesis that aaRSs are involved in other communi-
cation and signaling pathways, and may be used as sensors for the mitochondrial environment.
For instance, mt-MetRS has been shown to physically interact with thioredoxin 2, subsequently
contributing to mitochondrial redox regulation and detoxiﬁcation [56]. Furthermore, in cyano-
bacteria, the ValRS has been demonstrated to be anchored to the membrane of thylakoïds
and is connected to ATP synthase, suggesting that this enzyme may play a role as a functional
sensor between elements of gene translation and energy production machineries [57]. Prelimi-
nary information seems to indicate that some human mt-aaRSs may also be anchored to the
mitochondrial membrane, possibly connecting these two cellular processes; however, this
remains to be validated.
Another example includes the synthesis of nonessential amino acids, which are included
amongst the numerous essential metabolic pathways hosted by mitochondria. These amino
acids are synthesized from precursors generated either by glycolysis (cytosolic) or by the Krebs
cycle (mitochondria). For instance, aspartate is the most abundant metabolite in mitochondria
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[58] and is tightly connected to the respiratory chain complexes (aspartate synthesis is sensitive
to changes in the matrix NADH/NAD redox balance), and is also the precursor of N-acetyl-L-
aspartate, an essential neuron-speciﬁc transmitter [59]. One can envisage that mt-aaRSs could
monitor amino acid levels, as reported for the cytosolic LeuRS that was shown to be a leucine
sensor in the mTOR (mechanistic target of rapamycin) pathway which regulates both metabo-
lism and protein synthesis [60].
One can also consider that alternative, moonlighting, function(s) may be impacted by disease-
associated aaRS mutations. Moonlighting functions have been reported for mitochondrial
proteins in the nucleus [61] and for cytosolic aaRSs (Box 2 for examples). Indeed, molecular
evolution uses and reuses existing folded proteins for several ad hoc purposes. AaRSs are
ancient and abundant proteins, and it is possible that moonlighting functions have also arisen
for mt-aaRSs. This would correlate with the observation that some mutated positions are
exclusively conserved within the mammalian subphylum, and in regions that are not primarily
associated with the ancillary functions of aaRSs, meaning that these regions might theoretically
display alternative function(s) [22] (Box 3). Of note, mRNAs of mt-aaRSs present various splice
variants [62]. Some of the resulting shortened proteins are ‘catalytic nulls', implying that they
may be repurposed towards an alternative function. Moreover, some disease-related muta-
tions present in genomic DNA may be maintained in the splice variants, and others lost.
Therefore, one cannot exclude the possibility that mt-aaRS splice variants carrying mutations
might be deleterious, potentially executing impaired alternative functions. Although the splice
variant hypothesis cannot constitute a global explanation for each mt-aaRS and for each
disease, these truncated/modiﬁed proteins might play an important role for speciﬁc mt-aaRSs
and in speciﬁc diseases. Further experimental work is clearly required.
Moonlighting functions, or specialized functions that are necessary only in speciﬁc differenti-
ated cells, can be easily contemplated as tissue-speciﬁc. The ﬁrst alternative function of a mt-
aaRS was only recently described: rat mt-TrpRS was identiﬁed as a novel determinant of
angiogenesis in the heart and other tissues by acting as an integrator of pro-angiogenic
signaling, directing cell motility and division [63]. Moonlighting activity has also been reported
for the human mitochondrial ribosomal protein L12 (MRPL12), for which two mature forms,
generated by two-step cleavage during import, have been implicated in translation (canonical
role) and in transcriptional regulation (alternative role) [64]. Recently, the coexistence of two
forms of human mt-AspRS, matured after importation into mitochondria following the same
enzymatic cleavages, has also been demonstrated [65]. It is possible that one of the forms of
mt-AspRS harbors a moonlighting activity, and also that processing of mt-aaRSs (presently
poorly investigated) represents another means by which to generate and increase the reservoir
of alternative functions for mt-aaRSs. However, this hypothesis remains to be tested.
Because disease-related mutations in mt-aaRSs do not lead to multisystemic injuries, and the
CNS is the most frequently affected organ system, the preceding observations imply that
numerous speciﬁc mechanisms may affect, exploit, or modulate the mitochondrial translation
apparatus in neuronal cells. Indeed, we believe that future research should focus on identifying
the properties of mt-aaRSs that may be speciﬁc to neuronal cells in the context of health and
disease. By analyzing speciﬁc diseases, it may be possible to decipher distinct molecular
mechanisms underlying mt-aaRS-related pathologies affecting the CNS. Some examples of
neuron-speciﬁc molecules or mechanisms have been reported. For instance, one isodecoder
of cytosolic tRNAArg has been shown to exist only in neuronal tissues; indeed, mutations in this
tRNAArg can lead to neurodegeneration [66]. In addition, cell type-speciﬁc splicing efﬁciency
differences in mt-AspRS mRNA have been observed; correct inclusion of exon 3 in this mRNA
occurs less efﬁciently in neural cells than in other cell types (e.g., glia), as evidenced from in vitro
experiments using LBSL patient-derived cells [67]. It is therefore essential to reach an
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integrated view of mitochondrial translation in a wide range of cellular environments and also
under distinct physiological and pathophysiological conditions (Box 5).
Concluding Remarks
The present discussion indicates that mutations in all mt-aaRSs do not lead to pathologies via a
single unique molecular mechanism, even though this might be easy to assume because mt-
aaRSs constitute necessary and crucial components of the mitochondrial protein synthesis
process. Thus, although many questions are to be pursued (see Outstanding Questions), we
suggest that distinct mechanisms are at play in the pathogenesis of mt-aaRS-associated
diseases and, furthermore, that these mechanisms may not be necessarily the same for each
mt-aaRS. Among such putative mechanisms we have mainly considered that mt-aaRs muta-
tions may generate: (i) dysfunction in the translation machinery, potentially triggering the mt-
UPR; (ii) the alteration of alternative mt-aaRS function(s); and (iii) loss of activity as environmental
sensors or mediators that integrate cellular pathways. The understanding of complex mito-
chondrial pathologies requires novel fundamental insights into the mechanisms of mitochon-
drial translation within cells and on the precise roles that mt-aaRSs play in these integrated
molecular networks.
Cells have an absolute need for ATP produced by mitochondria. Unsurprisingly, the cell exerts
constant surveillance and quality control of mitochondrial processes, meaning that mitochondria
are fully integrated within cellular homeostasis. Mitochondrial translation, which is restricted to the
synthesis of 13 proteins in humans, constitutes a point of convergence within the cell, and merges
the products of nuclear and mitochondrial genomes. It is thus possible that mitochondrial
translation may have been maintained through evolution for networking purposes, guaranteeing
crosstalk between the cellular program and cellular energy demands, and enabling the surveil-
lance of metabolic activities and stress. It will therefore be exciting to follow future investigations on
the divergent pathways of mt-aaRSs in mitochondrial translation and disease.
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Box 5. Clinician’s Corner
The nucleus-encoded mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs) are central components of the mito-
chondrial translation apparatus; they charge a speciﬁc tRNA with the correct amino acid for protein synthesis.
Mutations in mt-aaRSs predominantly affect the CNS, but other organs may be affected.
The term ‘mitochondrial disease’ covers a large number of different pathologies and disorders. The diversity of onset-
ages, symptoms, organ involvement, and clinical presentations constitutes a challenge for the medical community in
terms of diagnosis and even more in the development of therapeutic treatments.
Until now, the clinical management of patients is limited to symptomatic treatments and nutritional supplements. CoQ,
vitamins A and E, carnitine, creatine, dichloroacetate, lipoic acid, and L-arginine are some of the supplements that are
used routinely in patients with mitochondrial diseases. However, such treatments do not cure the diseases. In recent
years numerous therapeutic approaches [including gene therapy using adeno-associated viral (AAVs) to correct the
mutation or CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9)
technology for genome editing] have been developed. Some of those experimental approaches have shown efﬁcacy in
animal models. The testing of the efﬁcacy of such treatments in humans is eagerly awaited.
The development and testing of any new therapeutic approach requires an understanding of the molecular mechanisms
underlying the disease, and for mt-aaRSs these remain unclear. Therefore, integrative collaborations between clinicians
and researchers should be encouraged to (i) assist diagnosis, (ii) counsel patients, and (iii) improve and develop novel
and efﬁcient therapeutic approaches.
Outstanding Questions
How can mutations in ancillary pro-
teins necessary to perform mitochon-
drial translation lead to a variety of
disorders that impact on a restricted
number of tissues/organs and with a
great temporal diversity?
Is this marked tissue- and cell-speci-
ﬁcity solely due to impaired mitochon-
drial translation in tissues or cells with
high energy demands?
Alternatively, does the tissue-speciﬁc-
ity result from non-translation functions
played by mt-aaRSs that are only cru-
cial in some tissues or cells? Are both
phenomena present for some aaRSs?
Can one systematically assign the
observed syndromes to results from
direct damage to a single molecular
process or to consequences from
other linked processes?
Do cells exploit still unknown molecular
mechanisms involving nucleus-
encoded mt-aaRSs to monitor mito-
chondrial activity and ATP production?
The mitochondrial UPR connects
nuclear and mitochondrial genomic
expression. Could some imported
and misfolded mutated aaRSs partici-
pate in this response, either directly or
indirectly, because they slow down
translation by impairing
aminoacylation?
Alternatively, ismitochondrial translation
particularly involved with or dependent
upon amino acid metabolic pathways?
We should clarify how mitochondrial
translation machineries are idiosyn-
cratically integrated within different
cells and tissues. We should disentan-
gle the environmental contributions
that either modify or modulate mito-
chondrial translation from those
involved in moonlighting activities.
Neuronal cells present a great diversity
of morphologies and an extremely high
energy demand. Functional mitochon-
dria must thus be efﬁciently transported
to distal regions of neuronal cells where
speciﬁc quality-control mechanisms
can remove dysfunctional mitochon-
dria. What, and how speciﬁc, are the
pathways of mitochondrial translation
within neuronal cells?
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Objectives of the thesis 
The evidence of the involvement of mitochondrial aminoacyl-tRNA synthetases 
(mt-aaRS) as a cause of mitochondrial disorders has increasingly attracted the interest 
of the scientific community on these proteins essential for the mitochondrial translation. 
Our laboratory, as well as others, has made major efforts in the characterization of 
different functional and structural properties of these mt-aaRS and in trying to 
understand the physiopathological mechanism(s) involved in the mitochondrial 
disorders produced as a consequence of their mutations. The objective of my PhD work 
followed the same order of interest but is aimed at expending the knowledge towards 
an unexplored system: the human mitochondrial arginyl-tRNA synthetase. Strikingly, 
mutations of this enzyme in patients are reported to be the cause of PCH6, a severe 
neurodevelopmental disease. This work has been organized following three main 
guidelines: 
1. Mitochondrial disorders linked to mutations in mitochondrial 
synthetases have shown striking tissue specificity towards the central nervous system. 
However, specific systems diverge towards other organs, producing distinct syndromes 
or specific affectations. The increasing number of cases reported called for an 
organization taking into account the clinical parameters related to each case described. 
This, I did an comprehensive analysis of the clinical data reported in pathologies related 
to mutations on mt-aaRSs, resulting in a categorization according to the anatomical 
system they affect. This organization allows us to extract messages and to establish 
functional research plans, directed mainly towards our system of interest: the 
mt-ArgRS. 
2. The host laboratory, in collaboration with other groups, has been 
providing important inputs in the characterization and understanding of the mt-AspRS 
system during the past years. Taking in account all this expertise and making 
improvements to the existing protocols, I performed studies on my system of interest: 
the mt-ArgRS. So in this part of the work, I characterized some of the cellular properties 
of the mt-ArgRS. This, not only allowed to decipher so-far unexplored characteristics 
to this enzyme, but also when to compare to information previously collected about the 
mt-AspRS, contributed to reveal that mt-aaRSs have distinct cellular properties. 
3. The first two parts were essential for the establishment of this third and 
final part of the work. Once the clinical analysis of the pathologies was performed; and 
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some of the intramitochondrial characteristics established, we investigated the impact 
of selected PCH6-related mutations on i) the newly-established cellular parameters of 
the mt-ArgRS and ii) on the catalytic function of this protein: the aminoacylation. 
Additional contributions regarding the mt-AspRS are provided in the Annex of this 
manuscript.  
Integrating different approaches, this thesis aims are contributing to the 
expansion of the general knowledge of the mt-ArgRS properties in its cellular 
environment, and beyond that to a better understanding of mosaïcity of effects 
connected with an in crescendo list of mitochondrial diseases correlated with mt-aaRSs. 
The establishment of different clinical manifestations in the pathologies correlated to 
mutation on mt-aaRSs, together with the determination of different cellular properties 
regarding the sub-mitochondrial organization of two mt-aaRSs, strongly suggest new 
peculiarities, alternate/novel function(s) of mt-aaRSs or their possible involvement into 
different cellular pathways. Altogether, the outputs of this work should shed light into 
molecular mechanisms underlying some of some of the pathologies correlated to the 
mt-aaRSs. 
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Results and Discussions 
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Chapter I  Clinical analyses of pathologies related to 
mutations in mt-aaRS: spotlight on the central nervous 
system 
 
1. Introduction 
Mitochondrial disorders are known to produce a large spectrum of clinical 
manifestations involving different tissues of the human body (Rötig, 2011). Since first 
identified in 1988 (Holt et al., 1988; Wallace et al., 1988), the concept of mitochondrial 
diseases has evolved. It includes not only pathologies related with mutations observed 
in the mitochondrial DNA (mt-DNA) but also genetic mutations in the nuclear DNA 
(nu-DNA). These latest may alter proteins from the respirator chain complexes, but also 
proteins involved in any other mitochondrial functions (DiMauro and Schon, 2008). 
The study of mitochondrial aminoacyl-tRNA synthetases (mt-aaRS), a group of nuclear 
encoded proteins in charge of the faithful mitochondrial translation, and their relevance 
as cause of specific neurological disorders has strikingly increased over the last years 
(Moulinier et al., 2017). Mutations of mt-aaRS rise in autosomal recessive diseases 
(Konovalova and Tyynismaa, 2013). However, no evidence has revealed the molecular 
basis of the tissue specificity of these disorders. 
Leukoencephalopathy with brain stem, spinal cord involvement and lactate 
elevation (LBSL) was the first identified mt-aaRS-related disease in 2007 (Scheper et 
al., 2007), produced by mutations in the DARS2 gene, that encodes the mitochondrial 
aspartyl-tRNA synthetase (mt-AspRS). Over the past ten years, all the genes coding for 
the 19 mt-aaRS have been associated with diseases that exhibit the central nervous 
system (CNS) as one of the most predominantly affected system (Sissler et al., 2017). 
The host laboratory has developed a web server dedicated to disease-associated 
mutations in human mt-aaRS: Misynpat (http://misynpat.org; (Moulinier et al., 2017). 
This database collects the list of publications that contains clinical and genetic 
information. In addition, this webserver suggest 3D model structures of the mt-aaRSs, 
and also proposes the analysis of mutations in a context of conservation and evolution 
of the sequence (Moulinier et al., 2017). 
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2. Broad range of clinical presentations 
The clinical manifestations present with diseases characterized by defined 
symptoms and/or neuroradiological features (e.g. LBSL), isolated clinical signs (e.g. 
non syndromic hearing loss), described syndromes (e.g. Perrault syndrome), among 
others. 
Kolanova et al. did the last clinical literature review of the pathologies related 
to mutations on mt-aaRSs in 2013 (Konovalova and Tyynismaa, 2013). Since then, the 
number of cases published has increased steadily (Moulinier et al., 2017). The purpose 
here is to update the clinical scenario and search for common clinical patterns for each 
mt-aaRS related disorder.  
The main objective here is to categorize the mt-aaRSs according to the affected 
tissue(s) and/or organ system(s). By doing so, we obtained four main groups (Table 2) 
that are further discussed below: i.- mt-aaRS with mutations affecting exclusively the 
CNS; ii.- mt-aaRS with mutations affecting the CNS AND an other system; iii.- mt-
aaRS with mutations affecting the CNS OR an other system and iv.- mt-aaRS with 
mutations affecting a system other than the CNS.  
2.1. mt-aaRS with mutations affecting exclusively the 
CNS 
This part is further divided into two subgroups containing mt-aaRS 
characterized by epileptic encephalopathies and leukoencephalopathies. In the first 
subgroup, the common clinical factor is epilepsy. While for the second subgroup, 
changes in the white matter are the main hallmark in the diagnosis of the disease. 
2.1.1. Epileptic Encephalopathy 
CARS2 
CARS2, encoding the mitochondrial cysteinyl-tRNA synthetase (mt-CysRS), is 
related to a severe mitochondrial epileptic encephalopathy. Patients harboring 
mutations in the mt-CysRS manifest severe myoclonus epilepsy; progressive cognitive 
decline and magnetic resonance imaging (MRI) features show brain atrophy (Coughlin 
et al., 2015; Hallmann et al., 2014). The age of onset of symptoms was in childhood (9 
 71 
and 5 years) for the siblings harboring homozygous mutations, whilst the proband with 
heterozygous mutations presented a neonatal onset (Coughlin et al., 2015; Hallmann et 
al., 2014). Mitochondrial respiratory chain (MRC) analyses were done in one of the 
probands and revealed combined deficiency of the activities of complexes I, III and IV 
in liver and of complexes I and IV in muscle samples. Nevertheless the authors 
suggested that the lack of statistical significance for these complexes deficiencies is due 
to a compensatory amplification of mtDNA as a result of mitochondrial dysfunction 
(Coughlin et al., 2015).  
FARS2 
Patients with mutations in FARS2, the gene encoding for the mitochondrial 
phenylalanyl-tRNA synthetase (mt-PheRS), present phenotypes that range from spastic 
paraplegia (Yang et al., 2016) to fatal infantile Alpers encephalopathy (Elo et al., 2012; 
Walker et al., 2016). Early onset epileptic encephalopathy represents the main disorder 
reported in the literature (Cho et al., 2017). The MRI in all patients showed progressive 
brain atrophy. Most of the cases presented with early seizures during the neonatal 
period, one exception was an infantile onset at 8 years old (Walker et al., 2016). 
Regarding the type of seizure, myoclonic seizure is the most listed one. Developmental 
regression was noticed in addition to progressive brain atrophy after seizure onset. 
Noteworthy, except for two patients, the seizures disappeared after childhood (Cho et 
al., 2017). 
NARS2 
NARS2 encodes for the mitochondrial asparaginyl-tRNA synthetase 
(mt-AsnRS). Mutations in NARS2 have been correlated with a broad range of clinical 
phenotypes, varying from non-syndromic hearing loss (NSHL), Leigh syndrome, 
Alpers’ syndrome to intellectual disability with epilepsy and severe myopathy 
(Mizuguchi et al., 2017). The patients classified with Alpers’ syndrome by Safou et al. 
showed MRI with diffuse degeneration of cerebral gray matter, which is characteristic 
of Alpers’ syndrome (Sofou et al., 2015). In 2015, Vanlander et al described two 
siblings with a phenotype characterized by proximal myopathy, excessive fatigability, 
and ptosis for one sibling and mild intellectual disability and epilepsy for the other. 
MRC studies reveled combined deficiencies in complexes IV and I in muscle. 
Non-syndromic hearing loss was reported solely in one patient with the homozygous 
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mutation p.V213F (Simon et al., 2015). Curiously, the cases reported with Alpers’ 
syndrome were also homozygous, but with a mutation in the next amino acid (p.P214L) 
(Sofou et al., 2015). Two brothers reported with Leigh syndrome, characterized by 
symmetrical lesions in the brain stem and thalamus, had similar clinical features 
including congenital auditory neuropathy followed by myoclonus, intractable seizures 
and early death (Simon et al., 2015). We observed that despite the variations in the 
clinical expression of genetic defects in NARS2, a common pattern of developmental 
delay/regression and epilepsy is present in most of the cases. 
PARS2 
PARS2, encoding for the mitochondrial prolyl-tRNA synthetase (mt-ProRS), 
was first described in one patient with fatal Alpers’ syndrome (Sofou et al., 2015). The 
reported case presented with infantile onset focal seizures followed by generalization 
and signs of psychomotor regression. A brain computed tomography (CT) revealed 
cerebral cortical atrophy. Biochemical studies of the RC enzyme activities in muscle 
biopsies revealed decreases in complexes I and IV (Sofou et al., 2015). Other mutations 
in PARS2 gene were published in 2017, and the authors described similar neurological 
features including epilepsy, developmental delay as those previously reported, however 
fatality was not brought up (Theisen et al., 2017). 
RARS2 
RARS2, encoding the mitochondrial arginyl-tRNA synthetase (mt-ArgRS), was 
found to be a disease gene for pontocerebellar hypoplasia type 6 (PCH6) (Edvardson et 
al., 2007). The characteristic clinical features include severe epileptic encephalopathy 
with intractable seizures, neonatal lactic acidosis, feeding problems, and deep 
developmental delay (Cassandrini et al., 2013). MRI revealed severe abnormalities 
including cerebellar hypoplasia and progressive pontocerebellar atrophy (Lühl et al., 
2016). Some patients, however, were presented without the neuroradiologic typical 
pontocerebellar hypoplasia, thus expanding the phenotypic spectrum of PCH6 (Lühl et 
al., 2016; Nishri et al., 2016). A classic neuroimaging sign in older patients is 
progressive cerebral and cerebellar atrophy that derives in striking microcephaly 
(Namavar et al., 2011). The effects in the activities of the complexes of the respiratory 
chain are variable, indicating that an absence of impact in MRC activity could not rule 
out the diagnosis of PCH6 (Zhang et al., 2018). 
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TARS2 
TARS2, encoding the mitochondrial threonyl-tRNA synthetase (mt-ThrRS), was 
reported in 2014 by Diodato et al. in two siblings with fatal mitochondrial 
encephalomyopathy, presenting axial hypotonia and limb hypertonia, psychomotor 
delay, and high levels of blood lactate. Both children died a few months after birth. The 
brain MRI showed lesions involving the corpus callosum and the globi pallidi. 
Biochemical analysis showed defects of the MRC complex activities in muscle 
homogenate, and no defect was observed in fibroblasts (Diodato et al., 2014b). We 
noted that TARS2 is one of the systems where fewer patients have been reported; one 
can assume that lethality of mutations in TARS2 might affect a normal fetal 
development avoiding a full term pregnancy.  
2.1.2. Leukoencephalopathies 
DARS2 
DARS2, encoding for the mitochondrial aspartyl-tRNA synthetase (mt-AspRS), 
was the first gene reported to produce a mt-aaRS-related disease (Scheper et al., 2007). 
Mutations in DARS2 produce a Leukoencephalopathy with brainstem, spinal cord 
involvement and lactate elevation (LBSL). Patients diagnosed with LBSL present a 
large spectrum of phenotypic manifestations including cerebellar ataxia, spasticity, 
seizures, variable cognitive impairments, and in some cases requirement of wheelchair 
assistance (van der Knaap and Salomons, 2015). Typical MRI features revealed 
changes in the cerebral subcortical, periventricular and deep white matter, posterior 
limbs of internal capsules, centrum semiovale, medulla oblongata, deep cerebellar 
white matter and variable involvement of the sensory and pyramidal tracts in addition 
to the brainstem and cerebellar connections (Uluc et al., 2008). Infantile onset was the 
most common form of presentation, however some patients started their first symptoms 
in adulthood (van Berge et al., 2014). Severity of LBSL varies from slow and mild 
neurodegeneration to severe fatal disease; intriguingly three subjects harboring DARS2 
mutations were described asymptomatic (van Berge et al., 2014). However, in some 
cases of LBSL the symptoms debuted after an infectious or traumatic process. Thus, 
asymptomatic subjects should be under medical supervision, in the hypothesis that the 
exposure to a stressful (eventual) process leads to the onset of the disease. 
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EARS2 
Mutations in EARS2, encoding the mitochondrial glutamyl-tRNA synthetase 
(mt-GluRS), have been described in patients with early-onset leukoencephalopathy 
with thalamus and brainstem involvement and high lactate elevation (LTBL) (Steenweg 
et al., 2012). LTBL appears during the neonatal period with diverse neurological 
manifestations including seizures, spasticity, psychomotor regression, and irritability, 
among others (Talim et al., 2013). The phenotype heterogeneity ranges from fatal 
outcome concomitant to a severe neurometabolic disorder, with neonatal or very early 
onset presentation of LTBL (Oliveira et al., 2017). A distinctive brain MRI pattern 
shows characteristic neuroradiological features with symmetrical abnormalities of 
cerebral white matter, and symmetrical signal changes in the thalami, midbrain, pons, 
medulla oblongata and cerebellar white matter (Sahin et al., 2016). High blood lactate 
and MRC activities defect in complexes I and IV were observed (Talim et al., 2013). 
In some cases, attenuation of the signs was described. The authors suggested that 
recovery depends on the severity of brain damage caused by the first episode (Steenweg 
et al., 2012). 
MARS2 
Mutations in MARS2, encoding the mitochondrial methionyl-tRNA synthetase 
(mt-MetRS), were first reported to produce the ARSAL syndrome (autosomal recessive 
spastic ataxia with leukoencephalopathy) (Bayat et al., 2012). Latter in 2015, Webb et 
al. reported two additional patients with developmental delay, growth failure, and 
sensorineural hearing loss, thus, expanding the phenotypic presentation correlated with 
mutations in MARS2 (Webb et al., 2015). Enzymatic studies reported deficiencies in 
complex I in lymphoblastoid cells from patients with ARSAL syndrome and in complex 
IV in patients with developmental delay (Webb et al., 2015). MRI findings for all 
patients included cerebellar and cortical atrophy, together with white matter 
abnormalities (Bayat et al., 2012; Webb et al., 2015).  
WARS2 
WARS2, encoding the mitochondrial tryptophanyl-tRNA synthetase (mt-TrpRS), 
was the last enzyme to be correlated with a disorder (Musante et al., 2017). Intellectual 
disability is a prevalent clinical sign (Burke et al., 2018; Musante et al., 2017; Theisen 
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et al., 2017). Additional symptoms include athetosis, speech impairment, muscular 
weakness and ataxia (Musante et al., 2017). MRI studies were done in one patient and 
revealed abnormalities in the white matter (myelination delayed) and diffused cerebral 
atrophy (Theisen et al., 2017). Defects in OXPHOS complexes were fluctuating: the 
activity was relatively unaffected in one patient (Burke et al., 2018), but strongly 
decreased in complexes I, III and IV found in fibroblast from another proband (Theisen 
et al., 2017).  
2.2. mt-aaRS with mutations affecting the CNS AND 
an other system 
AARS2 
AARS2, encoding the mitochondrial alanyl-tRNA synthetases (mt-AlaRS), was 
found to be mutated in patients with a leukodystrophy characterized by cognitive 
impairment and motor dysfunction (ataxia, spasticity). The onset of the clinical features 
appeared in patients during the third decade of life (Götz et al., 2011; Lakshmanan et 
al., 2017). One important remark is that ovarian failure was described in all known 
females with leukoencephalopathy caused by AARS2 mutations (Lakshmanan et al., 
2017). Neuroradiological features showed an abnormal diffuse white matter signal 
affecting the periventricular, tend and corpus callosum with pyramidal tract 
involvement, typically in the posterior limb of the internal capsule and brainstem 
(Lakshmanan et al., 2017). Severe defect was observed in the cytochrome c oxidase 
(Complex IV from the respiratory chain) from muscle homogenate, while activities of 
respiratory chain complexes were normal in fibroblasts from patients (Dallabona et al., 
2014). Mutations in AARS2 were also correlated with fatal cardiomyopathy (see below). 
However, the mutated positions in patients with cardiomyopathy are different from 
those in patients with leukodystrophy (Euro et al., 2015). 
HARS2 
HARS2, encoding the mitochondrial histidyl-tRNA synthetase (mt-HisRS), was 
reported as one of the genes producing Perrault syndrome, a rare autosomal recessive 
disorder characterized by sensorineural hearing loss and ovarian dysgenesis in females 
(Pierce et al., 2011). Clinical manifestations are slightly variable depending on the age 
of onset and on the severity. These manifestations include amenorrhea during the third 
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decade and neurological features including developmental delay or intellectual 
disability, cerebellar ataxia, and motor and sensory peripheral neuropathy. Solely two 
patients were reported without neurological signs (Lerat et al., 2016). So far, all males 
harboring mutations in HARS2 were fertile (Lieber et al., 2014). 
LARS2 
Perrault syndrome was also correlated to mutations in LARS2, encoding the 
mitochondrial leucyl-tRNA synthetase (mt-LeuRS)(Pierce et al., 2013). All reported 
patients display amenorrhea, severe/progressive sensorineural hearing loss with 
different ages of onset and no concomitant neurological symptoms (Solda et al., 2016). 
One isolated case of fatal multisystem failure was reported (Riley et al., 2016), 
expanding the phenotype of LARS2 mutations. 
IARS2 
Mutations in IARS2, encoding mitochondrial isoleucyl–tRNA synthetase 
(mt-IleRS), were correlated with a disorder manifesting with cataracts, short-stature 
secondary to growth hormone deficiency, sensorineural hearing deficit, peripheral 
sensory neuropathy, and skeletal dysplasia (CAGSSS) (Schwartzentruber et al., 2014). 
The MRI in one proband showed an atrophied pituitary adenohypophysis and a small 
neurohypophysis, according with growth hormone deficiency. No cognitive deficit was 
present (Schwartzentruber et al., 2014). Moreover, compound heterozygous mutations 
in IARS2 were identified in a single patient with a form of Leigh syndrome 
(Schwartzentruber et al., 2014). One last case was described in a child who presented 
with bilateral hip dislocations, short stature and hypotonia at birth, and developed 
additional CAGSSS-related symptoms (Moosa et al., 2017). 
VARS2 
Mutations in VARS2, encoding the mitochondrial valyl-tRNA synthetase 
(mt ValRS), provoke a severe encephalo-cardiomyopathy (Baertling et al., 2017; Bruni 
et al., 2018; Diodato et al., 2014b). Seventeen patients have been described with a 
phenotype mainly characterized by severe early onset hypotonia, stridor and respiratory 
failure (Bruni et al., 2018). Lethality of this disorder was significantly present for the 
reported patients. Hypertrophic cardiomyopathy is a common additional clinical sign 
present in this disorder. Involvement of other organs was reported in five patients, 
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presenting anuric kidney, pancreatitis and hepatosplenomegaly. Nonetheless, the 
authors presume of the use of some antiepileptic drugs were determinant in affecting 
those other organs (Bruni et al., 2018). MRI features were non-specific, displaying 
variable cerebral and cerebellar atrophies, white matter injuries and basal ganglia 
involvement. None of the biochemical profiles presented a unique pattern, showing 
defects of complexes IV and I in muscle biopsies, and were almost always normal in 
patient's fibroblasts (Bruni et al., 2018; Diodato et al., 2014b). 
2.3. mt-aaRS with mutations affecting the CNS OR an 
other system 
SARS2 
SARS2, encoding the mitochondrial seryl-tRNA synthetase (mt-SerRS), was 
first reported to be a disease gene for the HUPRA syndrome (hyperuricemia, pulmonary 
hypertension, renal failure in infancy, and alkalosis) (Belostotsky et al., 2011). Clinical 
manifestations include early progressive renal failure with hyperuricemia, pulmonary 
hypertension, failure to thrive, anemia and metabolic hypochloric alkalosis (Rivera et 
al., 2013). Enzymatic analysis of respiratory chain complexes showed mild deficiencies 
of complexes I, III and IV. So far, all patients diagnosed with HUPRA syndrome carried 
autosomal homozygous missense mutations (Belostotsky et al., 2011; Rivera et al., 
2013). In 2016, Linnankivi et al. described one patient with a homozygous splicing 
defect in SARS2, presenting with progressive spastic paresis instead of HUPRA 
syndrome, thus expanding the spectrum of phenotypes of mutations in the SARS2 gene 
(Linnankivi et al., 2016). MRI features showed atrophy of cerebellar hemispheres and 
vermis, as well as thalamic signal changes. Kidneys were normal, and there was no 
hematuria or proteinuria (Linnankivi et al., 2016).  
2.4. mt-aaRS with mutations affecting other system 
than the CNS 
AARS2  
Severe forms of fatal cardiomyopathy have been associated with mutations in 
AARS2 (Götz et al., 2011; Mazurova et al., 2017). The clinical hallmark was a 
hypertrophic cardiomyopathy and death occurred during the 1st year of life (Mazurova 
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et al., 2017). No signal of cardiac involvement was observed in foetal ultrasound, 
except in one case that led to intrauterine death (Mazurova et al., 2017). MRC 
enzymatic activities reveal combined deficiencies in complexes I and IV (Götz et al., 
2011; Mazurova et al., 2017). Interestingly, all the patients with the cardiomyopathy 
carried the mutation c.1774C>A (p.R592W) at least in one allele (Taylor et al., 2014); 
some authors hypothesized that the tissue-specific phenotype of the cardiomyopathy 
could be in relation with variable concentrations of amino acids in different tissues 
(Götz et al., 2011). 
YARS2 
Mutations in YARS2, encoding the mitochondrial tyrosyl-tRNA synthetase (mt-
TyrRS), have been identified as a cause of the tissue specific mitochondrial respiratory 
chain disorder: Myopathy, Lactic Acidosis, Sideroblastic Anaemia 2 (MLASA2) (Riley 
et al., 2010). Clinical common features include anemia, lactic acidosis and myopathy 
(Ardissone et al., 2015). The severity of the clinical course and the age of onset were 
variable. Indeed, 14/17 of the described patients debuted the clinical symptoms within 
the first decade of life, only 3/17 patients presented onset in adolescence or adulthood. 
Sideroblastic anaemia was mostly transfusion dependent (repeated blood transfusions 
are the only effective therapy). Nevertheless, the three cases with later age of onset 
manifested spontaneous recovery (Sommerville et al., 2017). A highlight is the absence 
of neurological manifestations in patients with mutations in YARS2. Biochemical 
measurements in muscle biopsies showed a combination of deficiencies of complexes 
I, III and IV (Sommerville et al., 2017). mt-TyrRS is the only case for which mutations 
reported so far are homozygous. Except for one described heterozygous case, in which 
the G191D mutation is associated with a nonsense mutation, meaning that only the 
G191D variation is present in the expressed dimeric protein in this patient. Altogether, 
it indicates that the pathogenicity of mutated mt-TyrRS exclusively relies on 
homodimeric mutated forms of the enzyme (Sissler et al., 2017). 
2.5. GARS and KARS: two systems apart.  
GARS and KARS, encoding the glycyl-tRNA synthetase (GlyRS) and the lysyl-
tRNA synthetase (LysRS), respectively, are the only genes known in Human to code 
for both the cytosolic and mitochondrial enzymes (Mudge et al., 1998; Shiba et al., 
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1994; Tolkunova et al., 2000). Mutations in those genes have been reported in both 
recessive and dominant inheritance with different clinical presentations. Autosomal 
dominant mutations in GARS and KARS lead to an affectation of the peripheral nervous 
system named Charcot–Marie–Tooth disease type 2 (CMT2) (Seburn et al., 2006). 
However, recessive mutations in these genes have been reported to produce phenotypes 
similar to those reported by mutations in mt-aaRSs (Taylor et al., 2014; Verrigni et al., 
2016). 
3. LBSL vs PCH6: clinical contrast of disorders affecting 
the CNS 
A comprehensive analysis of the clinical reports and the accumulation of 
experimental data over the past years led us to identify at least two contrasting 
situations, exemplified by the two following disorders. LBSL and PCH6 are disorders 
that affect both the central nervous system. However, clinical manifestations differ in 
signs and severity. LBSL leads to a neurodegenerative disease, and PCH6 leads to a 
neurodevelopmental disorder. LBSL patients usually develop movement problems 
during childhood or adolescence. However, in some cases, the clinical manifestations 
do not appear until adulthood. The clinical signs mainly presented by individuals with 
LBSL are spasticity (muscular muscle rigidity) and ataxia (difficulty with coordinating 
movements). These conditions use to affect more the legs than the arms. In the most 
severely affected patients the use of the wheelchair assistance is required (van Berge et 
al., 2014). Regarding PCH type 6, the patients manifests the symptoms early after birth 
with, in most of the cases, intractable seizures and recurrent apnea (Edvardson et al., 
2007). Other neurological signs include generalized hypotonia, microcephaly 
(unusually small head size caused by impaired growth of some parts of the brain) 
lethargic, poor sucking and poor feeding requiring nasogastric feeding. The most 
heavily affected patients live only into infancy or childhood and they never achieved 
developmental milestones (Joseph et al., 2014).  
Mutations within mt-AspRS are correlated with LBSL (Scheper et al., 2007). 
Investigations performed so far indicate that mutations have idiosyncratic impacts on 
molecular, cellular, and/or structural properties of the mt-AspRS (Messmer et al., 2011; 
Sauter et al., 2015; Scheper et al., 2007; van Berge et al., 2013). The absence of clear 
and common impact(s) on the canonical function of the enzyme strongly suggests a 
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neuron-specific non-canonical function/property that needs to be unveiled. This 
hypothesis is further supported by the observations (by others) that activities of 
respiratory chain complexes are barely or not affected by mutations (Orcesi et al., 
2011), and (by the host laboratory) that impacted residues are conserved only within 
mammals mt-AspRSs indicating a selective pressure restricted to higher eukaryotes, 
likely related to the emergence of a sub-phylum specific alternate function (Moulinier 
et al., 2017; Schwenzer et al., 2014a). On the other hand, mutations within mt-ArgRS 
are correlated with PCH6 (Cassandrini et al., 2013). Contrary to the case of mt-AspRS, 
some evidences led us to think that mutations within the mt-ArgRS would lead to the 
pathology through impairments of the aminoacylation function. These evidences are: i) 
the severity of the clinical presentation; ii) the observation of reduced activities of mt-
DNA encoded respiratory chain complexes in some muscle biopsies (Lühl et al., 2016), 
and iii) the observation that at least one of the two mutations (in allelic composition) 
impact a residue conserved in phylogeny (Moulinier et al., 2017). 
The different phenotypic expressions of the two diseases (severe for PCH6 and 
mild for LBSL), yet both causing central nervous system injuries, call for a better 
characterization of the cellular properties of the mt-aaRSs. One might suppose that the 
effect of the mutations produced on the aminoacylation function of the mt-ArgRS will 
be more drastic than that shown for the mt-AspRS (Scheper et al., 2007). Thus, the next 
chapter II and III, will be devoted to the establishment of cellular singularities of the 
mt-ArgRS, and to the study of the impact of the pathologic mutations on the cellular 
properties and on the aminoacylation function of this enzyme, respectively.  
4. Discussion/Conclusion 
Two important outputs emerge from this overview of mitochondrial disorders 
produced by mutations in the mt-aaRSs. The first output is the categorization of the 
mt-aaRSs into groups according to the clinical phenotypes observed in patients. From 
this, each message that can be extracted reinforces the variability of the clinical 
manifestations. Within this variability, we were able to identify two main patterns of 
presentation in the CNS: epileptic syndromes and leukodystrophic disorders. Another 
observation is that only few organ systems are affected at the same time as the CNS. It 
has been suggested that these secondary symptoms are probably the result of a primary 
defect in the CNS (Sissler et al., 2017). Regarding the correlation between the 
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mutations and ATP production, none of the subgroups showed an established pattern 
of affectation of the MRC. Several studies of MRC enzymatic activities in samples 
issued from affected patients showed variable (or any) effects in the OXPHOS function. 
However, it should be noted that most of these mitochondrial enzymatic studies have 
been performed on fibroblasts, which are cells from tissues not affected by diseases 
linked to mutations on the mt-aaRSs. Tissue-specific variability in the abundance of 
different components of the mitochondrial translation machinery and tissue-specific 
differences in the dependence of energy may play a crucial role on the phenotype of 
these disorders (Figure 9). Regarding the age of the manifestation of the clinical signs 
in the categorized groups, even though the predominance was early or infantile, 
exceptions occasionally appeared with patients with symptoms that appear later in life. 
From now on, taking into account this classification, the future cases reported can be 
assigned to a respective group. 
The questions that emerge from here are whether mt-aaRSs belonging to the 
different subgroups have different cell properties? Or whether it is too early now, and 
that the emergence of further patients might modify the categorization proposed here? 
The second output is the heterogeneity of the genotype-phenotype shown within 
the four groups associated to mutations in mt-aaRSs. This point is represented by the 
fact that most of the time the clinical manifestations correlated with mutations in 
mt-aaRSs rarely occur in the same way, neither at the same age nor with the same 
severity. There are still many things that need to be done to understand the factors that 
determine why mutations in the same mt-aaRSs manifest with mild symptoms in one 
patient and with severe or fatal symptoms in others. Further researches on mt-aaRS are 
essential to find peculiarities of these family of enzymes that could reveal some clues 
to the understanding of the molecular mechanism linked to these rare diseases. For this 
purpose, the next chapter will be devoted to extending the knowledge of the mt-ArgRS 
through cell models, trying to shed some light on the singularities of this enzyme. In 
the future, the generation of appropriate animal models and the compilation of clinical 
information from upcoming patients are a good beginning for the enlightenment of the 
relationship between genes and clinical presentation of these pathologies. 
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Figure 9. Tissue-specificity of mitochondrial disorders correlated with mutations on 
human mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs). This representation shows 
the total set of mt-aaRSs classified in four main groups: mt-aaRSs producing injuries 
exclusively in the central nervous system (CNS), mt-aaRSs affecting the CNS and another 
organ, mt-aaRSs affecting alternatively the CNS or other organ, and mt-aaRSs affecting other 
organ system than the CNS. 
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Table 2. Classification of the pathologies produced by mutations on human mitochondrial 
aminoacyl-tRNA synthetases. 
 
 
 
 
GENE PROTEIN MAIN PHENOTYPE MAIN 
AFFECTED 
ORGAN 
AGE ON 
ONSET 
mt-aaRS with mutations affecting exclusively the CNS 
Encephalopathies  
 
 
 
 
 
 
Brain 
 
CARS2 mt-
CysRS 
Mitochondrial epileptic 
encephalopathy 
Infancy-
Childhood 
FARS2 mt-PheRS Alpers encephalopathy Infancy 
NARS2 mt-
AsnRS 
Alpers’ syndrome 
Leigh syndrome 
Non-syndromic hearing loss 
(NSHL),  
 
Infancy-
Childhood 
PARS2 mt-ProRS Alpers’ syndrome Infancy 
RARS2 mt-
ArgRS 
Pontocerebellar hypoplasia type 6 
(PCH6) 
Infancy 
TARS2 mt-ThrRS Fatal mitochondrial 
encephalomyopathy 
Infancy 
Leukoencephalopathies  
DARS2 mt-
AspRS 
Leukoencephalopathy with 
brainstem, spinal cord involvement 
and lactate elevation (LBSL) 
Childhood-
Adulthood 
EARS2 mt-GluRS Leukoencephalopathy with thalamus 
and brainstem involvement and high 
lactate elevation (LTBL) 
Infancy 
MARS2 mt-
MetRS 
Autosomal recessive spasteic ataxia 
with leukoencephalopathy (ARSAL 
syndrome) 
Childhood-
Adulthood 
WARS2 mt-TrpRS Intellectual disability Infancy-
Childhood 
mt-aaRS with mutations affecting the CNS AND other system 
VARS2 mt-ValRS Fatal mitochondrial 
encephalocardiomyopathy 
 
 
Brain AND 
other 
Infancy 
AARS2 mt-AlaRS Leukoencephalopathy with ovarian 
failure  
Childhood-
Adulthood 
HARS2 mt-HisRS Perrault syndrome Childhood-
Adulthood 
LARS2 mt-
LeuRS 
Perrault syndrome Childhood-
Adulthood 
IARS2 mt-IleRS CAGSSS 
Leigh syndrome 
Infancy-
Childhood 
mt-aaRS with mutations affecting the CNS OR other system 
SARS2 mt-SerRS Hyperuricemia, Pulmonary 
hypertension, Renal failure in 
infancy, and Alkalosis (HUPRA) 
Kidney Infancy 
mt-aaRS with mutations affecting other system than the CNS 
AARS2 mt-AlaRS Hypertrophic cardiomyopathy Heart Infancy 
YARS2 mt-TyrRS Myopathy, Lactic Acidosis, 
Sideroblastic Anaemia 2 (MLASA2) 
Muscle/Bone 
narrow 
Childhood-
Adulthood 
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Chapter II Deciphering (some) cellular properties of the 
mt-ArgRS 
 
1. Introduction 
 The import of nuclear-encoded proteins is required for the correct functioning of the 
mitochondria. Once inside the mitochondria, the proteins follow the fluid-mosaic model 
proposed by Singer and Nicolson in 1972 (Singer and Nicolson). According to this model the 
proteins can be located either on the outer membrane, inner membrane, intermembrane space or 
on the matrix. The proteins found in the membrane can be embedded into the membrane 
(integral proteins) or loosely attached to the membrane (peripheral proteins). The import process 
is achieved for many of the mitochondrial proteins thanks to the presence of an N-terminal 
sequence named mitochondrial targeting sequence (MTS). The maturation process of the MTS 
is poorly defined, but is essential among others, for the proper folding and functioning of the 
imported protein into the mitochondria (e.g. (Chacinska et al., 2009)). Indeed, as recalled in the 
introduction, the relevance of the process of mitochondrial precursors by a sorting signal in the 
form of an N-terminal extension to direct the precursor across the outer and inner membranes 
into the mitochondria has been extensively described (reviewed in e.g. (Mossmann et al., 
2012)). 
In addition to this essential role for the mitochondria biogenesis, it has been shown at several 
instances that the N-terminal sequence of a protein may have a significant role on its expression 
on bacterial strains. For instance, the host laboratory has established the impact of selected N-
termini on the expression, the solubility, the stability and the activity of the recombinant human 
mt-AspRS, expressed in a bacterial strain (Gaudry et al., 2012). As another example, it has been 
shown in the case of the mt-LeuRS that the N-terminal of the protein has an important influence 
on aminoacylation and that its activity is lower when a part of the sorting mitochondrial signal 
remains upstream of its sequence (Yao et al., 2003). 
Previous studies from the host laboratory have revealed specific cellular 
characteristics/peculiarities for the human mt-AspRS, such as: the coexistence of two forms of 
the enzyme inside the mitochondria, produced by alternative cleavages of the MTS after 
importation (Carapito et al., 2017), and the establishment of the double localization of the mt-
AspRS inside mitochondria, present both in the membrane fraction and in the soluble fraction. 
Considering these above-recalled previous works, the aim of the present chapter is to establish 
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some of the cellular characteristics of the mt-ArgRS, making use of the tools and the 
experimental strategies previously developed for the mt-AspRS. We thus have 1) determined 
the in cellulo N-termini of the mt-ArgRS and searched for the most soluble recombinant version 
of the protein for optimal expression in a bacterial strain, 2) established the intra-mitochondrial 
location of the mt-ArgRS, and 3) identified its mode of membrane anchoring. In what follows, 
the results are compared and discussed with those previously obtained for the mt-AspRS. 
2. N-Termini determination of the human mt-ArgRS 
Mitochondrial targeting sequence of mt-ArgRS is predicted in silico to be cleaved 
between residues Val16 and Leu17 by the webserver MitoProt (Claros and Vincens, 1996). 
However, Agnes Gaudry (Assistant Engineer in the host laboratory) carried out a series of 
experiments of in vitro expression of the mt-ArgRS using a recombinant protein starting at this 
N-terminal Leu17, without any success. Although sometimes the use of in silico prediction is 
useful, it appeared not to be effective in the present case. 
The identification of the cleavage site on the N-terminal MTS of the mt-ArgRS remains 
a challenging task because of the absence of consensus sequences for cleavage sites and the 
possibility of multiple proteolytic steps for a single precursor protein (Carapito et al., 2017). 
Protein sequencing by Edman degradation is a first strategy to identify the N-terminus of a 
protein (Edman, 1949). This technique, however, requires important quantities of purified 
protein and may not work if the N-terminus has been chemically modified (Edman, 1949). 
Facing these difficulties, several strategies have been developed to determine the N-termini of 
mitochondrial proteins. Within these strategies, one can mention an adapted version of the 
classical shotgun proteomics. The classical LC-MS/MS analysis identifies fully-tryptic 
peptides, properly cleaved on both ends by trypsin. In the present case of matured mitochondrial 
protein, the N-terminal peptide may be cleaved only on C-terminal end by trypsin (semi-tryptic 
peptides). The identification of such semi-tryptic peptides thus required the elaboration of a 
dedicated database that contains all theoretically calculated possible N-terminal peptides. 
Theoretical masses of processed N-terminal peptides were then compared to the experimentally 
detected peptides by mass spectrometry (Carapito et al., 2017). However, when the maturation 
of the precursor protein occurs after a lysine or an arginine, the N-terminal peptide will be 
detected as a fully-tryptic peptide. In this situation, one cannot distinguish whether this peptide 
is an internal peptide (properly cleaved on both ends by trypsin) or a newly generated mature 
N-terminus (cleaved only on C-terminal end by trypsin) (Carapito et al., 2017). For these 
ambiguous peptides, the Doublet N-terminal Oriented Proteomics (dN-TOP) approach is an 
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accurate strategy (Vaca Jacome et al., 2015). Briefly, the dN-TOP technique is based on the 
double labeling of free protein’s N-termini using simultaneous chemical labeling with light and 
heavy trimethoxyphenyl phosphonium (TMPP). It enables the characterization, in a single 
experiment, of both the free protein N-termini and all other internal peptides (Vaca Jacome et 
al., 2015). Thus, in collaboration with Christine Carapito (LSMBO/IPCC, Strasbourg), we used 
the dN-TOP technique to identify N-Termini MTS of mt-ArgRS. This technique was previously 
applied in the laboratory and allowed to determine the presence of two forms of the mt-AspRS 
within the mitochondria, produced by alternative cuts of MTS after importation (Carapito et 
al., 2017).  
2.1. Chemical N-Terminal labelling prior to mass 
spectrometry analysis reveal four possible processed forms 
of mt-ArgRS 
The preparation of sample provided to Carapitos’s team for the dN-TOP method was as 
follows. Mitochondria (~500 mg) were enriched from HEK293T cells (~8.6x108 cells from 
ten cell dishes of 150 mm) transfected with the pCI plasmid expressing the WT mt-ArgRS 
protein with a C-terminal His6-Tag. Over expression of the mt-ArgRS was performed so that to 
increase its abundance over the other mitochondrial proteins. Then, protein enrichment was 
done with resin Ni-NTA Agarose in a NaH2PO4/Na2HPO4 pH 7.5 buffer.  The dN-TOP strategy 
was applied on this enriched sample of mt-ArgRS, following the published experimental 
procedure (Vaca Jacome et al., 2015). Briefly, the samples were separated on a SDS-PAGE, 
the bands corresponding to the expected size were cut off and the contained proteins were in-
gel digested with trypsin. The resulting peptides were then subjected to MS analysis. Validation 
of detected TMPP peptides requires very strict criteria to be met: the light and heavy labeled 
forms of the potential N-terminal peptide must be identified using database searches, both 
peptides must to be perfectly coeluted and the peptide sequence must be unique in the searched 
database (Figure 10, adapted from (Vaca Jacome et al., 2015)). An important advantage of this 
method is that internal peptides are not removed, thus, contributing to the identification of 
proteins (Vaca Jacome et al., 2015). This strategy allowed the identification of four N-termini 
for the mt-ArgRS at positions Asn18, Ser27, Leu72, Ile127 (Figure 11). 
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Figure 10. Schematic representation of the principle of the Doublet N-terminal Oriented 
Proteomics (dN-TOP) strategy. TMPP stands for trimethoxyphenyl phosphonium (Figure adapted 
from (Vaca Jacome et al., 2015)) 
 
Several studies have been devoted to the understanding of the complex process carried 
out for the import and cleavage of proteins into the mitochondria (Chacinska et al., 2009; 
Mossmann et al., 2012; Neupert, 1997). Among the most described peptidases in charged of 
the maturation of the MTS are: the mitochondrial processing peptidase (MPP), mitochondrial 
intermediate peptidase (MIP), the inner membrane peptidase (IMP). For the MPP the cleavage 
site motif has been analysed in several precursor proteins of different species and was 
previously grouped into four different classes according to the position of an arginine relative 
to the mature N-terminus: R-2 motif (R-2X↓X), R-3 motif (R-3X(Y/F/L)↓(S/A/X)), R-10 motif 
(R-10X↓(F/L/I)XX(T/S/G)XXXX↓X) and the R-none motifs (XXX↓X(S/X)). IMP is 
constituted by two catalytic subunits Imp1 and Imp2, and non-overlapping substrate specificity 
has been showed. Whereas Imp1 recognizes hydrophobic residues at position −3 and an 
asparagine residue at position −1 relative to the cleavage site, the only known substrate of Imp2 
has a serine (−3) and alanine (−1) residue at the respective positions. MIP is a soluble 
monomeric metalloprotease in the mitochondrial matrix. In contrast to IMP, which can cleave 
presequences independent of MPP, MIP only recognizes and cleaves its substrate after initial 
processing by MPP. The recent identification of further substrates in yeast allowed the analysis 
of the cleavage site in more detail and confirmed predominantly arginine in −10, phenylalanine 
and leucine in position −8, and the abundance of serine and threonine which are distributed 
across positions −5, −6 and −7 of the presequence (Gordon et al., 2001; Mossmann et al., 2012; 
Neupert, 1997). However, it has been reported situations with the absence of motifs for the 
N-Termini cleavage (Gavel and von Heijne, 1990). This last R-none motif has been described 
in a small group of mitochondrial proteins without assignment of other peptidase, and their 
processing remaining unexplained (Gakh et al., 2002a). 
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When analyzing the mt-ArgRS sequence (Figure 11.B), we found that only N18 fits with 
a MPP R-3 motif (R15V16L17↓N18). For the position S27, if we consider that mutational analysis 
of the asparagine in position −1 showed that Imp1 tolerates a broad variety of structurally 
distinct residues at these positions (Chen et al., 1999), we can suppose a cleavage by the Imp 1 
corresponding to (L24I25T26↓S27). For the other two positions, we can hypothesized that they 
result from the relatively high degree of amino acid sequence degeneracy at MPP cleavage sites 
(Gakh et al., 2002a), thus limiting the level of confidence for the prediction.  
 
Figure 11. N-Termini variants of the mt-ArgRS. A) Schematic representation of the human 
mt-ArgRS with the positions of the four possible N-Ternimi as identified by dN-TOP experiments. B) 
N-terminal sequence of the human mt-ArgRS where the four possible N-terminal residues are 
highlighted in bold characters. 
 
The cleavage of the MTS of mitochondrial proteins was described for some of the 
mt-aaRSs. The dN-TOP approach was applied on total purified mitochondria analyzing in a 
systematic way all other members of the mt-aaRSs family were generated (Carapito et al., 
2017). The results obtained from the dN-TOP method for another mt-aaRS, the alanyl-tRNA 
synthetase, were also successful exploited for the production of a recombinant soluble version 
of this protein (Hilander et al., 2018). Thus, supporting the accuracy of the dN-TOP results 
determining the mt-aaRSs. 
In the case of the mt-AspRS, this same dN-TOP approach identified three chemically 
modified peptides, revealing three possible N-termini residues (Leu33, Ile41, Pro42). It has been 
proposed that the forms starting at Leu33 and Ile41 could be produced either in response to a R-
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10 motif (R31S32↓L33LQS37SQRR41↓I42), cleaved by MPP and MIP between residues Ser32 and 
Leu33, and residues Arg40 and Ile41, respectively; or in response to two R-2 motifs (R31S32↓L33 
and R40R41↓I42) independently cleaved by MPP at the same two positions. For the mt-AspRS 
Pro42 form, the hypothesis was a subsequent cleavage of the protein starting at Ile41 by the 
Aminopeptisase P (APP), for which a mitochondrial isoform (APP3 or XPNPEP3) has been 
described (Carapito et al., 2017). These results were consistent with previous in vitro import 
experiments that revealed different processed forms of mt-AspRS after importation into the 
mitochondria (Messmer et al., 2011). Corroborating this proposal of the co-existence of two 
forms of mt-AspRS, we frequently observed the presence of two specific bands with different 
sizes in western blots on mitochondrial samples. Unlike the mt-AspRS, only one band is 
observed by western blot for the in cellulo detection of the mt-ArgRS. 
Concerning the results for N-termini of the mt-ArgRS, even if they represent 
preliminary data, we decided to continue the experiments and start the expression and solubility 
test with the four N-Termini possibilities. One could consider the repetition of the dN-TOP 
method to attempt to increase the accuracy of the preliminary results. 
2.2. Cloning, expression and solubility test of different 
N-termini mt-ArgRS variants 
A second important objective is to produce the recombinant mt-ArgRS in bacterial 
strain so that to investigate its enzymatic properties by in vitro aminoacylation assays and 
eventually to test for the impact of pathology-related mutation on this property (see Chapter 3). 
Thus, four forms of the mt-ArgRS starting at each of the four potential N-termini identified 
above were cloned and expressed in E. coli. To do this, 5'-primers were designed so that to 
initiate the protein sequence at each of the identified N-termini (Asn18, Ser27, Leu72 and Ile127) 
and to introduce a start codon coding for methionine indispensable to translation initiation. In 
addition, 3'-primers were designed so that to introduce a His10-Tag at the C-terminus of the mt-
ArgRS. The resulting constructions, amplified from the template sequence (see below) were 
cloned into a pDEST14 plasmid. To facilitate the nomenclature, resulting recombinant proteins 
(with N-terminal Met and C-terminal His10-tag) are named mt-ArgRS-N18, mt-ArgRS-S27, 
mt-ArgRS-L72 and mt-ArgRS-I127 (for sake of simplicity, the three-letter code of amino acids 
has been replaced by the one-letter code). 
The template used to produce these constructions was an optimized sequence of the 
human mitochondrial RARS2 gene for expression in E. coli strain designed by Agnes Gaudry 
and purchased in Integrated DNA Technologies-IDT®. In this optimization, the codons of the 
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human sequence of the mt-ArgRS were replaced by synonymous codons with more frequent 
usage and reading in bacterial strain. To test the impact of these different N-Termini on the 
expression and solubility of mt-ArgRS, BL21 (DE3) E. coli strain were transformed with each 
of the constructions as described in section 2.6. Material and Methods. The site Mitoprot 
predicted Leu17 as the potential N-termini for mt-ArgRs (Claros, 1995). Thus, this construction 
(mt-ArgRS-L17) was also used in the expression/solubility tests. The IPTG was used to induce 
protein expression taking advantage of the lac operon present in the pDEST plasmid. In a first 
series of experiment, two conditions were compared: control (no IPTG) versus induction with 
IPTG. Cell extracts containing the expressed protein variants were disrupted through sonication 
and then centrifuged so that to separate soluble from insoluble proteins. Total extract (disrupted 
cells before centrifugation) and soluble extract (supernatant after centrifugation) were loaded 
and separated in a SDS-PAGE gel. Protein bands of the mt-ArgRS were detected by western 
blot using anti His-Tag antibody. The size of the bands corresponded each time to the theoretical 
molecular weights of the different variants: mt-ArgRS-L17 – 65.5kDa, mt-ArgRS-N18 – 
65.14kDa, mt-ArgRS-S27 – 64.15kDa, mt-ArgRS-L72 – 59.13kDa, mt-ArgRS-I127 – 52.95kDa.  
Expression and solubility were estimated taking into account the intensity of the bands 
by western blot detection. mt-ArgRS-L17 and mt-ArgRS-L72 both showed the best expression 
and solubility. A subtle difference was shown between the amounts of protein in the two 
conditions (with and without IPTG), with a tiny increase of the intensity of the band detection 
in the fraction with IPTG (Figure 12). This indicates that the presence of the lac operon in the 
pDEST14 plasmid positively increased the protein expression. Regarding mt-ArgRS-N18 and 
mt-ArgRS-S27, the amounts of protein produced were remarkably low when compared to 
mt-ArgRS-L17 and mt-ArgRS-L72. For mt-ArgRS-N18 and mt-ArgRS-S27, a slight increase in 
quantity was shown when IPTG was used. Concerning mt-ArgRS-I127, protein was detected in 
the same way in the total extract with and without IPTG.  However, no bands were detected in 
the soluble extract, indicating that this variant is lost during the centrifugation step. This could 
be due to instability of the protein, or to its degradation. 
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Figure 12. Influence of N-terminal sequence on expression and solubility of recombinant mt-
AspRS variants. mt-ArgRS-L17, mt-ArgRS-N18, mt-ArgRS-S27, mt-ArgRS-L72 and mt-ArgRS-I127 
starting at residues L17, N18, S27, L72 and I127, respectively, were expressed in BL21 DE3. Cell 
extracts and soluble fractions were loaded and separated onto a 10% SDS-PAGE gel and the mt-ArgRS 
was detected by Western Blot analysis using anti-His antibody. The expected size of the mt-ArgRS 
variants is L17~65.5kDa, N18~65.14kDa, S27~64.15kDa, L72~59.13kDa, I127~52.95kDa. ø: no IPTG 
was used, IPTG: induction was done with IPTG 250 µM 
 
Based on these results, the variant mt-ArgRS-L72 was chosen for the investigation of 
the impact of individual mutations on the aminoacylation activity of the mt-ArgRS (see Chapter 
III), because of its good expression and solubility. 
3. Intramitochondrial localization of the human mt-ArgRS 
Earlier studies from the laboratory have suggested that mt-aaRSs may have different 
sub-mitochondrial localizations, some of them getting located in both soluble (matrix or 
intramembrane space) and membrane associated, and others being exclusively found in one of 
the two mitochondrial fractions. Nevertheless, those were preliminary results that needed to be 
validated. Later on, a former phD student, Loukmane Karim, improved and established a 
mitochondrial fractionation protocol, validating the data concerning the double localization of 
the mt-AspRS. He clearly showed that the mt-AspRS is located both in the soluble and the 
membrane fractions of the mitochondria. In the present work, the objective was focused on the 
mt-ArgRS. The same mitochondrial fractionation approach was applied, however the results 
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obtained were different. The article #2 include the results and discussions of this study, as well 
as the determination of the mode of anchorage of those proteins to the mitochondrial membrane.  
Additionally to the results presented in the article, further data concerning the location 
of mt-ArgRS and mt-AspRS in other cell lines are included and discussed below. 
3.1. The mt-ArgRS is located exclusively in the membrane 
fraction of the mitochondria 
Mitochondria from Human Embryonic Kidney cells (HEK293T) were enriched and 
fractionated into soluble fraction (S in Figure 13) containing molecules from the matrix and 
intermembrane space, and membrane fraction (M in Figure 13) containing molecules from the 
outer and the inner membranes. Different proteins of known intramitochondrial location were 
previously used by Loukmane Karim to assess the quality of the fractionation process (see 
details in article #2, Figure 1B). Prohibitin and SOD2 were systematically detected and 
analyzed in all experiments as controls of the soluble and membrane fractions, respectively. 
A typical experiment focused on the mt-ArgRS is shown in Figure 13. It reveals the 
presence of the human mt-ArgRS in solely the membrane fraction. This observation was 
constant in each mitochondrial fractionation experiment performed with HEK293T cell line. 
For this experiment, the detection by western blot of mt-AspRS was also routinely performed, 
and the identification of this protein was each time in both fractions of the mitochondria (soluble 
and membrane) according to the previous data highlighted by Loukmane Karim. 
 
 
 
 
Figure 13. Intramitochondrial localization of 
mt-ArgRS in cellulo. Mitochondria were purified 
from HEK293T cell line and fractionated into 
soluble (matrix and intermembrane space) and 
membrane (outer and inner membranes) fractions. 
Endogenous mt-ArgRS, mt-AspRS, prohibitin 
and SOD were detected with specific antibody. S, 
soluble fraction. M, membrane fraction. 
 
 
 
Regarding mt-ArgRS and its exclusive presence in mitochondrial membrane, no trans-
membrane domain was predicted based on the sequence of the protein using TMHMM Server, 
http://www.cbs.dtu.dk/services/TMHMM-2.0/. Other aaRSs have been reported to relocate into 
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a membrane under certain conditions. This relocation occurs in some cases to regulate the 
translation in a positive or negative way, or to allow the protein to perform another function 
alternative to translation. Early on, the MetRS was found to be associated with detergent-
insoluble components of the rough endoplasmic reticulum in cultured vertebrate cells (Dang et 
al., 1983). In this case, the mode of membrane association remained unknown, as well as the 
functional significance of the ER-association for the aaRS. It has been suggested, however, that 
this localization brought the aaRSs close to ribosomes, which may provide a high local 
concentration of aaRS for maximal efficiency of protein biosynthesis (Dang et al., 1983). The 
human cytosolic LysRS, naturally anchored to the cytosolic MSC, was shown to be relocated 
to the plasma membrane upon laminin-dependent phosphorylation at residue Thr52. Once in 
the plasma membrane, the LysRS associates with and stabilizes other membrane proteins such 
as p67LR and integrin α6, resulting in an increased cellular migration and invasion and in a 
possible implication in the tumorigenesis (Kim et al., 2012). The authors suggest that the 
recruitment of a key translational component to regulate cell migration is justified by the fact 
that it may reduce the level of operational translation machinery (Young et al., 2016). A similar 
postulate of negatively controlled protein synthesis has been proposed for the E. coli LeuRS. 
The enzyme is naturally soluble in the cytoplasm, but sequestered to the cytoplasmic membrane 
during metabolic stress or growth restriction caused by e.g. low levels of leucine (Williamson, 
1993). Conversely, in human, the translocation of LeuRS into the lysosome membrane is 
induced by leucine addition. In this situation, LeuRS acts as an intracellular leucine sensor and 
activates the mTOR-signaling pathway, which regulates translation, cell size and autophagy 
(Choi et al., 2017; Han et al., 2012). 
Strikingly, four aaRSs were shown to be anchored to the thylakoid membrane through 
an additional protein domain named CAAD (for Cyanobacterial Aminoacyl-tRNA synthetases 
Appended Domain) (Olmedo-Verd et al., 2011). The membrane-anchored ValRS was further 
shown to directly interact with the ATP-synthase, connecting elements from gene translation 
and energy production machineries (Santamaria-Gomez et al., 2016). This is the only 
description, so far, of an aaRS constitutively anchored to the membrane, and not responding to 
a stimuli, as it is the case for the human mt-ArgRS. This form of constitutive presence in the 
mitochondrial membrane displayed by the mt-ValRS and the mt-ArgRS, lets us speculate that 
probably the mt-ArgRS may in some way be involved in some alternative function of the 
mitochondria as well, other than translation. 
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3.2. Sub-mitochondrial localization of mt-aaRSs in other 
cell models 
After having validated that mt-ArgRS and mt-AspRS are present at different 
intramitochondrial locations using HEK293T as a cellular model, we extended the study to 
other cell lines.  
In collaboration with Dr. Etienne LEFAI (CarMeN Laboratory, Lyon-France), 
mitochondrial fractionation protocol was performed on mitochondria extracted from human 
myotubes, from HepG2 and from Huh7 cell lines. Human myotubes were isolated from muscle 
biopsies of patients without comorbidities. Lefai’s team performed the isolation and 
differentiation of the human primary muscle cells following a protocol published by Chanon et 
al. (Chanon et al., 2017). HepG2 and Huh7 are both immortalized cell lines from hepatocellular 
carcinoma. Mitochondrial activities were shown to vary in the different tissues. For instance, 
there is a high-energy demand in terms of ATP in muscles and the metabolic pathways as The 
Krebs cycle, and fatty acid oxidation are extremely important in the liver (Barclay, 2017; Rui, 
2014). It is then of particular interest to investigate the intra-mitochondrial locations of the mt-
AspRS and the mt-ArgRS in those tissues. The results, represented in figure 14, show that the 
location pattern of both enzymes is the same as the one established in HEK293 cells: the 
mt-ArgRS is exclusively located in the membrane fraction, and the mt-AspRS is double 
localized both in the soluble and the membrane fraction. 
Figure 14. Intramitochondrial localization of mt-ArgRS in selected human cells. Mitochondria 
were purified from myotubes, Hep G2 and Huh7 cells and fractionated into soluble (matrix and 
intermembrane space) and membrane (outer and inner membranes) fractions. Endogenous mt-ArgRS, 
mt-AspRS, prohibitin and SOD2 were detected with specific antibodies. S, soluble fraction. M, 
membrane fraction. 
Since the pathologies correlated with mutations in mt-ArgRS and mt-AspRS lead to 
disorders in the central nervous system, the next step was to investigate the location of these 
enzymes in a cellular model that simulate more closely the neurophysiologic environment. In 
order to do this, human neuroblastome cell line, SH-SY5Y, were used in two stages, 
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undifferentiated and differentiated. First, fractionation of enriched mitochondria from 
undifferentiated SH-SY5Y was performed. At this stage, the profile was again: in the membrane 
fraction for the mt-ArgRS and in both the membrane and soluble fraction for the mt-AspRS 
(Figure 15). Then, Florian Pierre (Engineer in the host laboratory) initiated in the laboratory 
the in vivo differentiation of the SH-SY5Y cells to neurons. This process of differentiation 
requires optimizations that are still being carried out. It consists of sequential changes of culture 
medium during defined timelines. These changes include different concentrations of main 
components in the serum as: the quantity of proteins containing in the serum, the introduction 
of hormonal and neurotrophic factors, among others (Shipley et al., 2016). This allows the 
selection of the phenotype of neuronal cells against epithelial cells, resulting in homogeneous 
populations of neuronal cultures. To validate the neuronal differentiation, an antibody against 
the microtubule associated protein 2 (Map2 antibody, Sigma-Aldrich®) was used. The 
preliminary results so far obtained for differentiated SH-SY5Y maintain the same profile, 
exclusive localization of the mt-ArgRS in the membrane fraction of the mitochondria and in 
the membrane and soluble fraction for the mt-AspRS (Figure 15). 
 
 
 
Figure 15. Intramitochondrial 
localization of mt-ArgRS in 
undifferentiated and differentiated 
SH-SY5Y. Mitochondria were purified 
from SH-SY5Y in two stages: 
undifferentiated and differentiated into 
neurons (as shown in the insets). They 
were fractionated into soluble (matrix 
and intermembrane space) and 
membrane (outer and inner membranes) 
fractions. Endogenous mt-ArgRS, mt-
AspRS prohibitin and SOD2 were 
detected with specific antibodies. S, 
soluble fraction. M, membrane fraction. 
 
 
The different pattern of location of mt-ArgRS and mt-AspRS maintained in both 
undifferentiated and differentiated conditions. Thus, suggesting that this cellular peculiarity is 
more ubiquitous than associated with a specific cell type. 
 
4. Diverse types of mt-aaRS interactions with the mitochondrial 
membrane 
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Distinct modes of membrane anchorage exist and they are schematically recalled in 
figure 16. A protein can either be ‘integral’ and permanently attached to the membrane via a 
transmembrane domain or hydrophobic region(s); or be ‘peripheral’ and temporarily adhered 
to the membrane through either electrostatic or ionic interactions (via another protein or via 
membrane lipids), disulfide bond interactions, or a covalently-bound lipid anchor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 (adapted from Figure 2A of the article #2). Schematic representation of the different 
modes of protein interaction with membranes. 
 
A selection of disrupting chemical agents reported to produce type-specific release of 
membrane-bound proteins was used at the moment of sonication of the enriched mitochondria, 
prior the fractionation process. Those were 8M Urea (Singh and Panda, 2005), 0.5M KCl 
(Arnoult et al., 2009; Rajala et al., 2014), 0.1M Na2CO3 pH11 (Fujiki et al., 1982; Herlan et 
al., 2003; Kim et al., 2015), 0.4M DTT (Winger et al., 2007), 1M NH2OH pH 7 or 1M NH2OH 
pH 11 (Cockle et al.; E.N. et al., 1985; Okubo et al., 1991) Previous work by Loukmane Karim 
established that human mt-AspRS is a peripheral proteins interacting with membrane via 
electrostatic interactions. 
The fact that the mt-ArgRS is located exclusively in the membrane fraction made 
essential the characterization of the type of anchoring to the membrane. The same protocol was 
performed to study the mt-ArgRS. As shown in figure 17.A, solely urea allowed the completely 
release of mt-ArgRS from the mitochondria membrane. SOD2 and Prohibitin are systematically 
detected/analyzed as control experiments from the matrix and the membrane fractions, 
respectively. While SOD2 remains soluble whatever is the applied chemicals, prohibitin was 
detected in the soluble fractions upon urea, carbonate pH 11 and hydroxylamine pH 11 
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treatments. Carbonate treatment (pH 11) was reported to lead to the release of some integral 
proteins with mode of anchorage weaker than complete transmembrane domain (Fujiki et al., 
1982; Herlan et al., 2003; Kim et al., 2015). 
We further studied the impact of urea over the membrane location of the mt-ArgRS to 
determine which concentration of urea was able to release the protein from the membrane 
fraction (Figure XX.B). In order to do this, different concentrations of urea were used: 1M, 2M, 
4M and 8M. The detection of the mt-AspRS was performed to compare the effect of urea on 
these two enzymes. We can appreciate in figure 17.B that the responses of mt-ArgRS and 
mt-AspRS to urea were different. For the mt-ArgRS, 8M of urea were required to completely 
release the protein from the membrane fraction, as it has been reported for the solubilization of 
integral proteins (Devraj et al., 2009). In contrast, lower urea concentrations produce an effect 
on mt-AspRS location.  
Figure 17. Diverse interaction 
modes of mt-ArgRS and 
mt-AspRS with the 
mitochondrial membrane. The 
sensitivity of mt-ArgRS and mt-
AspRS membrane anchoring to 
chemical disrupting agents (A.) 
and to urea concentration (B.) was 
deciphered by investigating the 
release of proteins from the 
membrane to the soluble fractions. 
For each experiment, 
mitochondria were enriched from 
HEK293T cells. Chemical 
disrupting agents, used at 
indicated concentrations, were 
applied during the sonication of 
the enriched mitochondria, prior 
to the fractionation. mt-ArgRS, 
mt-AspRS, prohibitin and SOD2 
were detected by Western blot 
analysis with specific antibodies. 
S, soluble fraction. M, membrane 
fraction. 
Altogether, our results showed that membrane-anchored fractions of mt-AspRS and mt-
ArgRS respond to different chemistry, indicating that the mode of anchorage is distinct: salt 
sensitive for mt-AspRS, indicative of an electrostatic-mode of anchorage; urea-sensitive for mt-
ArgRS, indicative of an hydrophobic mode of anchorage for mt-ArgRS. These results, as well 
as the methodology applied for the study of the type of interaction between the aaRSs and the 
mitochondrial membrane are also published and discussed in article #2. 
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5. Conclusion and perspectives 
Mitochondrial aaRSs are synthesized in the cytosol, and subsequently translocated 
across the mitochondrial membranes. For most of the proteins addressed to the mitochondria, 
this is performed thanks to the presence of a N-terminal MTS, which has to be cleaved upon 
entry into the organelle for the release of a properly folded and functional protein. The results 
we obtained in the present work allow us to enlarge the view of the mt-aaRSs in different topics: 
the study of the N-Termini for the mt-ArgRS, the search of the best recombinant and soluble 
form for the bacterial expression of the mt-ArgRS, the intramitochondrial localization of the 
mt-ArgRS and its mode of anchorage to the mitochondrial membrane. 
Regarding the study of the N-termini, the objective of finding a recombinant and soluble 
version of the mt-ArgRS was attained. When comparing the expression and the solubility of 
the four tested recombinant variants of the mt-ArgRS, mt-Arg-L72 appeared to be the best one. 
It will allow the investigation of the impact of selected PCH6-mutations on the aminoacylation 
function of the mt-ArgRS (See Chapter III). 
Former PhD students from the host laboratory initiated the investigation of the intra-
mitochondrial localization of some mt-aaRSs. Loukmane Karim demonstrated that the mt-
AspRS is dual localized, present both in the soluble and in the membrane fractions. He further 
showed that the mt-AspRS is anchored to the membrane via electrostatic types of interactions. 
Here we extend this analyses and I could demonstrate that the mt-ArgRS its exclusively present 
in the mitochondrial membrane. Chemical treatments further revealed that the enzyme is 
anchored to the membrane via hydrophobic interactions. Altogether, these results demonstrated 
that the two mt-aaRSs compared here have unique and distinct characteristics regarding their 
intra-mitochondrial localizations. This encourages us for the characterization of the additional 
mt-aaRSs. These experiments are currently under way, performed by Florian Pierre and master 
students hosted by our laboratory. The analysis of the sub-mitochondrial localization of the mt-
LeuRS and the LysRS after fractionation of the mitochondria revealed an additional situation 
since these two enzymes are exclusively detected in the soluble fraction of the mitochondria 
(Figure 18).  
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Figure 18. Intramitochondrial localizations 
of selected mt-aaRSs in human cell lines. 
Mitochondria were purified from HEK293T cell 
line and fractionated into soluble (matrix and 
intermembrane space) and membrane (outer and 
inner membranes) fractions. Endogenous 
mt-LeuRS – 102 kDa, LysRS – 74 kDa, 
mt-ArgRS – 66 kDa and mt-AspRS – 73 kDa 
were detected by Western blot analysis with 
specific antibodies. S, soluble fraction. M, 
membrane fraction. 
 
 
 
Previous investigations show that some of the key actors for mitochondrial translation 
machinery are located at the vicinity of the inner membrane, likely to allow for the direct 
incorporation of hydrophobic proteins into the membrane (reviewed in e.g. Ott and Hermman 
BBA 2010 (Ott and Herrmann, 2010)). This is for instance the case for the mito-ribosome, 
tethered to the matrix side of the mitochondrial inner membrane (Liu and Spremulli, 2000) via 
a protuberant domain (the mitochondrial ribosomal protein L45, MRPL45; (Greber et al., 
2015)) and for the mitochondrial elongation factor Tu, associated with the inner mitochondrial 
membrane, independently of the mito-ribosome, via a combination of ionic and hydrophobic 
(Bogenhagen et al., 2014; Suzuki et al., 2007). One could imagine that the direct or indirect 
association of the mt-aaRSs to the mitochondrial membrane should be required to perform 
translation. However, the data reveled by this work puts aside this idea. The analysis of these 
four mt-aaRSs shows that the situation is more complex than it appears. The establishment of 
variable sub-mitochondrial locations for these four mt-aaRSs strongly suggests the existence of 
additional enzyme properties that will require further investigations to be identified. 
Additionally, much remains to be done to clarify how is the interaction/assembly of all the 
components in the mitochondrial translation. In organello translation and co-
immunoprecipitation may shed light on the possible functional associations among the 
components of the mitochondrial translation, especially within the set of mt-aaRSs and the rest 
of the members of the mitochondrial translation machinery.  
The knowledge of the intramitochondrial organization clearly provides an invaluable 
knowledge about these enzymes. However, much remains to be done to be able to understand 
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the relationship between the synthetases and the pathologies produced. Therefore, the next 
chapter will be focused to the study of the impact of pathological mutations on i) the in cellulo 
intramitochondrial localization for the mt-AspRS and mt-ArgRS and ii) the in vitro analysis of 
enzymatic function of the mt-ArgRS. 
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Human mitochondrial aminoacyl-tRNA synthetases (mt-
aaRSs) are key enzymes in themitochondrial protein translation
systemandcatalyze the chargingof amino acids on their cognate
tRNAs. Mutations in their nuclear genes are associated with
pathologies having a broad spectrum of clinical phenotypes, but
with no clear molecular mechanism(s). For example, mutations
in the nuclear genes encodingmt-AspRS andmt-ArgRS are cor-
related with themoderate neurodegenerative disorder leukoen-
cephalopathy with brainstem and spinal cord involvement and
lactate elevation (LBSL) and with the severe neurodevelopmen-
tal disorder pontocerebellar hypoplasia type 6 (PCH6), respec-
tively. Previous studies have shown no or only minor impacts of
these mutations on the canonical properties of these enzymes,
indicating that the role of the mt-aaRSs in protein synthesis is
mostly not affected by these mutations, but their effects on the
mitochondrial localizations of aaRSs remain unclear. Here, we
demonstrate that three human aaRSs, mt-AspRS, mt-ArgRS,
and LysRS, each have a specific sub-mitochondrial distribution,
with mt-ArgRS being exclusively localized in the membrane,
LysRS exclusively in the soluble fraction, and mt-AspRS being
present in both. Chemical treatments revealed that mt-AspRs is
anchored in themitochondrial membrane through electrostatic
interactions, whereas mt-ArgRS uses hydrophobic interactions.
Wealso report that novelmutations inmt-AspRSandmt-ArgRS
genes from individuals with LBSL and PCH6, respectively, had
no significant impact on the mitochondrial localizations of mt-
AspRS and mt-ArgRS. The variable sub-mitochondrial loca-
tions for these three mt-aaRSs strongly suggest the existence of
additional enzyme properties, requiring further investigation to
unravel the mechanisms underlying the two neurodegenerative
disorders.
Mitochondria are double-membrane organelles with essen-
tial activities in cellular energy production as well as in a num-
ber of pathways linked to cellular life, disease, aging, and death.
They possess their own genome and an independent transla-
tion machinery devoted in human to the synthesis of 13 pro-
teins. The latter are hydrophobic subunits of the respiratory
chain complexes embedded in the mitochondrial inner mem-
brane (1). The human mitochondrial translation machinery is
of dual genetic origin where RNA constituents are encoded by
the mitochondrial genome (mt-DNA) and the protein constit-
uents are encoded by the nuclear genome. Previous investiga-
tions show that some of the key actors for mitochondrial trans-
lation machinery are located at the vicinity of the inner
membrane, likely to allow for the direct incorporation of hydro-
phobic proteins into themembrane (reviewed in Ref. 2). This is
for instance the case for the mitoribosome, tethered to the
matrix side of the mitochondrial inner membrane (3) via a pro-
tuberant domain (the mitochondrial ribosomal protein L45,
MRPL45) (4, 5) and for themitochondrial elongation factor Tu,
associated with the inner mitochondrial membrane, indepen-
dently of the mitoribosome, via a combination of ionic and
hydrophobic interactions (6).
Among the proteins involved in mt-DNA expression the
aminoacyl-tRNA synthetases (aaRSs)5 play a crucial role in
mitochondrial protein translation by charging tRNAswith cog-
nate amino acids. In human there is a specific set of aaRSs for
mitochondrial localization (mt-aaRSs) distinct from the one for
cytosolic localization (with the exceptions of LysRSs and
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GlyRSs, where cytosolic and mitochondrial versions are
encoded by single genes (7)). As for all proteins participating in
the mitochondrial translation, the mt-aaRSs are encoded by
the nuclear genome and are synthesized within the cytosol,
addressed to, and imported into, the mitochondria thanks to
mitochondrial targeting sequences (MTS). MTS are cleaved
upon entry into themitochondria (8). Although themacromol-
ecules involved in mammalian mitochondrial translation have
been under investigation for many years, there is an increasing
interest for the investigation of the human mt-aaRSs since the
discovery of a large and growing number of mutations in the
encoding genes that are linked to a variety of pathologies
(reviewed in Refs. 9–11). Despite being ubiquitously expressed
and having a common role in the mitochondrial translation
process, mt-aaRSs are impacted in various ways. Their muta-
tions cause an unexpected variety of phenotypic expressions,
including mainly neurological disorders but also non-neuro-
logical issues. Today, the number of reported cases is steadily
growing (12), but the way mutations affect mt-aaRSs in their
structure and/or function remains to be elucidated. The fact
that comparable mutations in mt-aaRSs lead to diverse dis-
eases, with different ages of onset, and within different tissues
represents a confounding issue.
The most prominent case of disease-related mt-aaRS gene
concernsDARS2, the gene coding for the mitochondrial aspar-
tyl-tRNA synthetase (mt-AspRS). Presently, more than 60 dif-
ferent clinically relevant mutations have been identified and
associated with leukoencephalopathy with brainstem and spi-
nal cord involvement and lactate elevation (LBSL) (12, 13).
LBSL is a progressive neurodegenerative disorder that affects
the brain white matter, and leads mostly to abnormal muscle
stiffness and difficulties with coordinating movements. Most
affected patients eventually require wheelchair assistance (14).
Mutations within RARS2, the gene coding for the mitochon-
drial arginyl-tRNA synthetase (mt-ArgRS), are correlated with
pontocerebellar hypoplasia type 6 (PCH6) (15). Symptoms such
as severe impairment of brain development, hypotonia, leth-
argy, poor sucking and/or recurrent apnea appear on the first
days after birth. For infants surviving beyond the newborn
period, the growth of the head is arrested and progressive
microcephaly is observed (16). Up to date, only 22 cases of
PCH6 are reported and most of the patients are presently
deceased. Investigations performed so far showed no or vari-
able impacts on the canonical properties of the enzymes, indi-
cating that the housekeeping role of the mt-aaRS in the protein
synthesis is not the general target of the mutations (17–19).
Here, we investigate the cellular properties of human mt-
AspRS andmt-ArgRS, and establish that the two enzymes have
different mitochondrial localizations, despite their involve-
ment in the same mitochondrial translation process. In addi-
tion, we report new LBSL and PCH6 patients, compound
heterozygous for two mutations in DARS2 and RARS2, respec-
tively. We investigate the impact of a series of disease-associ-
ated mutations, affecting the mt-AspRS and mt-ArgRS, on
newly established cellular properties. Combined with previous
work, the present results open new perspectives, which may
shed new light on the links between mutations and the related
diseases.
Results
Mitochondrial aminoacyl-tRNA synthetases have different
intra-mitochondrial localizations
To establish the sub-mitochondrial localization of mt-AspRS,
mt-ArgRS, and LysRS, mitochondria from human embryonic
kidney cells (HEK293T) were enriched and fractionated into a
soluble fraction (S in Fig. 1A) containing molecules from the
matrix and intermembrane space, and membrane fraction (M
in Fig. 1A) containing molecules from the outer and the inner
membranes.Western blots using antibodies against proteins of
known sub-mitochondrial localization were used to assess the
quality of the fractionation process. The superoxide dismu-
tase 2 (SOD2) (20) is a marker for soluble matrix proteins.
The voltage-dependent anion selective channel protein 1
(VDAC1) (21, 22) and prohibitin (23) are integral proteins,
anchored to the outer and inner membranes, respectively. The
mammalian mt ribosome (3), cytochrome c (Cyt c) (24), crea-
tine kinase (CKMT1A) (25), and heat shock protein 60 (Hsp60)
(26, 27) are reported to be dual localized in the soluble and
membranes fractions as peripheral proteins. All marker pro-
teins were detected in agreement with the literature (Fig. 1B),
attesting for the quality of the fractionation protocol and the
absence of cross-contamination.
The intra-mitochondrial localizations of mt-AspRS, mt-
ArgRS, and LysRS were established using specific antibodies.
This experiment reveals that the mt-AspRS is distributed in
both the soluble and membrane fractions, whereas the mt-
ArgRS is exclusively found in the membrane fraction and the
LysRS is exclusively found in the soluble fraction (Fig. 1B).
Identical results, showing different intra-mitochondrial
localizations for two of the mt-aaRSs, is observed using anti-
FLAG antibodies on BHK21 cells expressing FLAG-tagged
mt-AspRS or on HEK293T cells expressing FLAG-tagged
mt-ArgRS (Fig. 1C).
Mitochondrial aspartyl-tRNA synthetase and arginyl-tRNA
synthetase have differentmodes ofmembrane anchoring
A protein can either be “integral” and permanently attached
to themembrane via a transmembrane domain or hydrophobic
region(s); or be “peripheral” and loosely adhered to the mem-
brane through either electrostatic or ionic interactions (via
another protein or membrane lipids), disulfide bond interac-
tions, or a covalently bound lipid anchor. A series of disrupting
chemical agents have been reported to produce type-specific
release of membrane-bound proteins. Examples of chemicals
and their specificity of action are provided in Fig. 2A. A selec-
tion of these disrupting chemical agents (8 M urea (28), 0.5 M
KCl (26, 29), 0.1 M Na2CO3 pH 11 (30–32), 0.4 M DTT (33), 1 M
NH2OH, pH 7, or 1 M NH2OH, pH 11) (34–36) was applied on
isolated and enriched mitochondria, prior to the fractionation
process. As shown in Fig. 2B, all conditions except 0.4 M DTT
led to the release of mt-AspRS from themembrane fraction. Of
note, in the latter experiment, the portion of mt-AspRS in the
soluble fraction is either relocated within the membrane frac-
tion, or lost during the experimental treatment. Conversely,
solely urea and carbonate treatments allowed either the total or
the partial release of mt-ArgRS, respectively, which remained
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otherwise anchored to the mitochondrial membrane. SOD2
and prohibitin are detected/analyzed as control experiments
from the matrix and the membrane fractions, respectively.
Although SOD2 remains soluble whatever is the applied chem-
ical, prohibitin was detected in the soluble fractions upon urea,
carbonate, pH 11, and hydroxylamine, pH 11, treatments.
Carbonate treatment, pH 11, was reported to lead to the
release of some integral proteins with mode of anchoring
weaker than the complete transmembrane domain (30–32).
Altogether, these results showed that membrane-anchored
fractions of mt-AspRS and mt-ArgRS respond to different
chemistry, indicating that the mode of anchoring is distinct:
salt sensitive for mt-AspRS, indicative of an electrostratic
mode of anchoring; salt-resistant but urea-sensitive for mt-
ArgRS, indicative of a hydrophobic mode of anchoring for
mt-ArgRS.
Figure 1. Sub-mitochondrial localizations of mt-AspRS, mt-ArgRS, and LysRS. A, flow chart of the experimental procedure. Cells are either unmodified
HEK293T (for results shown in B), or transfected and infected BHK21 for FLAG-tagged mt-AspRS (following the protocol published in Ref. 19) and transfected
HEK293T for FLAG-taggedmt-ArgRS (for results shown in C). B, the purity of the soluble andmembrane fractions was assessed byWestern blotting detection
of mitochondrial marker proteins of known sub-mitochondrial localization: outer membrane (VDAC1), inter-membranes space (Cyt c and CKMT1A), inner
membrane (prohibitin), andmatrix (SOD2,MRPL18 andHsp60). Mt-AspRS,mt-ArgRS, and LysRSwere detected using specific antibodies. C, sub-mitochondrial
localizations of FLAG-tagged mt-AspRS or mt-ArgRS detected by Western blotting using an antibody against the FLAG tag. R, residual fraction; T, total
mitochondria; S, soluble fraction;M, membrane fraction.
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Figure 2. Differentmodes ofmembrane anchoring ofmt-AspRS andmt-ArgRS. A, schematic representation of the differentmodes of proteinmembrane
anchoring or binding. Some chemicals reported to be used for the release of anchored protein are indicated on the scheme, those indicated in red have been
applied in the present study (for references, see text). B,Western blot analysis (using antibodies targeted against mt-ArgRS, mt-AspRS, prohibitin, or SOD2) of
the soluble and membranes fractions after treatment as indicated on the top.
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Impact of disease-associatedmutations onmt-AspRS and
mt-ArgRS intra-mitochondrial distributions
The impact of LBSL-related mutations on the solubility of
the humanmt-AspRS was investigated in a previous study (19).
To do so, WT and mutant versions of the mt-AspRS were
expressed in modified vaccinia Ankara-infected BHK 21 cells
(37). Mt-AspRS being a dimeric enzyme (7) and, as demon-
strated here, being dual localized, the choice was made to ana-
lyze further mutant mt-AspRSs in the same heterologous
expression system. A possible impact of disease-related muta-
tions on themt-AspRS dual localizationwill thus bemore easily
detectable because none of the used antibodies (against either
the C-terminal FLAG tag or a peptide specific to the human
mt-AspRS) will detect the endogenous hamstermt-AspRS.Mt-
ArgRS being a monomeric enzyme and located exclusively in
the membrane fraction, any impact on the localization, if
observed, would necessarily arise from the disease-related
mutation. The choice was thus to expressWT and mutant ver-
sions of the mt-ArgRS in HEK293T cells (which contains
endogenousWTmt-ArgRS). Experiments shown in Fig. 1 con-
firm that the distribution of both mt-AspRS and mt-ArgRS is
conserved in the two types of cultured cells, indicating that the
two model systems are appropriate for further investigations.
The effects of eight LBSL-related and 12 PCH6-related
mutations, identified in patients inDARS2 and RARS2, respec-
tively, were investigated regarding their possible impacts on the
sub-mitochondrial localization of the corresponding enzyme.
WT and mutants mt-AspRS and mt-ArgRS were individually
expressed in cellular models and their distributions between
soluble (S), membranes (M), and residual (R) fractions were
determined by Western blotting. All experiments were
repeated three times and the percentage of each fraction was
calculated, assuming that S  M  R  100% of the total
expressed protein. Representative Western blots are given in
Fig. 3A and histograms corresponding to the relative distribu-
tion of mt-AspRS variants are given in Fig. S1. None of the
PCH6-related mutations alter the expression (Fig. S2) and the
membrane-anchored localization (Fig. 3A) of the mt-ArgRS. A
statistically significant (p values  0.05) reduction in the solu-
ble fraction was observed for Q184K6 and R263Q mutants of
mt-AspRS (Fig. 3A, Fig. S1). Evenwith variations, no significant
effect was noticed in the membranes fractions of mt-AspRS
mutants. The residual fraction of theQ184Kmutant was signif-
icantly increased compared with WT mt-AspRS (p value 
0.05), consistent with the lower solubility already observed for
this variant (19).
Fibroblasts derived either from the LBSL patient (p.R76SfsX5/
p.G338E), from the PCH6 patient (p.T100Cfs*5/p.A10V) (see
“Experimental Procedures” for cases reports), or from a healthy
control were fractionated following the same procedure. Of
note, due to the lower abundance ofmitochondria in skin fibro-
blasts as compared with immortalized HEK or BHK cells, a
number 10-fold greater of cells was necessary (2 107 fibro-
blast cells as comparedwith2 106 required forHEKorBHK
cells per experiment). No difference of growth between healthy
and LBSL- or PCH6-derived fibroblasts was noticed. Detec-
tions of either the endogenous mt-AspRS or the endogenous
mt-ArgRS within the two patient-derived cell lines show distri-
butions strictly comparable with the ones within fibroblasts
from healthy control (Fig. 3B).
Discussion
aaRSs are housekeeping enzymes that catalyze the aminoacy-
lation of cognate isoaccepting tRNAs, at least as the main rec-
ognized function. The human cytosolic aaRSs have been exten-
sively investigated and the organization of nine of them within
a macromolecular complex was established (e.g. Refs. 38 and
39). Alternative cellular and/or extracellular activities linked to
metabolism, angiogenesis, immune response, inflammation,
tumorigenesis, or neuronal development, among other func-
tions, have also been reported (38, 40–42). In contrast, the
knowledge regarding cellular organization of mt-aaRSs and
possible alternative function(s) remains scarce. It is only
recently that a pro-angiogenic function of the rat mt-TrpRS
(43) and a cysteine polysulfidation activity of the mice and the
human mt-CysRSs (44) have been identified.
In the present study, we establish the sub-mitochondrial
localization of three mt-aaRSs and demonstrate that regardless
of their common role in the aminoacylation of cognate tRNAs,
they have different distributions. The applied fractionation
protocol separates soluble proteins from the intermembrane
space or the matrix (soluble fraction) from those anchored to
the inner or the outer membranes (membrane fraction). We
show that the mt-ArgRS is exclusively localized in the mem-
brane, the LysRS is exclusively in the soluble fraction, and the
mt-AspRS is dual localized, being present in both soluble and
membrane fractions.Multiple localizations have been observed
at several instances for mitochondrial proteins. Few reports
have in addition established a link between multiple localiza-
tions and multiple functions or modulated activities of the cor-
responding protein (e.g. Refs. 29, 45, and 46). Previously, we
showed that the humanmt-AspRS is processed aftermitochon-
drial importation into three different products of maturation
fromwhich two co-exist in themitochondria (8). This observa-
tion open new perspectives in the biological understanding of
the mt-AspRS and is considered in line with the discovery of
twomature forms of themt-ribosomal protein of the large sub-
unit MRPL12, generated by a similar multiple steps cleavage
process during import and demonstrated to display distinct
functions (47). The question now is whether there is a correla-
tion between the two mature forms of mt-AspRS, the two sub-
mitochondrial localizations described in the present study, and
the possibility of this enzyme to have distinct functions ormod-
ulated activities.
We further demonstrate that the mode of membrane-an-
choring is different between the membrane fractions of the
mt-AspRS and the mt-ArgRS: salt-sensitive for the mt-AspRS,
indicating an electrostatic mode of membrane anchoring, and
urea-sensitive for the mt-ArgRS, indicating a hydrophobic
mode of membrane anchoring. None of the two proteins has
6 Rigorously, amino acid conversion of a givenmutation should be preceded
by the “p” letter to indicate that the protein level is considered and the
amino acid change should be indicated using the three-letter nomencla-
ture. For sake of simplicity, the “p” is omitted and the one-letter code is
used so that the mutation p.Gln184Lys is named here Q184K.
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a sequence-based predictable transmembrane domain (tested
in the TMHMM Server, http://www.cbs.dtu.dk/services/
TMHMM-2.0 (48), not shown).7 There are several examples
where an aaRS is relocated into amembrane upon stimuli. This
is either to positively or negatively regulate the translation or to
allow the occurrence of an alternate function of the aaRS by
removing it from translation. For instance, the human cytosolic
LysRS is naturally anchored to the cytosolic multi-synthetase
complex but relocated to the plasma membrane upon laminin-
dependent phosphorylation. Once at the plasma membrane,
the LysRS associates with membrane proteins p67LR and the
7 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
Figure 3. Impact of disease-associatedmutations on the intra-mitochondrial localization. A, cellular models. Shown are representativeWestern blots of
three independent experiments detecting WT and mutant mt-AspRS (top) and mt-ArgRS (bottom) using anti-FLAG antibody. SOD2 and prohibitin were
detected to attest for the quality of the fractionation and used as loading controls for the soluble and membrane fractions, respectively. B, fibroblasts from
patients. Shown are representative Western blots detecting WT and mutant mt-AspRS, mt-ArgRS, and prohibitin using specific antibodies. Control skin
fibroblast is from a healthy control person. PCH6-patient and LBSL-patient correspond to skin fibroblasts from patient 2 (p.T100Cfs*5/p.A10V) and patient 1
(p.R76SfsX5/p.G338E), respectively. R, residual fraction; S, soluble fraction;M, membrane fraction.
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integrin 6, increasing cellular migration and invasion (49).
The authors suggest that the recruitment of a key translational
component to regulate cell migration may reduce the level of
operational translation machinery (50). As another example,
the human cytosolic LeuRS is translocated to the lysosome
membrane upon leucine addition. In this situation, LeuRS acts
as an intracellular leucine sensor and activates the mammalian
target of rapamycin-signaling pathway, regulating translation,
cell size, and autophagy (51, 52). Finally, in cyanobacteria, four
aaRSs are anchored to the thylakoid membranes thanks to an
additional protein domain named CAAD (for cyanobacterial
aminoacyl-tRNA synthetases appended domain) (53). The
membrane-anchoredValRSwas shown to directly interactwith
the ATP-synthase, linking elements from gene translation and
energy production machineries (54). In this case, the aaRS is
constitutively anchored to the membrane (and not relocated
upon stimuli), a situation similar to what we observed for the
human mt-ArgRS.
Over the past 10 years, disease-related mutations affecting
DARS2 andRARS2 have been reported in patients with LBSL or
PCH6 syndromes, respectively (12). Schematic representations
of the modular organizations of mt-AspRS and mt-ArgRS are
given in Fig. 4. Previous studies, on the same subset of mt-
AspRS mutants, revealed that only some had lower aminoacy-
lation activities (mutants L626Q and R263Q) (17, 55). Addi-
tional investigations showed that the analyzed mutations have
no impact on the mt-AspRS architecture (19), but distinct and
variable impacts on mt-AspRS expression (T136S, Q184K,
L626Q) (17), dimerization (Q184K) (17), translocation from
the cytosol to the mitochondria (S45G) (56), or on in cellulo
solubility (Q184K, L626Q) (19). Strikingly, mutations R58G
and L613F have no noticeable impact on any of these parame-
ters. Regarding PCH6-related mutations of mt-ArgRS, limited
investigations have been performed so far. A striking reduction
in the amount of the mt-tRNAArg was found in patient’s fibro-
blasts (with the combination of the K291R mutation and the
IVS2  5 (A3G) mutation, which causes exon 2 skipping)
with, however, the observation that the residual mt-tRNAArg
transcript was almost fully acylated, suggesting that the
uncharged mt-tRNAArg become unstable (15). Lower mt-
ArgRS expression and activity have been observed in cultured
skin fibroblasts from two patients (with p.R245Q/p.R469H
or p.W241R/p.Q12R combinations of mutations). A drastically
less significant impact has, however, been reported in a third
patient (p.I9V/p.R504_L528del) (18). Altogether, the fact that
disease-related mutations impact variably the investigated
properties of the proteins is perplexing and points to the fact
that the housekeeping role of mt-aaRSs in protein synthesis is
Figure 4. Investigated disease-associated mutations of human mt-AspRS (A) and mt-ArgRS (B). The mt-aaRSs are shown to scale; known functional
domains are named and colored. Cat. Res. stands for “catalytic residues.” Allelic compositions, as identified in patients, are linked through black lines. R76SfsX5
is a truncated variant of mt-AspRS due to the c.228–20_21delTTinsC mutation. T100Cfs*5 and G550fs*5 are truncated variants of mt-ArgRS due to the
c.298G_13Aand the c.1651–2A3Gmutations, respectively.Mutations investigated in thepresent study arehighlighted inbold characters. Rigorously, amino
acid conversionof agivenmutation shouldbeprecededby the “p” letter to indicate that theprotein level is considered. For sakeof simplicity, the “p” is omitted.
All data are extracted from Ref. 12, which contains all related references. Figures were adapted from Ref. 11.
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not the general target of the mutations, and that different
mechanisms are at play in the pathogenesis of mt-aaRS-associ-
ated diseases.
In the present study, we have investigated the impact of
LBSL- and PCH6-causing mutations on mt-AspRS dual local-
ization and on mt-ArgRS membrane localization, respectively.
With the exception of Q184K, none of the investigated muta-
tions significantly impairs the intra-mitochondrial distribution
of the corresponding mt-aaRS, neither in cells expressing
mutant proteins nor in skin fibroblast cells derived from
patients. TheQ184Kmutation affects thematrix localization of
mt-AspRS, consistent with the lower solubility and higher pro-
pensity to aggregate, previously determined for this mutant in
vitro by biophysical approaches (19). It is worth mentioning
that the two patient-derived skin fibroblasts are heterozygous
compounds and contain a missense mutation and a splicing
defect. The splicing defect in the case of aDARS2-related LBSL
patient was reported to be leaky and to allow the production of
a significant amount of WT protein (13, 14). The same authors
have further demonstrated the cell-type dependence of splicing
of mt-AspRSmRNA and that themutations have a larger effect
on exon 3 exclusion in neuronal cell lines than in non-neural
cell lines (57). This may explain the lack of visible impact on
skin fibroblast cells expressing both a missense mutation and a
splicing defect.
The case of mutant S45G is puzzling. Indeed, it was previ-
ously shown that this mutation impairs the import of the pro-
tein into isolated mitochondria purified from HEK293T cells,
but does not affect the targeting or the processing (cleavage) as
demonstrated by in cellulo and in vitro approaches, respectively
(56). In the present study, the S45G mutant is expressed in
cellulo and shown to be soluble and dually localized in mito-
chondria similarly to the WT protein. It is thus hypothesized
that the S45G mutation, situated near one of the mt-AspRS
processing sites (8), may alter the efficiency of the import but
not the import itself. This processmight then bemore sensitive
in isolatedmitochondria than in a cellular context. Corroborat-
ing this hypothesis, the targeting and import of a same protein
was demonstrated to be different from one cell or tissue to the
other one (58). Also, mutation in the huntingtin protein was
shown to affect the mitochondrial import into neurons but not
into other cells, leading to premature neuronal death in patients
with Huntington disease (59).
Outlook
We have established the different intra-mitochondrial local-
izations for the human mt-aaRSs in kidney and skin fibroblasts
cells. This distribution should be further investigated in other
tissues, e.g. in neuronal cells and/or under distinct physiological
or pathophysiological contexts. It is worth mentioning that
both LBSL and PCH6 are neuronal affections. Similarly, the
absence of impact of disease-associated mutations on mt-
AspRS ormt-ArgRS intra-mitochondrial localizations does not
exclude a possible impact in other cellular contexts. This is
consistentwith the observation of the “lack of clear biochemical
phenotypes (OXPHOS or mitochondrial protein synthesis
defects) in skin fibroblasts and myoblasts frommost of mutant
mt-aaRSs patients,” previously described (60). Similar investi-
gations should now be performed on neuronal cellular models.
The discovery of different localizations and diverse modes of
membrane anchoring for twomt-aaRS should be considered in
line with the observation that the two related diseases have
distinct onsets and degrees of severity. The observation of con-
trasting scenarios further points to the fact that differentmech-
anisms are likely at play in the pathogenesis of mt-aaRS-associ-
ated diseases and suggests distinct intra-mitochondrial roles of
the two mt-aaRSs, which will need to be unveiled.
Experimental procedures
Informed consent for diagnostic and research studies was
obtained for all subjects in accordance with the Declaration of
Helsinki protocols and approved by local Institutional Review
Boards in Paris.
Cells, biochemical, and chemicals
HEK293T were from Invitrogen. Skin fibroblasts (patient-
derived and control) were from the Imagine Institute (Paris).
Baby hamster kidney cells strain 21 (BHK21) (ATCC number
CRL-12072) and modified vaccinia Ankara strain (MVA-
EM24) were gifts from Robert Drillien (IGBMC, Strasbourg).
Polyclonal anti-human mt-AspRS was produced in rabbit by
the service of antibodies production at the IGBMC (Illkirch)
and raised against the peptide 486LFLPKEENPREL497. Antibod-
ies against humanmt-ArgRS, humanLysRS, human superoxide
dismutase (SOD2), prohibitin, voltage-dependent anion-selec-
tive channel (VDAC1), and cytochrome c (Cyt c) were pur-
chased from Abcam. Antibodies against mt creatine kinase
(CKMT1A), heat shock protein 60 (Hsp60), and anti-FLAG
were purchased, respectively, from ProteinTech, Bethyl Lab,
and Sigma. Mt-ribosomal protein L18 (MRPL18) antibody was
a gift from Dr. Entelis (GMGM, Strasbourg). Horseradish per-
oxidase-conjugated goat anti-rabbit and sheep anti-mouse sec-
ondary antibodies were from Bio-Rad and GE Healthcare,
respectively. Chemiluminescent detection kit was from Pierce
(Thermo Scientific), Mini-Protean TGX Precast polyacryl-
amide gels and the Trans-Blot Turbo system were from Bio-
Rad. ArrestTM protease inhibitor mixture and polyethyleni-
mine (PEI, linear 25 kDa) were purchased from GBiosciences
and Polysciences, respectively. Tryptose phosphate broth
(TPB) was from Sigma. Trypsin, penicillin/streptomycin, phos-
phate-buffered saline (PBS), Dulbecco’s modified Eagle’s
medium, and Glasgow’s minimum essential medium (GMEM)
were purchased fromGibco. Fetal bovine serum (FBS)was from
Eurobio.
Cases reports
Patient 1—Patient 1, a girl, was born to healthy unrelated
parents after a term pregnancy and normal delivery. She did
well during her first years of life. At six years, she mentioned
short, recurrent and increasingly frequent episodes of tingling
sensation of the inferior limbs, originally ascribed to Lyme dis-
ease. She subsequently presented recurrent attacks of unilateral
lower limb weakness, frequent falls, and gait ataxia and limb
intention tremor. Left hemiparesis with pyramidal syndrome,
brisk deep tendon reflexes, cerebellar ataxia and pes cavuswere
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noted but she could attend school normally. Brain MRI
revealed bilateral hyper intensity of pyramidal track, pons, cer-
ebellar peduncles and corpus callosum. Her metabolic work up
including plasma lactate and pyruvate was normal. Next-gen-
eration sequencing revealed compound heterozygosity for two
DARS2 variants, amissense variant (c.1013GA; p.G338E) and
a previously reported nonsense truncating variant (c.228–
21_228–20delinsC; p.R76SfsX5) (13).
Patient 2—Patient 2, a girl, was born to second-cousin Turk-
ish parents after a term pregnancy and normal delivery. At day
4, she presented bouts of myoclonic jerks unresponsive to val-
proate and carbamazepine. She developedmyoclonic encepha-
lopathywith trunkhypotonia and inability to followwith eyes at
aged 2months. BrainMRI showed severe sus- and sub-tentorial
brain atrophy with pericerebral effusion, with no basal ganglia
involvement but NMR spectroscopy evidence of an important
lactate peak (cerebrospinal fluid lactate: 4.2 mmol/liter, nor-
mal  2.1). Next-generation sequencing revealed compound
heterozygosity for two RARS2 variants, a missense variant
(c.29CT; p.A10V) and a splicing variant (c.298G-13A)
causing a frameshift and a premature termination codon
(p.T100Cfs*5).
Plasmid constructions for protein expression inmammalian
cells
For expression in cultured cells, all sequences were cloned
with a downstream FLAG (DYKDDDDK) epitope tag coding
sequence, so that all proteins are FLAG-tagged at their C ter-
mini. The gene for WT mt-AspRS and those carrying muta-
tions c.172C3G (p.R58G), c.406A3T (p.T136S), c.550C3A
(p.Q184K), c.788G3A (p.R263Q), c.1837C3T (p.L613F), and
c.1876T3A (p.L626Q) were constructed and cloned as previ-
ously described (19). The ones carrying the c.133AG (p.S45G)
and c.1013GA (p.G338E) mutations were generated by
directed mutagenesis on a derivative of pBCJ739.14 (37). The
gene forWTmt-ArgRSwas cloned into theNdeI andXhoI sites
of the pCI vector (Promega) with standard molecular biology
procedures.Mutations c.25A3G (p.I9V), c.35A3G (p.Q12R),
c.721T3A (p.W241R), c.734G3A (p.R245Q), c.773G3A
(p.R258H), c.848T3A (p.L283Q), c.997C3G (p.R333G),
c.1024A3G (p.M342V), c.1211T3A (p.M404K), c.1406G3
A (p.R469H), c.1432G3A (p.G478R), and c.1588C3T
(p.H530Y) were introduced by site-directed mutagenesis using
Phusion High-Fidelity DNA Polymerase (Thermo Scientific).
The primers used for mutagenesis are listed in Table S1.
Cell culture and transfection
BHK21 cells were cultured in Glasgow’s minimum essential
medium supplemented with 10% fetal bovine serum, 1% peni-
cillin/streptomycin, and 5% tryptose phosphate broth in 5%
CO2 at 37 °C. Transfection of BHK21 cells was performed as
described (19). Briefly, cells were washed with PBS, infected
with modified vaccinia Ankara virus expressing isopropyl
1-thio--D-galactopyranoside-inducible T7 polymerase, and
subsequently transfectedwith plasmid expressing eitherWTor
mutant AspRSs under the dependence of T7 promoter using
PEI. Plasmid-PEI complexes were prepared in a ratio of 1:4.5
(w/w) and incubated for 15 min at 20 °C prior to the transfec-
tion (5 and 15 g of DNA per plate of 60 and 150 cm2, respec-
tively). Protein expression was induced by addition of 1 mM
isopropyl 1-thio--D-galactopyranoside.
HEK293T cells and skin fibroblasts were cultured in Dulbec-
co’s modified Eagle’s medium supplemented with 10% FBS and
1% penicillin/streptomycin in 5% CO2 at 37 °C. HEK293T cells
were transfected with PEI (with same procedure and plasmid/
PEI ratio as mentioned above) at 50% confluence with con-
structs expressing mt-ArgRS–FLAG (WT and mutants). The
transfected cells were incubated at 37 °C for 3 days and then
analyzed by Western blotting.
Mitochondrial enrichment
Cells were collected, washed with PBS, and resuspended in
an isotonic buffer (220 mM mannitol, 70 mM sucrose, 1 mM
MgCl2, 1mM EDTA, 10mMHEPES/KOH, pH 7.4) containing a
protease inhibitor mixture. Cells were then disrupted mechan-
ically using 2-mm diameter ceramic beads in a FastPrep-24TM
5G machine (MP Biomedicals). Intact cells, nuclei, and debris
(pellet) were discarded after 10min of centrifugation at 400 g
(4 °C). Supernatant was centrifuged 10 min at 12,000 g (4 °C)
to collect fraction enriched in mitochondria (40 mg were
obtained per 150-cm2 confluent plate).
Mitochondrial fractionation
Flow charts of experimental procedures to fractionate mito-
chondria are given in Fig. 1A. Mitochondria (30 mg) were
resuspended in 1 ml of washing buffer (10 mM K2HPO4/
KH2PO4, pH 7.5, 300 mM mannitol, 1 mM EDTA, containing a
protease inhibitor mixture), and sonicated 6  10 s on ice.
Sonicated mitochondria were centrifuged during 10 min at
16,000 g (4 °C). The resulted pellet (named residual fraction
R) corresponds to unbroken mitochondria and aggregates, if
any. The supernatant (T, for total mitochondria) was further
ultracentrifuged 30 min at 125,000 g (4 °C) to separate solu-
ble (S) from membranes (M) fractions.
Chemical treatment ofmitochondria
Enriched mitochondria (30 mg/experiment) were soni-
cated 6  10 s on ice in the presence of different chemical
agents (1-8 M urea, 0.1 MNa2CO3, pH 11, 0.5 M KCl, 0.4 MDTT,
or 1 M NH2OH, at pH 7 and 11) in 1 ml of 10 mM K2HPO4/
KH2PO4, pH 7.5, 300 mM mannitol, 1 mM EDTA, and contain-
ing a protease inhibitor mixture for 10 min at 20 °C. After son-
ication, mitochondria underwent the fractionation protocol as
described above.
Western blotting
Soluble (S) fractions were concentrated up to a volume of 80
l using Amicon 3 Ultra-0.5 centrifugal filters (10K, Milli-
pore). Residual (R) and membrane (M) fractions were solubi-
lized in 80 l of washing buffer. The protein concentration of
each fraction was quantified using Bradford assay. All fractions
were supplemented with 20 l of Laemmli dissociating buffer,
heated at 95 °C for 10min. Twentyl of each fraction (contain-
ing 20 g of proteins for total,140 g for the soluble frac-
tion, and65 g for the membrane fraction) were loaded on a
10% SDS-PAGE. Proteins were blotted on a polyvinylidene
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difluoride membrane and detected with specific antibodies.
Chemiluminescent detection was carried out using the Pierce
Detection Kit according to the manufacturer’s instructions.
Autoradiographs were digitized using Epson Perfection 3490
Photo. For comparison betweenmt-aaRSWT andmutants, the
relative amount of proteinswas estimated fromband intensities
using ImageJ software (61), and corrected based on SOD2 and
prohibitin intensities as loading controls. Soluble membranes
and residual fractions obtained from each set of experiments
have been quantified out of a same autoradiograph, assuming
that all mt-aaRS protein has been recovered during treatment
and percentage of each fraction in individual experiments has
been calculated (R SM 100%) so that the relative distri-
bution of proteins in each fraction for each condition is inde-
pendent of the expression rate. Mean values and S.D. were cal-
culated out of three independent replicates. Values were then
normalized for comparison purposes to the correspondingWT
fraction, artificially set to a value of 1. Due to the low abundance
of mt-AspRS mRNA when compared with other mt-aaRS
mRNAs in skin cells and when compared with other cells
(http://biogps.org),7 the detection of the corresponding protein
by Western blotting experiments was harder to reproduce in
the three fibroblast cell lines.
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Chapter III   Analysis of the impact of pathologies-related 
mutations on mitochondrial aminoacyl-tRNA synthetases 
properties  
 
1. Introduction 
In Chapter I, an exhaustive analysis of the disorders produced by mutations in the nuclear 
genes encoding for the mt-aaRSs was done. The ideas that emanated from this analysis were 
useful for the organization of the clinical manifestations. Since it was clearly demonstrated that 
PCH6 and LBSL present different clinical manifestations (even if they both affect CNS), 
distinct cellular properties were anticipated for the two mt-aaRSs.  
Chapter II follows then from the need to characterize the cellular peculiarities of these 
enzymes. Important new data allowed us to establish knowledge regarding the mt-ArgRS and 
compare them with previous results, identifying that the mt-aaRSs have distinct intra-
mitochondrial localizations. 
In this third chapter, we explore if this "different localization" parameter could be impacted 
by the pathologies-related mutations and could possibly explain the pathologies. The study of 
the impact of the mutations on the mt-aaRSs was divided into two parts: First, we evaluate in 
cellulo the impact of diseases-associated mutations on the intra-mitochondrial locations of mt-
AspRS and mt-ArgRS. The results from this work are part of article #2. In addition to this and 
considering the previously mentioned arguments (e.g. mutations at conserved positions for at 
least one allele, severity of the clinical manifestations; see chapter I), we had initially 
anticipated the possibility of an impact of PHC6-related mutations on the aminoacylation 
property of the mt-ArgRS. We thus performed in vitro analysis of the aminoacylation activity 
of the mt-ArgRS. The enzyme activity of mutated enzymes was established and compared to 
the wild-type form of the mt-ArgRS. 
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2. Impact of pathologies-related mutations on mt-aaRSs 
localizations in cellulo 
The discovery of different intra-mitochondrial localizations for distinct aaRSs not only 
suggested the existence of additional enzyme properties, but also raises the possibility that this 
cellular property might be affected by the pathologies-related mutations. We thus investigated 
the impact of selected mutations reported to be correlated to LBSL and PCH6 pathologies on 
the mt-aaRSs intra-mitochondrial localizations. 
Regarding mutations linked to LBSL, a former PhD student, Loukmane Karim, started the 
research work on mt-AspRS and established that in cellulo the double localization of this 
enzyme was not affected by the LBSL-associated mutations. Additionally, experiments 
analyzing the impact of mutations on the solubility of the mt-AspRS were performed, showing 
that for two missense mutations the proteins presented lowest solubility and highest propensity 
to aggregate in cellulo (Sauter et al., 2015). 
Twelve PCH6-related missense mutations were studied in cellulo: c.25A>G (p.I9V), 
c.35A>G (p.Q12R), c.721T>A (p.W241R), c.734G>A (p.R245Q), c.773G>A (p.R258H), 
c.848T>A (p.L283Q), c.997C>G (p.R333G), c.1024A>G (p.M342V), c.1211T>A (p.M404K), 
c.1406G>A (p.R469H), c.1432G>A (p.G478R), c.1588C>T (p.H530Y). The localizations of 
these mutations throughout the functional domains of the mt-ArgRS are represented in Figure 
19 (highlighted with blue dots). As seen in figure 16, amino acid substitutions either extend, 
shorten or delete side chain. We observe that all the mutated amino acids include all chemical 
natures, however, so far none of the incorporated amino acid has an electrically charged 
(negative) side chains. Thus, the diversity of reported substitution, affecting all functional 
domains, renders prediction(s) about a common mechanism difficult. 
Moreover, two new mutations, one linked to LBSL and the other to PCH6, were described. 
This two new reported cases are included in the article #2. LBSL patient was a girl who 
presented the clinical symptoms onset at six years, presenting different affections in the inferior 
limbs. Neuroimaging studies showed various alterations in the pyramidal track, pons, cerebellar 
peduncles and corpus callosum. Next generation sequencing revealed compound 
heterozygosity for two DARS2 variants, a missense variant (c.1013G>A; p.G338E) and a 
previously reported nonsense truncating variant (c.228-21_228-20delinsC; p.R76SfsX5). 
PCH6 patient was also a girl whose onset was in the neonatal period presenting myoclonic 
jerks. Neuroimaging studies revealed localized brain atrophy. Next generation sequencing 
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revealed compound heterozygosity for two RARS2 variants, a missense variant (c.29C>T; 
p.A10V) and a splicing variant (c.298G-1>A) causing a frameshift and a premature termination 
codon (p.T100Cfs*5). 
For either the PCH6 or LBSL patient, it should be noted that the clinical manifestations 
are similar to those previously described in previous reports. In these new cases we found the 
typical lower limb involvement in LBSL and the seizures in PCH6. As for the results of the 
imaging studies we also find neuroimaging standards described in chapter I for LBSL. 
However, although brain atrophy was described for PCH6, we did not obtained precise data on 
whether there is marked pontocerebellar hypoplasia. 
The results obtained from this in cellulo analysis show that regardless of the mutation 
studied, or regardless of the cellular system used (HEK293T or human fibroblasts), the 
exclusively presence of mt-ArgRS in the mitochondrial membrane remains unchanged (See 
Figure 20). To go a little further in this study, we also explore whether the mutations studied 
have any effect on the total expression of the protein in cellulo. Here also, regardless of the 
mutation studied, the expression of the protein was unchanged when compared to the wilt type 
mt-ArgRS. The image corresponding to this is represented in the supplementary information of 
article #2. Discarding the fact that the location of synthetase is part of the pathogenesis of the 
disease prompts us to continue exploring the properties of the enzyme that could explain the 
disease.  
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Figure 19. Locations and chemical nature of the amino acid substitutions of PCH6-associated 
mutations within functional domains of mt-ArgRS. (A) Schematic representation of the modular 
organization of the human mt-AspRS. Allelic compositions, as identified in patients, are linked through 
black lines. Mutations investigated in the present study are highlighted in bold characters. Those 
investigated for their impact on membrane localization of the mt-ArgRS are indicated by the blue dots, 
and those for their impact on in vitro aminoacylation property of the enzyme by orange dots. Rigorously, 
amino acid conversion of a given mutation should be preceded by the “p.” letter to indicate that the 
protein level is considered. For sake of simplicity, the “p.” is omitted. All data are extracted from 
http://misynpat.org (Moulinier et al., 2017), which contains all related references. (B) Representation of 
amino acid substitutions by their chemical nature. A code color was used to illustrate corresponding 
chemical nature: blue for non-polar side chains, purple for polar side chains, blue for electrically (basic) 
charged. 
 
Since mt-ArgRS is a monomeric enzyme and is located exclusively in the membrane 
fraction, any impact on location, if it exists, would necessarily arise from the disease-related 
mutation. It is worth mentioning that the fact of using HEK293T transfected, the results would 
be the result of the participation of the endogenous mt-ArgRS and the mutated transfected 
version of the protein. While an anti-ArgRS antibody will detect both enzymes, the ani-flag-
antibody will reveal solely the exogenous mt-ArgRS. Experiments studying the location of 
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mt-AspRS and mt-ArgRS were also performed in fibroblasts from these patients harboring 
these new mutations (Figure 20.B taken from figure 4 of article #2). Either in HEK293T cells 
or in human fibroblasts, the locations of mt-ArgRS and mt-AspRS were not affected 
independently of the studied mutations. The experimental process performed, as well as the 
discussion of the results obtained from this study, were included and published in article #2. 
 
Figure 20 (taken from figure 3 of article #2) Impact of PCH6-related mutations on the exclusively 
membrane location of the mt-ArgRS in cellulo. A) HEK293T cells were transfected with different 
construction of mt-ArgRS (WT and mutants). Mitochondria were enriched and fractionated into soluble 
(containing matrix and intermembranes space proteins) and membrane (containing inner and outer 
membrane proteins) fractions. Representative western blot of WT and mutants mt-ArgRS detected with 
anti-Flag antibody. Detection of both SOD2 and Prohibitin were performed as loading control of 
fractions. B) Fibroblasts from patients. Representative western blots detecting WT and mutants mt-
AspRS and mt-ArgRS, and prohibitin as a control, using specific antibodies. "Control" skin fibroblast 
is from a healthy control person. "PCH6-patient" and "LBSL-patient" correspond to skin fibroblasts 
from patient PCH6 (p.T100Cfs*5/p.A10V) and patient LBSL (p.R76SfsX5/p.G338E), respectively. R: 
Residual; S: soluble fraction; M: membrane fraction. 
  
3. In vitro analysis of the impact of pathology-related mutations 
on mt-ArgRS canonical function 
In the first chapter, the description of the disease caused by the mutations in RARS2, 
encoding for the mt-ArgRS, was made. The severity of the pathology was established when the 
clinical manifestations of the disease were compared to those produced by other mt-aaRSs. An 
example of this is that in some cases the symptoms in some patients are limited to weakness in 
the lower limbs, as has been reported for some LBSL patients. However, regarding PCH6 
patients, the motor and cognitive functions of the patients are so affected that most of the time 
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they are unable to carry out their daily activities on their own (Zhang et al., 2018). Due to the 
severity of the clinical manifestations of PCH6, and to the high level of conservation of the 
mutated amino acid (at least in one of the two mutated alleles, see mysinpat.org) one could 
assume that the aminoacylation function of the mt-ArgRS could be affected as a result of the 
mutations. In this part of the work, the objective was to evaluate the impact of five reported 
mutations on the canonical function of the mt-ArgRS. 
 The chosen mutations to be studied were: p.Phe131Cys, p.Arg245Gln, p.Leu283Gln, 
p.Arg469His and p.His530Tyr. To facilitate the nomenclature, the “p.” will be omitted and the 
one-letter code will substituted the three-letter code to name the mutations, thus, the mutation 
p.Phe131Cys will be named here F131C. The selected studied mutations are distributed in the 
catalytic domain of the enzyme and in the anticodon-binding domain (see orange dots in Figure 
19 and Figure 21 (mutations on the structure 3D). 
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Figure 21. Human mitochondrial aminoacyl tRNA synthetases (mt-tRNA) mutations in 3D 
structural representation. Coordinates for 3D model (including MTS) of mt-ArgRS were uploaded 
from MiSynPat (http://misynpat.org (Moulinier et al., 2017)). A) Representation of the reported mutated 
positions highlighted by the chemical nature, using the code colour showed in figure 16); left, chemical 
nature of the amino acid in the WT mt-ArgRS before the mutation; right, chemical nature of the new 
amino acid in the mutated mt-ArgRS. B.1) Representation in blue spheres of the selected studied 
mutations in cellulo. B.2) Representation in orange spheres of the selected studied mutations in vitro. 
C) Stereo view of the crystal structure of the yeast mt-AgRS (PDB: 1F7V) with its tRNA subtract in 
yellow (Delagoutte et al., 2000). For all structures, the MTS is in pink, the tRNA edge-binding domain 
in green, the catalytic domain in red, and the anticodon-binding domain in blue.  
 
 
These five mutations were chosen to represent different situations found in patients reported 
with PCH6. We thus considered i) mutations in a heterozygous state (R245Q and R469H are 
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present in a same patient, and L283Q is combined with a truncated protein); ii) mutations in an 
homozygous state (F131C in the catalytic domain and H530Y in the anticodon-binding 
domain); and iii) the conservation of the mutated residue within the sequence alignment (the 
arginine in position 469 affected by the R469H mutation is 100% conserved; see misynpat.org 
(Moulinier et al., 2017)). As already mentioned above mt-ArgRS is a monomeric enzyme, in 
this case heterozygous composite patients present a mixture of two mutated proteins where each 
one carries a different mutation. It should be mentioned that we are not in a position to estimate 
whether these two populations are present in equivalent amounts or not. This situation is totally 
different from what exists for mt-AspRS, which is a homodimeric protein. Indeed, a LBSL 
patient a priori possesses a mixture of homo-and hetero-dimers. 
3.1. Cloning, expression and purification of the mt-ArgRS 
WT and mutants 
The mutations were introduced by directed mutagenesis in the pDEST plasmid containing 
the sequence coding for the mt-ArgRS-L72 recombinant protein with a His10-Tag in the C-
terminal, following the protocol described in the section 3.1.2. In this experiment, the form 
mt-ArgRS-L72 is representative of the wild type (WT) mt-ArgRS (see Chapter II). Expression 
and purification were performed simultaneously for the WT enzyme and a single mutant at one 
time following the same experimental conditions (in order to obtain two sets of proteins 
prepared under strictly comparable conditions). Figure 22 represents an example of the protein 
purification. While the western blot seems rather encouraging, the coomasie blue staining 
shows that the protein remains highly contaminated after concentration. Given that the yield of 
protein expression is not highly effective (since 3 L of culture are necessary to obtain ~10 to 
20 mg of crude proteins extract) and the level of contamination is identical for both versions of 
the protein (WT or mutant), we agreed to perform this first series of experiments in the 
conditions described as follows. However, we are aware that these represent only preliminary 
data, and the conditions of purifications should be optimized to improve the quality and the 
purity of the protein.  
Expression of recombinant proteins was induced with IPTG, under the control of the lac 
operon and the T7 promoter. The purification protocol is based on previous expertise in the 
laboratory with purification of other mt-aaRSs by affinity chromatography (see section 5 in 
Materials and Methods). Briefly, cell extracts were sonicated and ultracentrifuged. The 
resulting supernatant was loaded onto a HIS-Select® HF Nickel Affinity Gel resin column 
previously equilibrated in a phosphate buffer. After extensive wash of the column, the proteins 
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were eluted with a linear gradient containing imidazole. All steps were monitored using the 
BioLogic DuoFlow System from BIO-RAD. Fractions containing the protein were pooled and 
concentrated. All the constructions were expressed and soluble. As already mentioned, an 
optimal level of purity of the enzyme was not reached; this was evidenced by multiple 
unspecific bands in the coomasie gel. To try to improve the purity of protein samples, some 
modifications were made to the buffers, like increasing the NaCl concentration from 150mM 
to 450mM. This attempt resulted, however, to the aggregation of the protein. Several aliquots 
were taken during the different purification steps, and loaded onto a 10% SDS-gel. Protein 
bands were detected by Western blot analysis using anti-His antibody (Figure 22). In figure 19 
we can appreciate a typical result of the version mt-ArgRS-L72 versus the F131C mutant. For 
each experiments, the proteins samples were analyzed on two gels: one to perform western blot 
analysis and the second one for blue coomasie staining. 
 
Figure 22. Expression, purification 
and concentration of the 
Mt-ArgRS-Leu72 and the variant 
Mt-ArgRS-Leu72(F131C). E. coli 
BL21 cells were transformed with the 
plasmid pDEST carrying the 
mt-ArgRS coding sequence starting at 
amino acid Leucine 72. Samples were 
taken after sonication (T-Total), 
ultracentrifugation (S-Soluble), and 
different elution fractions, and were 
loaded onto a 10% SDS-PAGE gel (in 
duplicate). One of the gels was used to 
western blot detection using an 
anti-His-tag (left column gels), and the 
other gel was used to a coomasie blue 
staining (right column gels). Samples 
obtained before and after 
concentration (B.C and A.C, 
respectively) of the eluted protein were 
also loaded onto a 10% SDS-PAGE 
gel.  
 
3.2. Aminoacylation assays 
The purified WT mt-ArgRS and five missense variants were used to perform in vitro 
aminoacylation in order to determine their ability to aminoacylate tRNAArg. Protein 
concentration was estimated using NanoDropTM spectrophotometer considering the theoretical 
extinction coefficient of mt-ArgRS (ε= 59120 M−1cm−1). 
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In vitro arginylation was performed in the presence of an established concentration of 
isotopic mixture of Arginine, total tRNA from E. coli and mt-ArgRS. At the end of the reaction, 
the detection of the radioactivity in counts per minute (cpm) allowed the quantification of the 
tRNAArg (in pMoles) aminoacylated with radioactive arginine. Total tRNA from E. coli was 
habitually purified from bacterial cultures in the laboratory by Agnès Gaudry. From the 
quantification of the total tRNA we estimated the concentration of the tRNAArg considering that 
this tRNA represents 1/20 of the total tRNA population. Routinely 40 pmoles of tRNAArg from 
E. coli were used for each aminoacylation reaction, however this concentration was modified 
in some assays to observe the possible changes in the reaction in the presence of more (or less) 
subtract. Different concentrations of enzyme (50 nM, 100 nM, 200 nM, 250 nM, 400 nM, 
800 nM and/or 1500 nM) were also tested. The aminoacylation reaction mixture was 
equilibrated to 37°C before the addition of the enzyme to a final volume of 50 µl. At different 
times (5 min, 10 min, 15 min and 30 min), 10 µl of the aminoacylation reaction were spotted 
onto Whatman papers previously equilibrated with 5% trichloroacetic acid (TCA). The papers 
were immediately placed in cold 5% TCA to precipitate tRNA and terminate the reaction. The 
papers were then washed and dried. The dried papers were placed in counting vessels and 
incorporation of radioactive arginine was measured by liquid scintillation counting using a 
scintillation counter. 
Due to the particularities of the human mt-ArgRS (not known before the present study) as 
for example the attachment to the mitochondrial membrane by hydrophobic interaction, 
experiments previously performed in the laboratory attempting to purify the human mt-ArgRS 
never yielded promising results. Thus, the results of experiments in which in vitro assays were 
tested with the human mt-ArgRS never showed a catalytic activity. One of the slightest but 
seemingly favorable changes for enzyme purification was to change the component of the 
buffer from potassium to NaH2PO4/Na2HPO4 pH 7.5. Until now it was a determining factor that 
showed us the most encouraging results. 
Since no pre-existing functional enzyme was available for positive controls, it was 
absolutely necessary to verify whether the experimental conditions were optimal to the 
functionality of our human mt-ArgRS-L72 in aminoacylation assay. To establish the 
experimental conditions, one of the most important factors to consider for the in vitro 
aminoacylation assays is the ATP/MgCl2 ratio (Sohm et al., 2003). Previous in vitro 
aminoacylation assay of mt-aaRSs commonly used a buffer with a ratio ATP/MgCl2 ~0.20 
(Bonnefond et al., 2005a; Sohm et al., 2003). However this ratio did not work for the mt-ArgRS 
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requiring hardly optimization by several assays by Agnes Gaudry, until reach an optimal ratio 
of 1 (8 mM ATP/ 8 mM MgCl2). Thus, the first step was to test the WT mt-ArgRS-L72. Even 
though the step of protein purification was improved in our experiments, we are aware that the 
low level of purity of the protein represents a major limitation to our work. Thus, unusually 
large amount of enzyme was needed to perform the aminoacylation assays. Nevertheless, the 
fact that the experiments were performed in the same established conditions allow comparing 
the enzymatic activity obtained between the WT mt-ArgRS and the mutants. Here 10 µl of the 
purified WT mt-ArgRS-L72 were used to perform the reaction. The results of the assay are 
shown in Figure 23, revealing that the mt-ArgRS-L72 aminoacylates its cognate tRNA from 
E. coli. This result showing the aminoacylation even up to ~50 pMoles of tRNAArg indicates 
that probably the initial calculated tRNAArg concentration was underestimated. While trying to 
improve the aminoacylation conditions, some others tRNAs (in vitro tRNAArg transcript and 
yeast tRNAArg commercially purchased) were used. None of them were efficiently 
aminoacylated by the mt-ArgRS, under our experimental conditions. Of note, an enzymatic 
activity was efficiently measured solely with the total tRNA from E. coli. The experimental 
conditions were, however, not optimal to reach a plateau aminoacylation in 30 min of reaction. 
These results further suggest that the quality and/or the quantity of the enzyme was not 
sufficient. 
 
 
Figure 23. Aminoacylation activity of the human mt-ArgRS-L72. Aminoacylation assay was 
performed using 100 nM of protein and 40 pmol  tRNAArg from E. coli in a buffer pH 7.5 at 37°C. 
Aliquots of 10 µl were taken at 0, 5, 10, 15 and 30 min of reaction. 
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4. Impact of PCH6-mutations on aminoacylation activity 
To test the impact of PCH6-related mutations on the aminoacylation function of the 
mt-ArgRS, aminoacylation reactions were performed using each time the "WT" mt-ArgRS 
(L72) and one mutant in the same experiment (Figure 24). Aminoacylation assays were 
performed at least in two individual experiments (n=2) using protein samples obtained from 
a single purification process. Enzymatic activities were calculated in UE/mg, representing 
the pMoles of amino acid incorporated per mg of protein per minute. The means of the 
mt-ArgR-L72 enzymatic activities were normalized and arbitrarily set to the value of 1, in 
order to compare and establish a relation between the enzymatic activities of the WT vs. the 
mutants. The results are given in table 3. 
 
Figure 24. Arginine charging of mt-tRNAArg by the wild type human mt-ArgRS and F131C, 
R245Q, L283Q, R469H and H530Y mutants in in vitro aminoacylation assay. Aminoacylation 
assays were performed using ~100nM of protein, and total tRNA from E. coli (in a quantity that 
correspond approximately to 40 pmol of tRNAArg) at 37°C. Aliquots of 10 µl were taken at 0, 5, 10, 15 
and 30 min. 
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 Relative enzymatic activity 
mt-ArgRS-L72 (WT) 1 
mt-ArgRS-L72/F131C 1.1 
mt-ArgRS-L72/R245Q 0.4 
mt-ArgRS-L72/L283Q 0.15 
mt-ArgRS-L72/R469H 3 
Table 3. Relative enzymatic activity of the mt-ArgRS-L72 compared with five PCH6-related 
mutations. 
 
Table 3 shows that mt-ArgRS-L72/F131C has an enzymatic activity very similar to the one 
of mt-ArgRS-L72(WT). mt-ArgRS-L72/R245Q, mt-ArgRS-L72/L283Q and mt-ArgRS-
L72/R469H have activities 2.5 fold decreased, ~6 fold decreased and 3 fold increased, 
respectively. These results were extremely striking. We previously proposed that the severity 
of the symptoms caused by PCH6 could be linked to drastic effects on the aminoacylation 
function of the mutated enzyme. Surprisingly, in all the studied mutations, the catalytic function 
of the enzyme was maintained, very mildly affected or even increased. Indeed, one of the cases 
to highlight is the mutation of arginine 469, which is 100% (strictly) conserved in the alignment 
of the sequences (Moulinier et al., 2017). It is widely believed that mutation of strictly 
conserved residues would be detrimental to the architecture or the activity. We show here that 
the relative enzymatic activity of the mutation R469H is reproducibly increased 3 fold when 
compared with the WT enzyme. R469H is present in patients in a heterozygous state, associated 
with mutation R245Q. Strikingly, the R245Q mutation leads to a decrease of 2.5 fold of the 
aminoacylation activity, suggesting a compensatory effect that would lead to normal activity. 
This is however speculative. Actually, our in vitro aminoacylation assays do not reproduce the 
genetic situation of the patients, where the activity of the synthetase is determined by a 
combination of two different mutant alleles, with possibly two distinct levels of expression. 
Thus, we are not able to determine whether a compensatory effect by one mutation could rescue 
(or impair in cases of increased impacts) the enzymatic activity of the protein. Nonetheless, the 
experiments performed here reveal that none of the tested PCH6-related mutations has a drastic 
impact on the arginylation property of the mt-ArgRS, which leaves unsolved the pathogenic 
mechanism of these mutations. 
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Earlier aminoacylation studies for the impact of disease-related mutations on other mt-
aaRSs had been performed, and variable effects had been shown. The available aminoacylation 
data reveal diverse (e.g., mt-AspRS (Scheper et al., 2007), mt-PheRS (Walker et al., 2016)) or 
only a weak (e.g., mt-TyrRS (Riley et al., 2013), mt-LeuRS (Riley et al., 2016)) effects of the 
disease associated mutations on the level of aminoacylation. The host laboratory has carried 
several investigations in order to decipher the relationship between LBSL mutations on the 
enzyme activity of the mt-AspRS. A series of mutations have been tested and showed variable 
impacts on the aminoacylation property of the human mt-AspRS, ranking from no impact, to a 
decrease of ~80 fold (Scheper et al., 2007; van Berge et al., 2013). Most importantly, the 
authors have shown situations where non-deleterious mutations are present in a same patient. 
This investigation has been extended to other functional and structural parameters and revealed 
that the analyzed mutations have no impact on the mt-AspRS architecture (Sauter et al., 2015), 
but distinct and variable impacts on mt-AspRS expression (van Berge et al., 2013), dimerization 
(van Berge et al., 2013), translocation from the cytosol to the mitochondria (Messmer et al., 
2011), in cellulo solubility (Sauter et al., 2015), or on intramitochondrial localization 
(Gonzalez-Serrano et al., 2018). Strikingly, two of the investigated mutations have no 
noticeable impact on any of these parameters. Altogether, the fact that disease-related mutations 
impact variably the investigated properties of the mt-AspRS is perplexing and points to the fact 
that the housekeeping role of the enzyme in protein synthesis is not the general target of the 
mutations.  
For mt-PheRS, experimental in vitro aminoacylation measurements revealed an impact of 
the p.I329T replacement on aminoacylation levels (∼4-fold decrease in the catalytic efficiency 
of amino acid activation) (Elo et al., 2012). Biochemical characterization of recombinant 
mutant mt-PheRS proteins showed that mutations can affect synthetase function in different 
ways, such as by reducing the binding of ATP, of phenylalanyl, or of tRNA, and/or by affecting 
synthetase folding and stability (Elo et al., 2012). Further investigations were performed for the 
mt-PheRS, demonstrated that mutated mt-PheRS on p.P85A charges tRNA very similarly to 
WT, but p.H135D demonstrated failure in aminoacylation activity (Walker et al., 2016). 
In vitro aminoacylation assays of a recombinant p.Gly191Asp YARS2 displayed a 38-fold 
loss in catalytic efficiency compared to the wild-type mt-TyrRS (Riley et al., 2013). The authors 
predicted reduced mitochondrial protein synthesis, as it had been previously shown with the 
p.Phe52Leu mutation on mt-TyrRS, where the reduction in aminoacylation efficiency resulted 
in defective mitochondrial protein synthesis (Riley et al., 2010). 
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Investigations were done in two mutations of LARS2 founded in the allelic composition of 
a patient presenting Sideroblastic Anemia (Riley et al., 2016). Recombinant mt-LeuRS 
p.Thr522Asn and p.Ala430Val presented a 9- and 18-fold loss of catalytic efficiency, 
respectively. The authors suggested that the combined effect of the two mt-LeuRS variants on 
aminoacylation activity in the patient most likely results in reduced mitochondrial protein 
synthesis in affected organs and hence mitochondrial RC dysfunction. They supported this idea 
with data showing respiratory chain deficiencies in the muscle and liver (Riley et al., 2016). 
Here we show that, at least in vitro, the aminoacylation function of the mt-ArgRS is 
maintained when testing individual mutants. So far, the effect of pathological mutations using 
recombinant proteins and testing in vitro aminoacylation has been limited to the systems 
described above (mt-TyrRS, mt-AspRS, mt-PheRS, mt-LeuRS and mt-ArgRS in this work). 
They reveal distinct ranges of impacts. Further and complementary investigations on other mt-
aaRSs seem necessary to provide valuable information in understanding how the mutations 
could produce dysfunctions on these proteins, if any. 
5. Conclusion and perspectives 
From the report of LBSL, the first mt-aaRS-related pathology with mutations on mt-AspRS, 
it has long been suggested that the cause of the diseases produced by mutations on mt-aaRSs is 
due to an impact on the ability of the enzyme to aminoacylate its cognate tRNA. The host 
laboratory and other teams have studied the effect of some mutations on the canonical function 
of the mt-aaRSs and the results are fluctuating. Since mt-aaRSs were supposed to be solely 
involved in the mitochondrial translation, this hypothesis of impact on the canonical function 
was conceivable. Given that disease-related mutations in mt-aaRS genes are present in all 
nuclear copies of the genome, a constitutive failure in mitochondrial translation in all organs 
could have been expected. However, this is not the case and it has been recalled at several 
occasions that although there is a target towards the central nervous system, the clinical 
manifestations extend to other anatomical systems. 
 Despite great efforts made to date, it was not yet possible to establish a mechanism for 
the pathogenicity of mutations on the mt-aaRSs that could explain the tissue specificity. The 
results of my work together with additional data obtained by others on other mt-aaRSs strongly 
suggest the absence of a common and unique mechanism correlating mt-aaRSs mutations and 
the reported diseases. Thus, different molecular mechanisms specific to each synthetase (or 
common to a few of them) might be conceivable. Additional experiments will be indispensable 
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before being able to reach conclusive outcomes. For instance, at this stage, a contamination 
with the E. coli ArgRS cannot be excluded. One possible experiment could be to design a new 
variant of the human mitochondrial ArgRS with a point mutation within one of the catalytic 
residues. This variant should be fully inactive and be considered as a negative control (meaning 
in case we observe activity similar to the one obtained for mt-ArgRS L72, this would 
demonstrate that the activity is exclusively provided by the contaminant E. coli ArgRS). In any 
situation, Northern blot experiments made on mitochondria (obtained from fibroblast from 
PCH6-related patients) that are under preparation should provide valuable complementary 
pieces of data and should confirm is the activity is affected or not. To mention, however, in 
order to be truly complementary, fibroblasts should need to be obtained from patients with a 
mutation identical to the one tested within our in vitro experiments. 
 Perhaps the manifestation of diseases, rather than the consequence of a specific event such 
as aminoacylation, represents a combination of incidents, such as the alteration of the 
components of mitochondrial translation that leads to an alteration of the production of ATP, 
and the possible alteration of some hitherto unknown other function of these enzymes. One can 
indeed hypothesizes a possible participation of these enzymes in molecular mechanisms that 
would be tissue-specific (such as e.g. the formation of specific components of the central 
nervous system as neurotransmitter) or that would be specific to some developmental stages. 
Speculatively, the alteration of such mechanism would then lead to the disease. Due to the 
specific injuries to the neuronal tissue, studies of the possible integration of these enzymes in a 
neurophysiologic context, for example in the formation of myelin, or in the regulation of energy 
production in a neuronal environment, should help in the understanding of the reported 
pathological processes. To further explore the tissue-specific issue some strategies have been 
initiated in our laboratory searching a possible involvement of mt-aaRSs in local processes of 
the central nervous system. One of them is the study of effects on neural cells by LBSL-
mutations (See annex). 
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Annexes 
1. Background: Release of the human mt-AspRS from 
mitochondria 
 A former PhD student Loukmane Karim demonstrated that under some conditions, the 
mt-AspRS display an extra-mitochondria localization. During the screening of chemicals to see 
whether the dual localization of mt-AspRS is dynamic, few of these chemicals (among which 
10 mM of ATP) provoked the unexpected release of mt-AspRS from mitochondria into the 
extra-mitochondrial medium (See Figure 25). The applied protocol was as follows: enriched 
mitochondria were incubated for 10 min with different concentrations of ATP (0.1, 1, 2, 4, 6, 
8, 10, 20 and 50 mM), and ADP (10 mM). After treatment, mitochondria were centrifuged 10 
min at 16 000 g (4 °C), then the supernatant corresponding to the extra-mitochondrial medium 
(EM) was separated from mitochondrial pellet. EM were ultracentrifuged 30 min at 125 000 g 
(4 °C), then concentrated in order to be analyzed by western blot, dynamic light scattering (not 
shown here), mass spectrometry or electron microscopy (not shown here). 
 Mt-AspRS was detected in both soluble and membranes fractions after fractionation of 
untreated mitochondria, however mitochondria treated with either ATP or GTP (10 mM) 
displayed highly reduced intensities of mt-AspRS in soluble and membranes fractions, but 
significant intensities in the extra-mitochondrial media (EM) (Figure 25). This observation was 
specific to mt-AspRS since neither SOD2 nor Prohibitin were detected in the EM, but remained 
in their respective fractions, whatever is the applied treatment. These observations clearly 
showed the release of mt-AspRS outside mitochondria upon treatment with either ATP or GTP.  
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Figure 25. Analysis of the extra-mitochondrial medium (EM) after ATP or GTP treatment. 
Mitochondria were purified from HEK293T cells and treated with 10mM of ATP or GTP. A. Workflow 
of mitochondrial treatment and fractionation. B. Untreated mitochondria (control) or treated with 10mM 
of either ATP or GTP prior to fractionation were analyzed by western blot. Prohibitin and SOD2 were 
used as control to proof the purity of the S and M fractions, and the integrity of the mitochondrial upon 
treatment. S, and M, Soluble and Membrane fraction, respectively. Figure taken from L. Karim’s Thesis 
- Oct, 2016. 
 
Additional investigations revealed that other proteins, among which the Cyt c, are also 
released out of the enriched mitochondria under the same experimental conditions. Theses 
experiments haven’t yet been pursued, and neither the biological relevance of the release of the 
mt-AspRS nor the coincidental release of the Cyt c (and thus a possible role of the mt-AspRS 
in cell death or survival (pro- or anti-apoptotic)) has been further investigated.  
My contribution in the follow-up of this research was the application of the protocol 
established by L. Karim to mitochondria that had been previously transfected with plasmids 
expressing the mt-AspRS with LBSL-related mutation. The aim was to investigate whether 
LBSL-related mutations have an impact on the extra-mitochondrial re-location of the 
mt-AspRS. To do this, BHK 21 cells were transfected with the plasmid pBCJ-mt-AspRS, 
encoding for the WT and the mutants [c.133A>G (p.S45G), c.172C>G (p.R58G), c.406A>T 
(p.T136S), c.550C>A (p.Q184K), c.788G>A (p.R263Q), c.1013G>A (p.G338E), c.1837C>T 
(p.L613F) and c.1876T>A (p.L626Q)] versions of the enzyme. Results are shown in Figure 26. 
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We can appreciate that no matter which mutation was tested, the mt-AspRS always re-located 
to the EM fraction upon ATP treatment. 
 
 
Figure 26. Extramitochondrial location of the mt-AspRS. BHK 21 cells were transfected with WT 
or LBSL-related mutant versions of the mt-AspRS. Mitochondria were enriched prior to treatment with 
ATP (10 mM), and the Mitochondrial (Mt) and extramitochondrial (EM) fraction were analyzed by 
western blot. WT W: Mitochondrial with the WT mt-AspRS untreated (control). Cyt c, Cytochrome c. 
 
This new location of the mt-AspRS in an extra-mitochondrial compartment goes in line 
with the so-called possibility of the involvement of the mt-aaRSs in additional or alternative 
processes others to aminoacylation. 
2. Human mt-ArgRS is not released from mitochondria 
To continue with this study, we then wanted to know how the mt-ArgRS would react to 
the same ATP treatment. Florian Pierre (Laboratory Engineer) applied the previously 
established protocol, using enriched mitochondria from HEK293T cells, on which 10 mM of 
ATP were applied prior to the separation onto the two fractions (mitochondria and 
extramitochondria). Mt-AspRS was systematically identified in the western blot analysis, as a 
control of a protein that relocates to the extramitochondria fraction. We can appreciate (see 
Figure 27) that contrary to the relocation profile shown for mt-AspRS, the mt-ArgRS remains 
in the "mitochondrial" fraction when subjected to 10 mM of ATP. 
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Figure 27. Analysis of the extramitochondrial medium (EM) after ATP treatment. Mitochondria 
purified from HEK293T cells are treated with ATP (10mM). Proteins from mitochondria and 
extramitochondrial media are analyzed by western blot. Left panel) @mt-ArgRS detection exclusively 
in the mitochondrial fraction (Mt) in both conditions: without ATP (control) versus incubation with 10 
mM ATP (ATP). Right panel) @mt-AspRS detection in both Mt and EM fraction when using ATP, and 
just in the mt fraction in the control. SOD2 detection was used as control to proof of the fractions. 
 
These results are astonishing; a distinct behavior of these two proteins, the mt-AspRS 
and the mt-ArgRS has already been highlighted and discussed throughout this thesis work. Here 
we add an additional distinguishing feature between these two enzymes, for which (we remind 
once again) the sole yet known function is to participate to the mitochondrial translation. 
Although these observations further extend our understanding of the mt-aaRS, they also raise 
more questions. Why the mt-AspRS is the only synthetase released from the mitochondria in 
stress condition? Could the fact that the ArgRS is membrane-anchored an impediment to the 
relocation into other compartments? Is this relocation an exclusive property of the mt-AspRS? 
Or do other mt-aaRS also relocated under some stress conditions? What is the biological 
relevance of this new location of the mt-AspRS outside the mitochondria? There are certainly 
directions that are waiting to be explored. Surely, as these answers will be found the global 
picture of mt-aaRS will expand the participation of the mt-aaRSs beyond their role in 
mitochondrial translation. 
3. Search for mt-AspRS neuron-specific partner protein(s) 
Several arguments led us to propose a non-canonical function/property (likely neuronal-
specific) of the human mt-AspRS that will need to be searched for. Those arguments are i) the 
absence of a clear and/or common impact(s) of LBSL-related mutation on the canonical 
function of the mt-AspRS; ii) the observation that this enzyme has peculiar cellular properties 
[dual intra-mitochondrial location (see Chapter II), release out of mitochondria under some 
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stress conditions (see above)]; iii) the observation that LBSL-related mutations are mainly 
situated at the dimeric interface (not shown).  
Also, the classification made in Chapter I identified three mt-aaRSs (mt-AspRS, mt-
GluRS and mt-AlaRS) for which mutations lead to a leukodystrophy. Additional reports from 
the literature correlate as well mutations within the cytosolic AspRS to a similar leukodystrophy 
(Wolf et al., 2014). When looking at the degree of conservation of the affected positions (using 
misynpat.org) for the three mitochondrial enzymes (see Table 4), we suggest that 
leukodystrophies linked to mutations in mt-GluRS or mt-AspRS (at non-conserved positions) 
are likely due to a molecular mechanism different from the one leading to the leukodystrophy 
linked to mutations of mt-AlaRS (at highly conserved positions) for which aminoacylation 
deficiencies are strongly suspected (Sissler et al., 2017). In the former two cases, however, it 
has been shown that, when considering exclusively the subphylum of mammals, all reported 
mutations impact positions highly/strictly conserved ((Sauter et al., 2015) and unpublished 
data). This observation suggests for these two enzymes a selective pressure restricted to 
mammals.  
Table 4. Schematic 
representation of the 
conservation in affected 
positions either 
throughout phylogeny, 
or in the subphylum of 
mammals. 
 
 
 Mt-AspRS, mt-GluRS and the cytosolic AspRS have in common the aspartate and the 
glutamate, amino acids that are essential precursors in the formation of the 
N-Acetyl-L-Aspartate Glutamate (NAAG), a neurotransmitter of the central nervous system. 
One hypothesis, currently investigated in the laboratory, is to search for a possible link between 
mt-AspRS and Asp-NAT (L-aspartate N-acetyltransferase). The L-aspartate N-acetyl-
transferase (Asp-NAT, encoded by the NAT8L gene) is a mitochondrial inner membrane-bound 
enzyme, highly specific to L-aspartate and exclusively expressed in the neurons (Truckenmiller 
et al., 1985; Wiame et al., 2009). It synthesizes N-acetyl L-aspartate (NAA), one of the most 
concentrated molecules in the CNS, from N-acetyl Coenzyme A and L-aspartate (Moffett et 
al., 2007). NAA is transferred to the oligodendrocytes (the neuroglial cells responsible for 
creating the myelin sheath), where the aspartoacylase, aminoacylase II (ASPA) hydrolyzes it 
 Conservation of affected position 
Related leukodystrophy throughout 
phylogeny 
in mammals 
subphylum 
Mt-AlaRS ALSP +++ +++ 
Mt-AspRS LBSL Ø +++ 
Mt-GluRS LTBL Ø +++ 
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and uses the acetate moiety for lipid and myelin syntheses (Madhavarao et al., 2005). NAA is 
also the precursor of N-acetyl L-aspartate glutamate (NAAG), a major neurotransmitter in the 
brain (Moffett et al., 2007) (Figure 28). An alteration of both the myelin sheath of the neurons 
and of the NAA concentration in the cerebrospinal fluid has been reported in patients with 
leukodystrophy due to mt-AspRS mutations (van der Knaap et al., 2003). 
 
 
Figure 28. NAA synthesis and metabolism in 
the brain. NAA is synthesized in neuronal 
mitochondria, and can then either be transported to 
oligodendrocytes for fatty acid synthesis and 
energy production, or can be used for the synthesis 
of NAAG in neurons. Taken from (Moffett et al., 
2007). 
 
 
 
 
 
 
 
3.1. Asp-NAT expression in HEK293T cell line 
 The two enzymes, Asp-NAT and mt-AspRS, share the aspartate as a substrate. An novel 
hypothesis is mt-AspRS has a role in the process of NAA synthesis (see above). We thus 
propose to search for a possible link between mt-AspRS and Asp-NAT. Asp-NAT being 
exclusively expressed in neurons, an impairment of such process by LBSL-related mutations 
might then explain the tissue-specificity of the disease. Of note, NAA synthesis was 
demonstrated in SH-SY5Y cells suggesting the expression and functionality of Asp-NAT in 
neuroblastome (Arun et al., 2009); and transfected HEK cells expressing Asp-NAT (not 
naturally expressed in kidney) were shown to artificially synthesize NAA (Wiame et al., 2009). 
SH-SY5Y, Asp-NAT-transfected HEK and non-transfected HEK cells are thus good models to 
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investigate co-localization and physical interaction between Asp-NAT and mt-AspRS. If such 
an interaction exists, it should be visible in the two first cell types, but not in the last one. 
 In order to test the possible association between the mt-AspRS and Asp-NAT, we first 
transfected HEK293T cells with a pCI plasmid encoding to the Asp-NAT (34kDa) protein. 
Given that Asp-NAT in only expressed in neurons it was necessary to verify whether the protein 
was expressed, correct translocated to the mitochondria and well located in the mitochondrial 
membrane (Figure 29). 
 
 
Figure 29. Asp-NAT detection in 
HEK293T cell. Enriched mitochondria 
were transfected with the pCI plasmid 
containing the gene nat8l encoding for 
the Asp-NAT protein prior to 
mitochondrial fractionation to verify 
the correct expression and location of 
Asp-NAT by western blot analysis. The 
detection was done using an anti-His-
tag encoded by the plasmid, at the C-
terminus of the protein. S, soluble; M, 
menbrane fraction. 
 
 
We wonder whether the expression of Asp-NAT display an effect on mt-AspRS double 
location inside mitochondrial. In order to evaluate this, HEK293T cells were transfected with 
pCI plasmid containing nat8l gene followed by a sequence coding for an His-Tag. The, western 
blots analysis was performed first, to confirm Asp-NAT expression and second to check on 
mt-AspRS location. Mt-AspRS was mainly detected in the membrane fraction in both 
transfected and non transfected cells (Figure 30).  
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Figure 30. mt-AspRS location in Asp-
NAT presence. HEK293T cells were 
transfected with pCI plasmid + nat8l 
gene. Mitochondrial fractionation was 
performed prior to western blot analysis 
of the soluble and membrane fraction. 
Mock (control), no Asp-NAT; 
pCI_nat8l, Asp-NAT expression; S, 
soluble and M, membrane fraction.  
 
 
 
After verification of the correct expression of the Asp-NAT protein, translocation to the 
mitochondrial and correct insertion in the mitochondrial membrane, we next performed 
Crosslinking experiences for the purpose of possible interaction of mt-AspRS and Asp-NAT. 
 
3.2. In vitro Crosslinking of mt-AspRS 
To continue the research of a possible interaction between these two proteins, in vitro 
crosslinking was performed (as described in 2.4.4 Material and Methods). Different 
conditions were tested. To test the influence of the presence of Asp-NAT, HEK293T cell were 
transfected with the pCI plasmid containing the sequence coding for the Asp-NAT followed of 
a His-Tag. Briefly, 100 µg of mitochondria protein from transfected and non-transfected (as a 
control) HEK293T were incubated with glutaraldehyde (at 0.02% final concentration) for 20 
minutes under rotation at room temperature. After incubation, the crosslinking reaction was 
stopped by quenching with Tris–HCl 1.5 M (pH 8.8). Samples were concentrated to a final 
volume of 80 µl and supplemented with 20 µl of Laemmli dissociating buffer for SDS-PAGE 
and Western blot analysis.  
As shown in Figure 31, the proteins are detected at their correct theoretical molecular 
weights and in the expected fractions. We refer to “control” when the mitochondrial used were 
from cells not transfected with pCI-nat8l-HisTag. As expected, Asp-NAT is not detected by 
the anti-His-Tag antibody in non-transfected HEK293T cells. In the situation “Transfected 
Asp-NAT” the protein was correctly expressed at the expected theoretical molecular weight. 
The detection of the mt-AspRS was done using a specific antibody addressed against this 
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protein. A change in the quantity of the mt-AspRS is shown when using the crosslinker, and 
the appearance of higher molecular weight complexes is evident (Figure 31). Since these are 
preliminary results, it is necessary to repeat these experiments in order to draw accurate 
conclusions. In previous studies (not shown), similar high molecular weight complexes were 
observed when performing cross-linking experiments with Glutaraldehyde on recombinant mt-
AspRS, expressed in E. coli and purified. We thus hypothesize that those high molecular weight 
forms correspond to an auto-association of the protein, leading to dimers and tetramers of 
mt-AspRS. What is puzzling is the mt-AspRS is not detected in the condition where Asp-NAT 
is expressed. Additionally, the antibody against the His-Tag detect of protein of ~70 kDa (left 
panel) in the same condition, indicating that the Glutaraldehyde either promotes the 
dimerization of the Asp-NAT or that this protein is truly cross-linked with a mitochondrial 
protein partner. Additional experiments are required before being able to reach any conclusion.   
 
 
 
 
 
 
 
 
Figure 31. In vitro crosslinking of mitochondrial proteins by glutaraldehyde. Protein extracts from 
mitochondria from non-transfected (Control) or transfected (Transfected Asp-NAT) HEK293T cells 
were submitted to in vitro crosslinking. Glutaraldehyde was incubated during 20 min to 100 µg of 
protein mitochondria (CL), washing buffer was used as negative control of the crosslinking (W). 
Western blot analysis was done using @mt-AspRS antibody and @His-Tag antibody (for the 
Asp-NAT). 
 
4. Conclusions 
The search for alternative functions for the mt-aaRSs has been an emerging topic of study 
over the past few years. The compendium of a series of characteristics dealt with in this thesis 
manuscript prompts us to propose research strategies aimed at seeking the involvement of at 
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least our two best known proteins, the mt-AspRS and the mt-ArgRS, in other physiological 
processes. We have highlighted at numerous occasions that mutation in patients of these 
enzymes lead to tissue-specificity impairments; mainly focus to the central nervous system. The 
observation of the double location for the mt-AspRS or of its release to the extramitochondrial 
environment under some stress conditions was the inspiration for the research proposed in this 
thesis annex. 
More clues must be found, more strategies established. So, and to give continuity to the 
hypotheses raised here, other work proposals have been drawn up: i) Biochemical 
characterization of a possible partnership in vitro: Asp-NAT is membrane-bounded in 
mitochondria via transmembrane and proline-rich domains. Its production as an active 
recombinant enzyme in bacterial strain was recently established (Wang et al., 2016b). 
Recombinant Asp-NAT could be prepared following the provided protocol, and a possible 
interaction with mt-AspRS may be characterized using classical biochemical approaches 
(mobility shift on native PAGE, gel filtration, among others). In case of a significant interaction 
with the wild-type mt-AspRS, impact of the LBSL-related mutations on the partnership would 
be characterized by investigating recombinant mutant mt-AspRSs. ii) Characterization of 
partnership in cellulo and impact of LBSB-associated mutations: The mt-AspRS was shown to 
have dual localization in HEK cells, and to be released out of purified mitochondria under stress 
conditions (see above). The aim here would be to investigate a possible co-localization between 
mt-AspRS and Asp-NAT in cellulo. As already mentioned, NAA synthesis was demonstrated 
in SH-SY5Y cells (Arun et al., 2009), and, transfected HEK293T cells expressing Asp-NAT 
(not naturally expressed in kidney) were shown to artificially synthesize NAA (Wiame et al., 
2009). SH-SY5Y, Asp-NAT-transfected HEK293T and non-transfected HEK293T cells should 
be thus good models to investigate co-localization and physical interaction between Asp-NAT 
and mt-AspRS. If such an interaction exists, it might be visible in the neurons cell type and 
transfected HEK cells, but not in non-transfected HEK293T cells. 
In all case, we do believe that in order to understand the physiopathological basis of the 
diseases produced by these proteins it is necessary the integration of these molecules in 
processes where their activity may be indispensable, and their dysfunctions accompanied by 
consequences translated into the manifestation of pathologies. 
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Conclusions and perspectives 
 Scientific context. The first description of a correlation between a mutation affecting a 
mt-aaRS and a human disease dates back to a decade, when mutations within the DARS2 gene 
(coding for the mt-AspRS) were associated with a leukodystrophy (Scheper et al., 2007). This 
first description attracted the attention of the medical community so that many other 
disease-associated mutations have been described since. Today, mutations in all the 
19 mt-aaRS-encoding genes have been reported and the related diseases are now described at 
an increased frequency and revealing to be complex (Diodato et al., 2014a; Konovalova and 
Tyynismaa, 2013; Moulinier et al., 2017; Rötig, 2011; Schwenzer et al., 2014b; Sissler et al., 
2017). The complexity is not only due to the variety of phenotypic expressions, with tissue-
specific phenotypic imprints, but also due to the absence, for the moment, of clear mechanistic 
explanations for most of the systems. This leads to an emerging demand for basic knowledge 
on functional properties and organization of mt-aaRSs. In this context, one of the main goals of 
our research group is to understand the fundamental mechanisms of the human mitochondrial 
translation machinery, focusing the interest on the mt-aaRSs and mt-tRNAs. In the past years, 
the host laboratory has particularly focused on the human mt-AspRS and established some 
functional (Bonnefond et al., 2005a; Fender et al., 2012; Fender et al., 2004; Messmer et al., 
2009; Neuenfeldt et al., 2013; Schwenzer et al., 2014a) and structural (Gaudry et al., 2012; 
Neuenfeldt et al., 2013) properties/peculiarities of this enzyme; as well as investigated its role 
in mitochondrial diseases (Gonzalez-Serrano et al., 2018; Messmer et al., 2011; Sauter et al., 
2015; Scheper et al., 2007; van Berge et al., 2013). The above-mentioned works plus the 
contributions of many other groups have rapidly revealed that the human mt-aaRSs have 
numerous functional and structural peculiarities (recalled in the introduction) that distinguish 
them from the classical view/knowledge, now of text-book type, established for aaRSs from 
other organisms. Those peculiarities and the lack of deep and comprehensive fundamental 
knowledge is a strong obstacle for the understanding of the related human disorders.   
My contribution. The work performed during my PhD follows the long-standing efforts 
of the host laboratory but was aimed at expanding the interest and the knowledge towards an 
unexplored system: the human mitochondrial arginyl-tRNA synthetase. This enzyme was 
poorly characterized despite an increasing number of descriptions of patients, mutated in this 
enzyme and suffering from a severe neurodevelopmental disease. My PhD work was a 
significant contribution to this new orientation to the team's interests, and the major outcomes 
from my work are summarized here. 
 148 
The clinical analysis of the phenotypes presented by the patients provided a more 
comprehensive vision of the mitochondrial pathologies related to mt-aaRS. This allowed the 
identification of groups of mt-aaRS that affect a same anatomical organ system: those affecting 
exclusively the central nervous system (CNS), affecting the CNS AND an other system, 
affecting the CNS OR an other system and the last one affecting other system than the CNS. 
Among those affecting the CNS, we could highlight differences in clinical manifestations, the 
severity of these as well as the age of onset of the disease. This was the case with LBSL and 
PCH6, which represent our comparative systems for two synthetases that cause damage to the 
CNS. This categorization allowed an overview of the situation regarding the clinical 
manifestations of pathologies correlated with the mt-aaRSs. 
 The analysis of the cellular properties of the mt-ArgRS was also essential and widened 
the collection of peculiarities so far described for human mt-aaRSs. Whereas mt-AspRS had 
been identified double localized in the mitochondria (in the soluble and in the membrane 
mitochondrial fractions), I demonstrated that mt-ArgRS is exclusively located in the membrane 
fraction and its anchoring is done by hydrophobic interactions. The observation of distinct 
locations for two enzymes presumably involved in the same cellular translation process suggests 
that these proteins have distinct cellular properties, thus probably allowing additional unveiled 
functions. The analysis is currently being extended to other mt-aaRSs in the laboratory, and so 
far now, it has been shown that two other enzymes, LysRS and mt-LeuRS, are present only in 
the soluble fraction. Thus, we establish the sub-mitochondrial localization of four mt-aaRSs and 
demonstrate that regardless of their common role in the aminoacylation of cognate tRNAs, 
the mt-aaRSs have distinct intra-mitochondrial localizations and distributions. 
A further investigation during my PhD work was to assess the impact of some PCH6-
causing mutations first in cellulo on properties of mt-ArgRS, and second in vitro on the 
aminoacylation function of the protein, not explored so far. I show that none of the 
PCH6-mutations has an impact on the location or on the aminoacylation property of the 
mt-ArgRS, whereas a strong impact was anticipated. I also investigated the impact of LBSL-
related mutations on the release of the mt-AspRS out of the mitochondria under specific 
chemical conditions, observed by a previous PhD student. I show that none of the tested mutants 
affects this release. All these contributions further reveal that disease-related mutations have 
either no or only minor but distinct impacts on the canonical properties of the investigated mt-
aaRSs. This indicates that, at least for the mt-ArgRS and the mt-AspRS, the housekeeping 
role of the mt-aaRS in the protein synthesis is not the general target of the mutations. This 
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is finally in concordance with the absence of patients with multi-systemic affections and 
prompts us to envision new perspectives.  
 Major outcomes and towards new questions to solve. Some of the major outputs from 
this present work are: i) that mt-aaRSs have different cellular properties which suggests different 
functional roles that will need to be unveiled; ii) all the mt-aaRS are correlated with pathological 
disorders; iii) until now, there is no common combination of molecular mechanisms that explain 
the various phenotypic expressions observed in patients leaving unsolved the physiopathology 
of these disorders; iii) the pathologies have a target for high energy-demand tissues. All these 
observations may reflect the integration of mitochondrial translation process within cellular 
homeostasis; these may occur through specific crosstalk(s) between the cellular program and 
cellular energy demands, especially in neuronal cells. It calls for the necessity of a better 
comprehension of how the mitochondrial translation is indeed integrated within different cells 
and tissues. This should be done taking into account the notion of space (possible modulations 
or peculiarities that would be tissues-specific), of time (possible modulations or peculiarities 
that would vary during the different developmental stages), and under different conditions 
(physiological and/or physiopathological).  
 The following are some of the ideas that emerge from the integration of information 
from previous work by our team and others, along with the information obtained from my 
research work. I have listed below perspectives not previously mentioned at the end of each 
chapter. I contributed to initiate those currently under investigations in the laboratory.  
 
Possible perspectives, among others. 
 The host laboratory has previously developed a knowledge-based repository coupled 
with a web server (http:// misynpat.org), which at the moment integrates and links clinical, 
genetic, and structural data on disease-related mutations of human mt-aaRSs (Moulinier et al., 
2017). One important contributions of my present work is the clinical categorization of the mt-
aaRSs-related diseases. We believe that the development of a database (or the extension of the 
existing one) where the medical community can systematically update each new diagnosed 
case, add a detailed clinical description, with complementary medical analyses, associated 
genetic studies (of the patient and the relatives concerned) and, above all, where a chronological 
follow-up of the clinical history of patients with mt-aaRSs disorders must fulfilled, would be 
an additional useful tool for both fundamental researchers and physicians. To further complete 
this initiative, the creation of a bank of biopsies (from living or post-mortem patients) where 
 150 
the materials obtained would be accessible to the scientific community involved in these 
mitochondrial pathologies, would contribute a further value to the advancement of global 
research in this field. Nowadays, the clinical management of patients with mt-aaRSs disorders 
is still limited to symptomatic treatment. The fundamental understanding of mt-aaRSs at a first 
glance, followed by shedding new lights on of the particularities that each mt-aaRSs could 
perform in specific organ- tissue- or cells will be the key to establish clear and concrete 
explanations of the pathological mechanisms related to these diseases. 
 In order to increase the fundamental knowledge of the human mt-aaRSs, we shall for 
example recall that the MTS, besides the fact that it creates difficulties in the design of soluble 
and functional recombinant proteins, also constitutes a pool of diversity for some mitochondrial 
proteins. This was shown for the mt-AspRS, but is probably also the case for mt-ArgRS and/or 
other mt-aaRSs (Carapito et al., 2017). The existence of different forms of mt-aaRSs after in 
organello maturation and cleavage would, if their existences are confirmed and biological 
relevance established, represents a valuable breeding ground for protein multifunctionality. 
This is an aspect that has not yet been investigated and should be taken into account. 
 Regarding the cellular integration of the mitochondrial translation and considering the 
possible modulations or peculiarities that would be tissues-specific, perspectives remain 
challenging. Several hypotheses have been evoked when trying to understand the tissue 
specificity of some mt-aaRS-related diseases. For instance, it has been suggested that 
tissue-specific differences in mitochondrial chaperone activities have a participation in 
determining the stability or the instability of some mutants (Konovalova and Tyynismaa, 2013). 
In the case of LBSL patients, most of them have a mutation in intron 2 of DARS2, which affects 
the splicing of the third exon. Using a splicing reporter construct, van Berge et al. find cell-
type-specific differences in the sensitivity to these mutations: the mutations have a larger effect 
on exon 3 exclusion in neural cell lines, especially neuronal cell lines, than in non-neural cell 
lines (van Berge et al., 2012). Other hypothesis regarding the tissue-specificity was proposed 
by Götz et al. when studying the clinical manifestations of the cardiomyopathy produced by 
mutations in mt-AlaRS. They hypothesized that the tissue-specific manifestation of the 
cardiomyopathy could be explained by variable amino acid concentrations in different tissues, 
especially those of glycine and serine, which in the case of proofreading-deficient mt-AlaRS 
could influence the misincorporation rate of serine and glycine in RC complexes. Their results 
did not show considerable differences in glycine or serine concentrations between tissues, but 
increased levels of alanine in the patient heart and muscle, but not in the liver. The authors 
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proposed that given that alanine can be secreted from RC-deficient skeletal muscle for 
gluconeogenesis in the liver, the high alanine might be an unspecific response to RC defect 
(Götz et al., 2011). 
  Another way to tackle this issue is to consider the implication of the mt-aaRSs into 
alternate functions. Several examples of such alternate function have been provided for human 
cytosolic aaRSs, but only a few are reported for the mt-aaRS. It is only recently that a pro-
angiogenic function of the rat mt-TrpRS (Wang et al., 2016a) and a cysteine polysulfidation 
activity of the mice and the human mt-CysRSs (Akaike et al., 2017) have been identified. We 
should unveil the environmental contributions that either modify or modulate mitochondrial 
translation from those involved in moonlighting activities. Following these lines, we initiated a 
project, whose aim is to uncover a CNS-specific role(s) of the mt-AspRS. To do so, we first 
consider a possible implication of the mt-AspRS in the process of N-acetyl L-Aspartate (NAA) 
synthesis by a neuron-specific transferase (literature-based hypothesis), knowing that the two 
enzymes use aspartate as a substrate. The rational of this project, as well as the experiments that 
are currently performed and the corresponding perspectives are provided in the Annex. 
Meanwhile, a complementary strategy has been initiated in collaboration (Hélène Puccio, 
IGBMC, Illkirch). Neuronal (SH-SY5Y) and oligodendrocyte (MO3.13) cellular models 
(conditional mutants) will be generated using CRISPR-Cas9 approaches to investigate the 
impacts of LBSL-related mutations on the cellular function, with a particular focus on 
mitochondrial function. Our rationale is to focus on missense disease-related mutations 
identified in patients that have kept canonical aminoacylation properties (See Table 5). We 
hypothesize that these mutations have a common impact on the neuronal-specific alternate 
role/property of the mt-AspRS (visible only in SH-SY5Y-derived cells), in addition to the 
distinctive impacts on the canonical properties of the enzyme, visible in all investigated cell 
types (SH-SY5Y, M03.13 and HEK293T).   
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Mutations Expected impact of mutation on the function 
Expected phenotype in 
HEK 293 
Expected 
phenotype in 
Neurones 
Expected phenotype 
in Oligodendrocytes 
R263X 
Complete KO – 
Loss of canonical and 
moonlighting function 
no growth no growth no growth 
Q184K Loss of canonical and moonlighting function Mild/severe Severe Mid/severe 
R263Q Loss of canonical and moonlighting function Mild/severe Severe Mild/severe 
R58G Loss of moonlighting function No effect Severe No effect 
T136S Loss of moonlighting function No effect Severe No effect 
L613F Loss of moonlighting function No effect Severe No effect 
L626Q Loss of moonlighting function No effect Severe No effect 
Table 5. Choice of mutations that we will use to generate cellular models and their possible impact in 
different cell types based on in vitro data and our hypothesis. All the selected mutations are reported in 
LBSL-patients. 
  Regarding the cellular integration of the mitochondrial translation, the specific case of 
neuronal cells should be mentioned. Indeed, neuronal cells present a great diversity of 
morphologies and an extremely high-energy demand. Due to these extremely varied 
morphological features, neurons face exceptional challenges to maintain the energy 
homeostasis. Neurons require specialized mechanisms to efficiently distribute mitochondria to 
far distal areas where energy is in high demand, such as synaptic terminals, active growth cones, 
and axonal branches. Functional mitochondria must thus be efficiently transported to distal 
regions of neuronal cells where specific quality-control mechanisms can remove dysfunctional 
mitochondria. Thus, one can wonder if the mitochondrial translation itself undergoes specific 
pathways in response to such exceptional situation.  
 Now, considering the cellular integration of the mitochondrial translation taking in a 
notion of time, and considering possible modulations or peculiarities that would vary during 
the different developmental stages, the perspectives are even more challenging. We indeed have 
referred that the mutations on mt-aaRSs may participate at some point in the development of 
embryonic tissues. It is easy to realize that the verification of this idea is not easy to accomplish, 
at least in human. The production of conditional tissue-specific animal models for different mt-
aaRSs could provide an insight into the pathological mechanisms and the selective tissue 
involvement caused by mutations in these ubiquitously expressed enzymes. The cessation of 
the embryonic process at different stages, followed by the verification of each affected organ, 
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would allow elucidating the possible involvement of the mt-aaRSs in specific embryonic 
development of an organ or tissue. One of the characteristics highlighted during the clinical 
analysis of mutation-related pathologies in mt-aaRS (chapter I) was the onset-age of the clinical 
manifestations. Pontocerebellar hypoplasia type 6 (PCH6) is one of the ideal models to 
investigate the notion of time. PCH6 is produced by mutations in RARS2 (Edvardson et al., 
2007) and has a very early onset, in most cases within few hours after birth (Zhang et al., 2018), 
suggesting that damages might occur during the embryonic development. The hallmark sign of 
this pathology is a hypoplasia of the pons (Kastrissianakis et al., 2013), a sign easy to identify 
using neuroimaging analysis. The creation of animal models carrying the PCH6 genotypic 
compound, followed by cessation of the gestation in different stages may allow the 
determination of pathologic changes in the brain structures. This would allow us to establish if 
there is a specific moment during embryogenesis that the participation of mt ArgRS is more 
essential than in another. 
All this together, we point out that there is still much to do, that each new piece of 
information opens up more perspectives for research. In any case, we believe that the 
contribution of this work will promote more lines of investigations, and that in the end, the 
integration of a clinical and a fundamental research will allow us to continue expanding the 
knowledge of this family of enzymes. Above all, to understand the pathologies and later in the 
future to be able to develop therapeutic strategies. 
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Materials and Methods 
 
1. Materials 
 
1.1. Chemical products 
Acetic acid Roth 
Acrylamide/bisacrylamide (Rotiphorese Gel 30/40) Carl Roth 
Ammonium chloride (NH4Cl) Sigma-Aldrich 
Ammonium sulfate Roth 
Ammonium persulfate (APS) Carl Roth 
Ampicillin Sigma-Aldrich 
Arginine, L-[2,3,4 -3H] Hartmann Analytic 
Calcium chloride (CaCl2) Roth 
Chlorophorm Carl Roth 
ECL Western blotting Substrate Fisher Scientific 
Ethanol VWR 
Ethidium bromide ICN 
Ethylenediaminetetraacetic acid (EDTA)  Euromedex 
Glucose Sigma-Aldrich 
Glutaraldehyde Sigma 
Glycerol Carl Roth 
HEPES Euromedex 
HIS-Select® HF Nickel Affinity Gel Sigma-Aldrich 
Hydrochloric acid AnalaR NORMAPUR 
Imidazole Sigma-Aldrich 
IPTG Euromedex 
Isopropanol Sigma-Aldrich 
K1 – Potassium phosphate dibasic (H2PO4-, K+) Merck Millipore 
K2 – Potassium phosphate monobasic (HPO42-, 2K+) Merck Millipore 
L-Arginine Sigma-Aldrich 
LB Carl Roth 
Magnesium chloride (MgCl2) VWR 
Methanol VWR 
Mini-Protean Ò TGX Precast polyacrylamid gels BioRad 
n-Dodecyl-b-D-Maltopyranoside (DDM) CliniSciences 
Na1 – Sodium phosphate dibasic (NaH2PO4) Merck Millipore 
Na2 – Sodium phosphate monobasic (Na2HPO4) Merck Millipore 
Phenol Carl Roth 
Potassium carbonate Sigma-Aldrich 
Potassium chloride (KCl) Panreac 
Potassium hydroxide (KOH) Sigma-Aldrich 
ProteaseArrest™ Protease Inhibitor Cocktails G-Biosciences 
Sodium acetate Carl Roth 
Sodium carbonate Sigma-Aldrich 
Sodium chloride (NaCl) VWR 
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Sodium dodecyl sulfate (SDS) Sigma-Aldrich 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Spermidine Sigma-Aldrich 
ß-Mercaptoethanol Carl Roth 
TBE Euromedex 
TEMED Acros 
Trans-Blot Turbo PVDF system BioRad 
Trichloroacetic acid (TCA) Carl Roth 
TriReagent Sigma-Aldrich 
Tris-base Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
Urea Sigma-Aldrich 
 
1.2. Cell culture 
BHK-21 ATCC 
HEK293T Invitrogen 
SH-SY5Y Sigma-Aldrich 
Fibroblasts Imagine Institute (Paris) 
Hepatocytes CarMeN Laboratory (Lyon) 
Myotubes CarMeN Laboratory (Lyon) 
 
Dubelcco’s Modified Eagle’s Medium (DMEM) Gibco 
Fetal Calf Serum (FCS) Eurobio 
Glasglow-MEM (GMEM) Gibco 
Modified Vaccinia Ankara (MVA-EM21) IGBMC (Strasbourg) 
Penicillin-streptomycin (pen-strep) Gibco 
Phosphate Buffered Saline (PBS) Gibco 
Polyethlenimine (PEI) Polyscience 
Trypsin EDTA Gibco 
Tryptose phosphate broth Gibco 
Roswell Park Memorial Institute (RPMI) 1640 Medium Gibco 
 
1.3. Bacterial Strains 
 
E. coli One ShotÒ TOP 10 Invitrogen 
BL21(DE3) Competent E. coli  New England BiolabsÒ 
  
1.4. Enzymes 
 
DpnI New England BiolabsÒ 
FastAP Thermo Scientific 
NdeI New England BiolabsÒ 
NotI New England BiolabsÒ 
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Phusion High Fidelity DNA Polymerase Thermo Scientifics 
SalI New England BiolabsÒ 
T4 DNA ligase  Thermo Fisher Scientific 
Taq polymerase IBMC production 
XhoI New England BiolabsÒ 
XmaI New England BiolabsÒ 
 
1.5. Plasmids 
 
pCI Mammalian Expression Vector Promega 
pDEST14 Thermo Fisher Scientific 
pBCJ749.77 (Jester et al., 2011) 
 
 
 
 
1.6. Primers 
 
Primers were purchased lyophilized, from Integrated DNA Technologies (IDTÒ). Upon 
arrival primers were resuspended in H2O mQ to a final concentration of 100 µM and stored as 
stock solution at -20°C.  
 
I. Amplification of hm_mt-ArgRS from pBCJ739.14 
Type Sequence 5’ ® 3’ 
Fw AAATCTCGAGATGGCGTGCGGCTTTCG 
Rv TTTGGCGGCCGCTTAGTGGTGGTGGT 
 
II. Mutagenesis PCR for mutants of mt-ArgRS in pCI Purpose 
Fw GCTTTCGCCGCGCTGTTGCTTGCCAGC 
p.I9V 
Rv GCTGGCAAGCAACAGCGCGGCGAAAGC 
Fw GCTATTGCTTGCCGGCTTTCCAGAGTG 
p.Q12R 
Rv CACTCTGGAAAGCCGGCAAGCAATAGC 
Fw GCACTTTCACTGAGGCAAAAATTTCG 
p.W241R 
Rv CGAAATTTTTGCCTCAGTGAAAGTGC 
Fw CACTGTGGCAAAAATTTCAGGACTTGAGCATTGAAG 
p.R245Q 
Rv CTTCAATGCTCAAGTCCTGAAATTTTTGCCACAGTG 
Fw CATTCGGGTTTACAAGCATCTGGGAGTATATTTTG 
p.R258H 
Rv CAAAATATACTCCCAGATGCTTGTAAACCCGAATG 
Fw GGTCTTAAAGTTGCAGGAGAGTAAAGGAC 
p.L283Q 
Rv GTCCTTTACTCTCCTGCAACTTTAAGACC 
Fw GCTGCTATAGATGGAATGGACAAG 
p.R333G 
Rv CTTGTCCATTCGATCTATAGCAGC 
Fw GGACAAGTATAATTTTGATACAGTGATATATGTGACAGATAAAGG p.M342V 
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Rv CCTTTATCTGTCACATATATCACTGTATCAAAATTATACTTGTCC 
Fw GAGATTCAATTAAGGAAGCTACAGAACATGGC 
p.M404K 
Rv GCCATGTTCTGTAGCTTCCTTAATTGAATCTC 
Fw CACACACGCCCACCTCCACAGTTTG 
p.R469H 
Rv CAAACTGTGGAGGTGGGCGTGTGTG 
Fw GGAAGAGACTTTTAGATGTGGGTACC 
p.G478R 
Rv GGTACCCACATCTAAAAGTCTCTTCC 
Fw CCTTCTAACTTTAAGTTATCTTGCAGCTGTGG 
p.H530Y 
Rv CCACAGCTGCAAGATAACTTAAAGTTAGAAGG 
 
 
IV. Mutagenesis PCR for mutants of L72_mt-ArgRS in pDEST Purpose 
Fw CGTTGTGGAATGCAGTAGTCCC 
p.F131C 
Rv GGGACTACTGCATTCCACAACG 
Fw GGCAGAAATTCCAGGATCTGAGTATCG 
p.R245Q_1 
Rv CGATACTCAGATCCTGGAATTTCTGCC 
Fw GGCAGAAATTCCACGATCTGAGTATCG 
p.R245Q_2 
Rv CGATACTCAGATCGTGGAATTTCTGCC 
Fw GGTGCTGAAACTTCAAGAAAGTAAGGG 
p.L283Q_1 
Rv CCCTTACTTTCTTGAAGTTTCAGCACC 
Fw GGTGCTGAAACTTCTAGAAAGTAAGGG 
p.L283Q_2 
Rv CCCTTACTTTCTAGAAGTTTCAGCACC 
Fw GTATACGCATGCGCATCTTCATTCGCTCG 
p.R469H 
Rv CGAGCGAATGAAGATGCGCATGCGTATAC 
Fw CTTTTAACGCTTTCTTATCTGGCCGCGGTC 
p.H530Y 
Rv GACCGCGGCCAGATAAGAAAGCGTTAAAAG 
 
 
V. Northen Blot Hybridization 
Type human mt-tRNAArg nucleotides 10421-10441 
Fw GAGTCGAAATCATTCGTTTTG 
                               human mt-tRNALeu nucleotides 3275-3293 
Fw CAGTCAGAGCTTCAATTCC 
 
 
 
 
 
III. Cloning different N-Termini of mt-ArgRS in pDEST Purpose 
Fw GGCGCGCATATGAACCTGCCGCCAGAGAATCTGATTACGTCGATCTCCGCCGTGCCCATCT
CGCAAAAGGAAGAGG N-Term N18 
Fw GGCGCGCATATGTCGATCTCCGCCGTGCCCATCTCGCAAAAGGAAGAGGTAGCAGATTTTC
AGCTGTCCGTGG N-Term S27 
Fw GGCGCGCATATGCTTCGCTGCGATACCGTCGTC N-Term L72 
Fw GGCGCGCATATGTGCGATACCGTCGTCTCTGAGATCTCTACTGGACAGCGCACTGTCAACTT
TAAAATCAACCGCGAGC N-Term C74 
Fw GGCGCGCATATGATCGTTGTGGAATTCAGTAGTCCCAATGTGGCG N-Term I127 
Rv ATTTTTACTCGAGTCAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGCATACGGCAAACTGG
CGTAATACC All_reverse 
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1.7. Antibodies 
 
Protein Antigen Specificity Clonality Source Dilution Reference 
Mitochondrial aspartyl-
tRNA synthetase mt-AspRS 486-497 aa Human Polyclonal Rabbit 1/40000 
IGBMC 
(Illkirch) 
Mitochondrial arginyl-
tRNA synthetase mt-ArgRS 377-406 aa Human Polyclonal Rabbit 1/1000 
Abcam 
Prohibitin PHB 100-200 aa Hu, Ms, Rt Polyclonal Rabbit 1/30000 
Superoxide dismutase SOD2 Full length Hu, Ms, Rt Polyclonal Rabbit 1/10000 
Anti-Flag  Flag-Tag HRP DYKDDDDK - Monoclonal Mouse 1/2000 
Anti-His tag His-Tag HRP HHHHHH - Polyclonal Rabbit 1/30000 
Anti-Rabbit secondary 
antibody 
Rabbit-
HRP - Rabbit Polyclonal Goat 1/15000 BioRad 
 
Table 6. List of all used commercial antibodies. 
1.8. Patients’ features 
 
Fibroblasts were isolated from healthy, LBSL- and PCH6-diagnosed patients (skin 
biopsy) at the Institute IMAGINE (Paris). Informed consent for diagnostic and research studies 
was obtained for all subjects in accordance with the Declaration of Helsinki protocols and 
approved by local Institutional Review Boards in Paris. 
LBSL patient is compound heterozygous for two DARS2 variants, a missense variant 
(c.1013G>A; p.G338E) and a previously reported nonsense truncating variant (c.228-21_228-
20delinsC; p.R76SfsX5) (Scheper et al., 2007) 
PCH6 patient is compound heterozygous for two RARS2 variants, a missense variant 
(c.29C>T; p.A10V) and a splicing variant (c.298G-1>A) causing a frameshift and a premature 
termination codon (p.T100Cfs*5) 
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2. Methods 
2.1. Cell Culture 
2.1.1. Cell lines 
2.1.1.1.  HEK 293T 
 
 Human Embryonic Kidney 293T cells (HEK293T, Invitrogen) were grown in 
DMEM supplemented with 10% FCS and 1% Penicillin-Streptomycin at 37°C in a 5% 
CO2 humidified incubator. For cell splitting (~every 2 days), cells at 80% of confluence 
were washed with PBS (Phosphate Buffered Saline, Gibco) and trypsinized (0,25% 
Trypsin-EDTA) for two minutes. Then, 10 ml of medium containing FCS were added 
to stop the trypsin reaction. Cells were seeded in new plates at dilution 1/10. For 
cryopreservation, cells (~2.106 cells/ml) were frozen in growth medium containing 10% 
DMSO at -80°C using Mr. FrostyTM Freezing Container (Nalgen®) for one day, then 
cells were stored in liquid nitrogen.  
2.1.1.2. SH-SY5Y 
 Human neuroblastoma SH-SY5Y cells (SH-SY5Y, Sigma Aldrich) were grown 
in RPMI supplemented with 10% FCS and 1% Pen-Strep at 37°C in a 5% CO2 
humidified incubator. For cell splitting, cells at 80% of confluence were washed with 
PBS and trypsinized for two minutes. Then, 10 ml of medium containing FCS were 
added to stop the trypsin reaction. Cells were seeded in new plates at dilution 1/8. 
Growth medium was changed every 2 days. For cryopreservation, cells (~2.106 
cells/ml) were frozen in growth medium containing 10% DMSO at -80°C using Mr. 
FrostyTM Freezing Container for one day, then cells were stored in liquid nitrogen. 
2.1.1.3. Fibroblasts derived from patients 
 Human skin fibroblasts were from the Imagine Institute (Paris). Fibroblasts 
were grown in DMEM supplemented with 10% FCS and 1% Pen-Strep at 37°C, in a 
5% CO2 humidified incubator. Growth medium was changed every 2 days and cells 
were split approximately once a week. Fibroblasts at 60-70% of confluence were 
washed with PBS and trypsinized for two minutes. Then, 10 ml of medium containing 
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FCS were added to stop the trypsin reaction. Cells were seeded in new plates at dilution 
1/5. For cryopreservation, cells (~2.106 cells/ml) were frozen in growth medium 
containing 10% DMSO at -80°C using Mr. FrostyTM Freezing Container for one day, 
then cells were stored in liquid nitrogen. 
2.1.1.4. BHK21 
 Baby Hamster Kidney (BHK21) cells were grown in GMEM medium 
supplemented with 10% FCS, 5% Tryptose Phosphate Broth and 1% Pen-Strep at 37°C, 
in a 5% CO2 humidified incubator. Cells at 80% of confluence were washed with PBS 
and trypsinized for two minutes. Then, 10 ml of medium containing FCS were added 
to stop the trypsin reaction. Cells were seeded in new plates at dilution 1/10. Cell 
splitting was done every two days. For cryopreservation, cells (~2.106 cells/ml) were 
frozen in growth medium containing 10% DMSO at -80°C using Mr. FrostyTM Freezing 
Container for one day, then cells were stored in liquid nitrogen. 
2.2. BHK21 cell infection/transfection and mt-AspRS 
production 
2.2.1. BHK21 infection/Vaccinia Virus expression 
system 
 
An engineered mammalian expression system composed of Modified Vaccinia 
virus Ankara (MVA) and Baby Hamster Kidney cells (BHK21) was developed in the 
lab and published (Jester et al., 2011). This method is based on the controlled 
expression of recombinant proteins using the T7 RNA polymerase provided by the 
MVA. The original vector pBCJ739.14, designed and prepared by Brian Jester (Jester 
et al., 2011) contains the sequence coding for the wt mt-AspRS under the dependence 
of T7 promotor. The mutated sequences of mt-AspRS were prepared by L. Karim 
(Sauter et al., 2015). 
2.2.2. mt-AspRS production in BHK21 
 Transfection of BHK21 cells was performed as described in Sauter et al. 2015. 
(Sauter et al., 2015). Briefly, for one 150-cm2 plate of BHK21 previously seeded with 
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4.106 cells, cells were washed with PBS and infected with modified vaccinia virus 
(MVA) expressing IPTG-inducible T7 polymerase. Infection was performed by adding 
50 µl of MVA in 1 ml of GMEM (without FCS) per plate of 150-cm2. Every 10 minutes, 
plates were tilted to avoid drying and to spread virus over cells. After 30 minutes of 
incubation with MVA, 14 ml of GMEM (supplemented with 10% FCS, 5% TPB and 
1% Pen-Strep) were added to cells. Then, cells were transfected using polyethylenimine 
(PEI) with plasmids expressing either the wild-type mt-AspRS  (pBCJ749.77) or the 
LBSL-related mutants. Expressed proteins correspond to full-length enzymes including 
the N-terminal mitochondrial targeting sequence (MTS) and the C-terminal Flag-Tag 
sequence (DYKDDDDK). Protein expression is under the dependence of T7 promoter. 
Plasmids/PEI complexes were prepared in a ratio of 1:4.5 (w/w) and incubated for 15 
minutes at room temperature prior to transfection (5 µg DNA per plate 150-cm2). After 
36 hours of transfection, cells were harvested for further studies. 
 
2.3. HEK 293T cell transfection and mt-ArgRS 
production 
2.3.1. Vector 
 The pCI Mammalian Expression Vector (Promega) was use to express wild-
type mt-ArgRS (corresponding to the full length of RARS2 including its MTS and 
followed by the sequence coding for the Flag Tag and the (His)6-Tag at the C-Terminal) 
and mutants. The sequence coding for the wt mt-ArgRS was amplified from a plasmid 
available in the laboratory, previously prepared by Agnes Gaudry and named pBCJ-
ArgRS-full length-Flag-Histag, and then cloned into the NdeI and XhoI sites of the pCI 
vector. Mutations c.25A>G (p.I9V), c.35A>G (p.Q12R), c.721T>A (p.W241R), 
c.734G>A (p.R245Q), c.773G>A (p.R258H), c.848T>A (p.L283Q), c.997C>G 
(p.R333G), c.1024A>G (p.M342V), c.1211T>A (p.M404K), c.1406G>A (p.R469H), 
c.1432G>A (p.G478R), c.1588C>T (p.H530Y) were introduced by site-directed 
mutagenesis using Phusion High-Fidelity DNA Polymerase (Thermo ScientificTM) 
following the protocol described below. The primers used for mutagenesis are listed in 
section 1.6, II. 
 
 165 
2.3.2. mt-ArgRS production in HEK293T cells 
 The expression of recombinant mt-ArgRS (WT and mutants) was performed by 
transfection of HEK293T cells using pCI mammalian expression vector. A 150-cm2 
plate of HEK293T cells at 50% of confluence was washed with PBS and 14 ml of 
DMEM (supplemented with 10% FCS and 1% Pen-Strep) were added one hour before 
transfection. Plasmids/PEI complex was prepared in a radio 1:4.5 (w/w) in 1 ml of 
DMEM (without FCS) and incubated for 15 minutes at room temperature prior to 
transfection (5 µg DNA per plate 150-cm2). After 36 hours of transfection, cells were 
harvested for further studies. 
2.4. Mitochondrial enrichment and fractionation 
2.4.1. Mitochondrial isolation 
Mitochondria were enriched from different cell lines using differential 
centrifugation steps. Cells were harvested and washed two times with PBS. Afterwards, 
cells were resuspended in an isotonic buffer (220 mM Mannitol, 70 mM Sucrose, 1 mM 
MgCl2, 1 mM EDTA, 10 mM HEPES-KOH pH 7.5) and mechanically disrupted using 
2 mm diameter ceramic beads in a FastPrep-24TM 5G Machine (MP biomedicals). The 
lysate was centrifuged 10 minutes at 400 g at 4°C to remove the pellet containing 
residual intact cells, nuclei and debris. The supernatant (containing mitochondria) was 
centrifuged 10 minutes at 16 000 g at 4°C to collect crude mitochondria. 
2.4.2. Sub-mitochondrial fractionation 
Enriched mitochondria (~30 mg) were resuspended in 1 ml of isotonic washing 
buffer (300 mM Mannitol, 10 mM K2HPO4/KH2PO4 pH 7.5, 1 mM EDTA) containing 
1x Protease inhibitor cocktail (Protease Arrest, G-Bioscience). Mitochondria were 
sonicated three times for 10 seconds (4W) on ice and then centrifuged at 16 000 g to 
remove unbroken mitochondria (residual fraction). The mitochondria lysate was 
subsequently ultracentrifuged at 125 000 g, 30 minutes at 4°C in 1,5 ml Microfuge 
Tube Polypropilene (Beckman Coulter®) to separate the soluble fraction (supernatant, 
containing molecules from the mitochondrial matrix and the inner mitochondrial space) 
and the membrane fraction (pellet, containing molecules from both inner and outer 
membranes). Membrane and residual fractions were solubilized in 80 µl of washing 
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buffer, while soluble fraction was concentrated to the same final volume (80 µl) using 
Amicon® Ultra – 0.5 ml, exclusion size 10 kDa (Millipore). 
2.4.3. Treatment of isolated mitochondria 
2.4.3.1. Chemical treatments 
Enriched mitochondria (~30 mg per experiment) were sonicated (three times for 
10 seconds at 4W on ice) in the presence of different chemical agents (1M - 8M 
Urea, 0.1 M Na2CO3 M pH 11, 0.5 M KCl, 0.4 M DTT, or 1 M NH2OH at pH 7 
and pH 11) in 1 ml of washing buffer containing protease inhibitor cocktail. After 
sonication, mitochondria underwent sub-mitochondrial fractionation (section 
2.4.2). 
 
2.4.3.2. Incubation of mitochondria with ATP 
Enriched mitochondria (~30 mg per experiment) were incubated with ATP 
(10 mM) in 1 ml of washing buffer containing a protease inhibitor cocktail for 10 min 
at 20 °C. After treatment, mitochondria were centrifuged 10 minutes at 16 000 g at 4°C 
so that to separate the supernatant (named extra-mitochondrial medium or EM) from 
mitochondrial pellet. This latter was either kept intact or fractionated. Extra-
mitochondrial medium was ultracentrifuged 30 minutes at 125 000 g at 4°C, and the 
resulting supernatant is then concentrated to a final volume (80 µl) using Amicon® Ultra 
– 0.5 ml, exclusion size 10 kDa (Millipore). 
2.4.4. In vitro Cross-linking with Glutaraldehyde 
Mitochondria enriched (~50 mg) from HEK293T cells  were resuspended in 
20 mM KH2PO4/K2HPO4 pH 7.5 (10 µl/mg wet pellet) containing a protease inhibitor 
cocktail. After sonication 6 times for 10 seconds (4W) on ice, the mitochondrial lysate 
was centrifuged 10 minutes at 16 000 g at 4°C. The pellet was discarded and the 
proteins content within the supernatant was quantified following a standard Bradford 
assay (Bradford 1976). 100 µg of mitochondrial proteins were incubated with 
glutaraldehyde (at 0.02% final concentration) for 5, 10 and 20 minutes in 1 ml of 
20 mM KH2PO4/K2HPO4 pH 7.5 under rotation at room temperature. After incubation, 
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the cross-linking reaction was stopped by quenching with 100 µl of 1.5 M Tris–HCl pH 
8.8. Samples were concentrated to a final volume of 80 µl using Amicon® Ultra – 
0.5 ml, exclusion size 10 kDa (Millipore) and supplemented with 20 µl of Laemmli 
dissociating buffer for SDS-PAGE and Western blot analysis.  
2.5. DNA manipulation 
2.5.1. Cloning 
2.5.1.1. PCR-mediated amplification of mt-aaRS 
sequences 
2.5.1.1.1. Gene amplification 
 
Forward primer was designed to anneal the 5’ extremity of mt-ArgRS sequence 
of the pBCJ-mt-ArgRS-full_length-Flag-HisTag and to add the NdeI unique restriction 
site. Reverse primer was designed to anneal the 3’ of the same sequence and to 
introduce NotI unique restriction site. PCR reaction components and program are 
indicated in section 1.6, I. PCR products were separated on 1% agarose gel 
supplemented with 1/15 000 (v/v) GelRedTMdye (1 hour at 100 V). Corresponding 
bands were cut out and the DNA was recovered from the gel using the NucleoSpin Gel 
purification kit (Machinary and Nagel) following the manufacturer's instructions and 
DNA concentration was determined using NanoDropTM spectrophotometer. 
 
Component Volume 
DNA 50 ng/µl 1 µl 
dNTP (5mM) 4 µl 
Forward primer (10mM)  2 µl 
Reverse primer (10mM) 2 µl 
Taq buffer (10x)  5 µl 
Taq Polymerase 0.5 µl 
H2O  35.5 µl 
 
Table 7. PCR reaction components and program 
 
 
 
 
 
 
Denaturation 95°C 2 min 
Denaturation 95°C 1 min 
30 cycles Annealing Tm -2°C  1min 
Extension 72°C 2 min 30 sec 
Final extension 72°C 10 min 
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2.5.1.1.2. Enzymatic digestion 
Five µl of PCR product (insert) and ~100 ng of pCI mammalian vector were 
separately double digested with 1 µl XhoI, 1 µl NotI, 2 µl of Buffer CutSmart 10x and 
H2O MilliQ to reach a final volume of 20 µl of reaction. The reaction was performed 
during 3 hours at 37°C, afterwards insert and vector were separated on agarose gel 1% 
(1 hour at 100 V), then purified using NucleoSpinTM gel extraction kit and their 
concentrations were determined using NanoDropTM spectrophotometer. 
2.5.1.1.3. pCI mammalian vector 
dephosphorylation 
50 ng of the vector were supplemented with 1.2 µl of Buffer CutSmart 10x and 
1 µl of FastAP (Alkaline Phosphatase) and incubated 10 minutes at 37°C for 
dephosphorylation, then 5 minutes at 75°C to inactivate the enzyme. 
2.5.1.1.4. Ligation of the insert in pCI 
mammalian vector 
Insert (10µl) was ligated into dephosphorylated vector (12 µl) in the presence of 
1 µl of T4 DNA ligase and its appropriate buffer, in a final volume of 40 µl. The 
reaction was performed at 16°C overnight. Ligation product was directly used for 
bacterial transformation. 
2.5.2. Directed mutagenesis 
Substitution of nucleotides was performed according to PCH6-related mutations 
reported in patients (p.I9V, p.Q12R, p.W241R, p.R245Q, p.R258H, p.L283Q, 
p.R333G, p.M342V, p.M404K, p.R469H, p.G478R, p.H530Y). Self-complementary 
primers are listed in section 1.6, II. PCR reaction components and program are 
indicating in table 8. 
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Table 8. Components of PCR mutagenesis reaction and program 
 
After the PCR reaction, 1 µl of DpN1 (digesting exclusively methylated DNA, 
which corresponds to the template DNA, not mutated) was added to the reaction 
mixture (overnight at room temperature). The PCR product was directly used for 
bacterial transformation. 
This same protocol was used to introduce PCH6-related mutations (p.F131C, 
p.R245Q, p.L283Q, p.R469H and p.H530Y) in the 
pDEST_N-ter_L72_RARS2_HisTag construction. The primers used for mutagenesis 
are listed in section 1.6, IV. 
2.6. Bacterial transformation 
Chemically competent One Shot® TOP 10 cells were transformed with either 
5 µl of ligation mixture or with the mutagenesis PCR product following the given 
protocol: 
• Thaw on ice a vial of competent cells One Shot® TOP 10 (50 µl) 
• Add DNA to cells and incubate 30 minutes on ice 
• Incubate cells 30 seconds at 42°C and then 2 minutes on ice 
• Add to the vial 250 µl of prewarmed SOC (Super Optimal Catobolite) medium 
and incubate 1 hour at 37°C, shaking at 350 rpm 
• Spread 80 and 160 µl of the vial content on 2 different LB-agar plates 
(supplemented with 100 µg/ml of ampicillin) 
• Invert and incubate the plates overnight at 37°C 
 
Colonies were picked and amplified in 5 ml of LB medium containing 100 µg/ml 
of ampicillin. After overnight incubation cells were centrifuged and the plasmid DNA 
was extracted using a MiniPrep kit (Macherey-Nagel). The concentration of DNA was 
Component Volume 
DNA 50 ng/µl 1 µl 
dNTP (5mM) 4 µl 
Forward primer (10mM)  2 µl 
Reverse primer (10mM) 2 µl 
Buffer HF 5x  10 µl 
Phusion 0.5 µl 
H2O  30.5 µl 
Denaturation 95°C 2 min 
Denaturation 95°C 1 min 
30 cycles Annealing Tm -2°C  1min 
Extension 72°C 2 min 30 sec 
Final extension 72°C 10 min 
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determined using NanodropTM spectrophotometer. Plasmids were then sequenced by 
GATC Biotect Company. 
2.7. Plasmid amplification and purification 
Bacterial strain containing the desired vector is grown in 250 ml of LB medium 
containing 100 µg/ml of ampicillin overnight at 37°C. Then, the plasmid DNA was 
purified using a MaxiPrep kit (Macherey-Nagel) following the manufacturer's 
instructions. The DNA was resuspended in H2O milliQ and the concentration was 
determined using NanoDropTM spectrophotometer. 
2.8. Preparation of plasmids for the expression of 
N-terminal variants of the recombinant WT mt-ArgRS 
in bacterial strain 
Agnès Gaudry previously cloned in the pDEST14 vector the RARS2 gene, with 
a sequence optimized for the bacterial expression. In this construction the sequence 
starts at the codon coding for the Leucine 17 in the putative MTS of the mt-ArgRS and 
is followed by the sequence coding for the (His)6-Tag at the C-Terminus. Thus, the 
resulting plasmid is pDEST_N-ter_L17_RARS2_HisTag. 
2.8.1.1. Design of the primers. 
Forward primers were designed to anneal the 5’ extremity of the mt-ArgRS 
sequence of the pDEST_N-ter_L17_RARS2_HisTag, to add the NdeI unique 
restriction site followed by the corresponding sequence coding for the respective 
different N-termini (starting at N18, S27, L72, or I127). Reverse primer (common for 
all constructions) was designed to anneal the 3’ of the same sequence and to introduce 
XhoI unique restriction site. Primers are indicated in section 1.6, III. Then, a PCR was 
performed (same protocol 3.1.1.) to introduce the different inserts (corresponding to the 
different N-termini) in the pDEST vector. 
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2.8.1.2. Expression of recombinant mt-ArgRS in E. 
coli 
The plasmid pDEST_N-ter_L72_RARS2_Histag expressing the mt-ArgRS 
starting at residue L72 and the mutants was expressed in BL21 DE3 bacterial strain as 
follows. 
Preculture: BL21 DE3 cells containing the pDEST_N-ter_L72_RARS2_Histag 
were grown in 50 ml LB containing 50 µl of ampicillin (at 100 mg/ml) overnight at 
37°C. 
Main culture: After dilution to 1:10 with 1000 mL of fresh LB medium containing 
20 g of glucose and 1 ml of ampicillin 100 mg/ml in three separate flask of 5L (1L per 
flask), cells were grown at 37°C for 2.5 hours until an OD 600 of 0.7 was reached. Cells 
were then centrifuged at 4200 g for 20 minutes (4°C) to removed the glucose and the 
medium was replaced by fresh LB medium containing 100 µg/mL ampicillin and 10 
µM/L IPTG, and cells incubation continued 4 hours at 37 °C. The cells were harvested 
by centrifugation at 4200 g for 20 min (4°C). Bacterial pellets were stored at -20°C. 
2.9. Purification of mt-ArgRS 
2.9.1. Affinity chromatography 
BL21-DE3_pDEST_N-ter_L72_RARS2_Histag cell pellets were resuspended in 
20 ml of buffer Ni-A (50 mM NaH2PO4/Na2HPO4 pH 7.5, 150 mM NaCl, 10 mM 
β-Mercaptoethanol and 10% Glycerol) containing a protease inhibitor cocktail before 
sonication on ice at 120 V for 40 seconds, 7 times. Lysed cells were then subjected to 
centrifugation at 30 000 g for 20 minutes (4°C). The supernatant was then 
ultracentrifuged at 45 000 g for 40 minutes (4°C) before loading onto a 5 ml column 
HIS-Select® HF Nickel Affinity Gel (Sigma-Aldrich). The column was equilibrated in 
buffer Ni-A (1 ml/min, the maximal pressure was always maintained at < 100 psi). 
Then, the sample (usually ~25 ml) were loaded onto the column and the affinity 
chromatography was performed as follows: I. Isocratic flow: 25 ml volume, 1 ml/min, 
(sample load; collect in 5 ml-fractions), II. Isocratic flow: 50 ml, 2 ml/min, buffer Ni-
A (correspond to washing step of the column, until the DO becomes stable to zero 
again; collect in 5 ml-fractions), III. Linear gradient: 30 ml, 2 ml/min, buffer Ni-A to 
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Ni-B (buffer Ni-A containing 500 mM imidazole) (corresponding to the elution; collect 
in 1 ml-fractions) and IV. Isocratic flow: 10 ml, 2 ml/min, buffer Ni-B. 
 
2.9.1.1. Dialysis and concentration 
The enzyme-containing fractions, detected by the OD280 profile and a SDS-PAGE 
analysis, were pooled and dialyzed for 2 hours against 1 L of buffer dialysis 1 (50 mM 
Hepes NaOH pH 7.5, 150 mM NaCl, 1 mM EDTA, 10 mM β-Mercaptoethanol and 
10 % Glycerol). The buffer was change by fresh buffer dialysis 1 and dialysis continued 
overnight at 4°C. In a final dialysis step, the buffer was replaced by 1 L buffer dialysis 
2 (50 mM Hepes NaOH pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 1 mM DΤΤ, 10 % 
Glycerol) and the protein was dialyzed for additional 2 hours. 
The protein solution was concentrated by means of centrifugation using 
Amicon® Ultra – 0.5 ml, exclusion size 10 kDa at 5000 g. Protein concentration was 
determined using NanoDropTM spectrophotometer considering the theoretical 
extinction coefficient of mt-ArgRS (ε= 59120 M−1cm−1). 
2.10. Aminoacylation assay 
In vitro arginylation was performed in 50 mM HEPES-KOH pH 7.5, 30 mM KCl, 
8 mM MgCl2, 8 mM ATP, 0.2 mg/ml BSA, 1 mM spermine, 25 µM of isotopic mixture 
with Arginine L-[2,3,4-3H] (40 Ci/mM), different concentrations of total tRNA 
(routinely 40 pmoles, but this concentration changed depending of each experiment) 
from E. Coli (purified from bacterial cultures in the laboratory by A. Gaudry), and 
different concentrations of enzyme (50 nM, 100 nM, 200 nM, 250 nM, 400 nM, 
800 nM and/or 1500 nM). The aminoacylation reaction mixture was equilibrated to 
37°C before the addition of the enzyme to a final volume of 50 µl. At different times, 
10 µl aliquots were spotted onto Whatman 3MM filter-papers previously equilibrated 
with 5% trichloroacetic acid (TCA) (v/v). The papers were immediately placed in cold 
5% TCA to precipitate tRNA and terminate the reaction. Then the papers were washed 
three times (10 minutes) with 5% TCA and one time with ethanol before be dried under 
a heat lamp. The dried papers were placed in counting vessels and incorporation of 
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radioactive arginine was measured by liquid scintillation (Ecoscint 0TM, National 
diagnosis) counting using a scintillizer (LS6500, Beckmann Coulter). 
 
 
2.11. Proteins preparation and analysis 
2.11.1. Protein separation in SDS-polyacrylamide 
gel electrophoresis 
The separation of proteins, depending on their size was performed on SDS-
polyacrylamide gels (SDS-PAGE). The gels contained a 10% resolving gel solution 
(pH 8.8) and a 4% stacking gel solution (pH 6.8). Protein samples were supplemented 
with Laemmli dissociating buffer and heated at 95°C for 10 minutes. Samples were 
briefly centrifuged before loaded onto the gel. Electrophoresis was performed with 1x 
TGS running buffer (25 mM Tris, 192 mM glycine and 0.1% SDS) at 100V and 180V 
for the staking and resolving gel, respectively. To visualize the protein bands, the gel 
was stained SDS-staining solution for at least 30 minutes, and then washed with 
distaining buffer (25% Ethanol and 10% Acetic Acid) 
2.11.2. Western blot analysis 
After separation on SDS-PAGE gel, proteins were blotted on a PVDF membrane 
using the Trans-blot Turbo Transfer System from BioRad following the manufacturer’s 
instructions. For immuno-detection, the PVDF membrane was blocked with 5% milk 
in 1x TBST for 1 hour. Incubation with the primary antibodies were done in the adapted 
dilution of each antibody with 1% milk in 1x TBST (Table 6.) overnight at 4°C. After 
incubation, the membrane was washed three times with 1x TBST (50 mM Tris, 150 
mM NaCl and 0.1% Tween). If required, incubation with secondary antibody was done 
for 1 hour at room temperature. The membrane was again washed three times with 1x 
TBST, and dried on Whatman paper. Chemio-luminescent detection was carried out 
using the Pierce Detection Kit low and high sensitivity (ECL Western blotting 
Substrate, and SuperSignal West Femto Maximum Sensitivity Substrate, respectively) 
according to manufacturer’s instructions, mixed at a 1:1 ratio and added to the 
membrane. After 1 to 2 minutes, PVDF membrane was dried and exposed to 
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radiographic film (Fuji Medical X-ray Film, Fujifilm). Autoradiographies were scanned 
using Epson Perfection 3490 Photo and the relative amount of proteins was estimated 
from band intensities using ImageJ software. 
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Introduction 
Les mitochondries jouent un rôle primordial dans la respiration et le métabolisme 
énergétique cellulaires (voir figure annexe), et les dysfonctionnements mitochondriaux 
sont souvent associés à diverses pathologies. La mitochondrie possède sa propre 
machinerie de transcription/traduction. Le génome mitochondrial (mt) code chez 
l’homme pour 13 protéines de la chaine respiratoire, 22 ARNt et 2 ARNr. Le reste des 
protéines, codé par le génome nucléaire, est importé après traduction dans le cytosol. 
Parmi les protéines importées figurent les aminoacyl-ARNt synthétases (aaRS), 
enzymes clés de la traduction mitochondriale, responsables de l’attachement spécifique 
de chaque acide aminé à son ARNt correspondant. Elles sont adressées à la mitochondrie 
grâce à la présence d'une séquence N-terminale (MTS pour "mitochondrial targeting 
sequence"), clivée après importation.  
En 2007, le laboratoire d’accueil a contribué à la première description corrélant 
des mutations dans le gène DARS2 (codant pour l’AspRS mt) à une 
leucoencéphalopathie (LBSL pour « Leukoencephalopathy with brainstem and spinal 
cord involvement with lactate elevation »). Les caractérisations fonctionnelle et 
structurale, ainsi que des études en vue de comprendre le lien entre les mutations et les 
phénotypes observés dans la maladie LBSL ont été faites en partie au laboratoire. 
Aujourd’hui, toutes les aaRS mt sont impliquées dans des maladies aux conséquences 
souvent sévères. Des mutations dans le gène RARS2, qui code pour l’ArgRS mt, sont 
corrélées à une maladie neurodéveloppementale sévère, PCH6 (pour "Pontocerebellar 
Hypoplasia type 6"). L’implication de ces deux protéines dans la traduction 
mitochondriale pourrait conduire à l’idée que une fois mutées, leurs dysfonctionnements 
produisent des conséquences similaires. Or ce n’est pas le cas et les présentations 
cliniques des maladies PCH6 et LBSL diffèrent phénotypiquement. 
 Le travail de cette thèse s’articule autour de 3 axes : (I) L’analyse des phénotypes 
cliniques des pathologies liées aux mutations dans les aaRS mt, (II) La caractérisation 
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des propriétés cellulaires de l’ArgRS mt, et (III) L'étude de l’impact de mutations 
« pathologiques » sur diverses propriétés de l’ArgRS mt.  
 
 
 
 
Figure annexe. Résumé graphique des différentes fonctions de la mitochondrie.  
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Résultats et discussion 
(I) Analyse des phénotypes cliniques des pathologies liées aux mutations 
dans les aaRS mt 
La diversité des présentations cliniques des pathologies liées aux aaRS mt mutées 
(décrites au cours des 10 dernières années) fait appel à la nécessite d’une analyse pour 
organiser ces maladies prenant en compte leurs phénotypes de présentation, les organes 
et/ou systèmes anatomiques affectés, l’âge de début des maladies ainsi que leurs 
sévérités cliniques. Les pathologies liées aux mutations dans les aaRS mt montrent une 
convergence d’affectation vers le système nerveux central (SNC) dans 80% des cas, avec 
cependant un nombre non négligeable d'exceptions. Ainsi, nous pouvons distinguer les 
aaRS mt qui conduisent i) à des affections uniquement du SNC, ii) à des affections du 
SNC et d'un autre organe, généralement le système reproductif, chez un même patient 
(e.g. mt-HisRS, mt-LeuRS et mt-AlaRS), iii) à des affections du SNC ou d'un autre 
organe chez des patients distincts (e.g. mt-AlaRS et mt-SerRS), et enfin iv) à des 
affections de seulement un autre système anatomique (e.g. mt-TyRS). La question 
soulevée est de savoir si ces différents sous-groupes d'aaRS mt ont des propriétés 
cellulaires distinctes, ou si les descriptions futures de nouveaux patients modifieront 
totalement cette catégorisation. En outre, il est observé à l'intérieur même d'une de ces 
catégories des différentes significatives en termes d'expressions phénotypiques et de 
sévérité de la maladie : pour exemple, les mutations de l'AspRS mt et de l'ArgRS mt 
conduisent toutes les deux à des affections du SNC seulement : LBSL et PCH6, 
respectivement. La première est une maladie neurodégénérative, la seconde est une 
maladie du neurodévelopement. Là encore, des différences de propriétés cellulaires des 
deux enzymes sont attendues. Cette analyse est publiée dans deux articles de revues. 
 
(II) Caractérisation de propriétés cellulaires de l’ArgRS mt 
Des travaux antérieurs du laboratoire ont permis de dévoiler des caractéristiques 
cellulaires spécifiques de l’AspRS mt humaine, tels que : la coexistence de deux formes 
de l’enzyme à l’intérieur de la mitochondrie, produits par coupures alternatives du MTS 
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après importation; l’établissement de la double localisation de l’AspRS mt, présente à la 
fois dans la fraction membranaire et dans la fraction soluble, et que son ancrage à la 
membrane se fait via des interactions électrostatiques ; la mise en évidence que l’AspRS 
mt sort de la mitochondrie dans certains conditions de stress mitochondrial (ajout de 
10 mM ATP). J'ai étendue cette étude à l'ArgRS mt et démontré qu'elle possède des 
propriétés cellulaires totalement distinctes. 
Le processus de maturation et de clivage des séquences MTS est mal défini, et 
pourtant essentiel à l'acheminement précis et à la fonctionnalité des protéines 
mitochondriales. Par ailleurs, il est indispensable de connaître le site de coupure du MTS 
pour le design d'une protéine recombinante et son expression en système bactérien pour 
des études in vitro. Nous avons appliqué, en collaboration, la technique de spectrométrie 
de masse ("Doublet N-terminal Oriented Proteomics") utilisée pour définir le MTS de 
l'AspRS mt, et identifié différents sites possibles de coupure du MTS de l’ArgRS mt: 
N18, S27, L72, I127. Les quatre protéines recombinantes correspondantes ont été 
clonées, et leurs solubilités et stabilités analysées. La forme L72_ArgRS est la 
construction la plus soluble de l’enzyme et fût choisie pour la suite de expériences 
fonctionnelles in vitro (voir partie III). 
Concernant la localisation intra-mitochondriale, j'ai démontré que l'ArgRS mt est 
localisée exclusivement dans la fraction membranaire, alors que aucun domaine 
transmembranaire ne lui est prédit. Grâce à l'ajout d'agents chimiques connus pour 
rompre les différents types de liaisons d'une protéine à la membrane, j’ai démontré que 
l’ArgRS mt n'est sensible qu'à des concentrations élevées d'urée, indiquant que la liaison 
à la membrane mitochondriale se fait via des interactions hydrophobiques. Cette 
localisation a été confirmée dans diverses lignées cellulaires issues de différents tissus 
humains. Par ailleurs, j'ai montré que l'ArgRS mt ne sort pas de la mitochondrie en 
condition de stress. Une partie de ces travaux a fait l'objet d'une publication, dont je suis 
co-premier auteur. 
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(III) Etude de l’impact de mutations « pathologiques » sur les propriétés 
de l’ArgRS mt. 
Afin d’évaluer l’impact de mutations sur la localisation exclusivement 
membranaire de l’ArgRS mt, un système d’expression reposant sur la transfection de 
cellules HEK293T avec différentes constructions plasmidiques (contenant soit la 
séquence sauvage soit les séquences contenant les mutations corrélées à PCH6) a été 
utilisé. La première étape a été de valider ce système et de démontrer que l'adressage, 
l'internalisation, et la localisation membranaire de la forme recombinante contenant une 
étiquette poly-histidine de l'ArgRS mt se font correctement, de façon identique à 
l’ArgRS mt endogène. 
Ce système d’expression a permis d’analyser individuellement l’impact de 12 
mutations "pathologiques" sur la localisation de l’ArgRS mt in cellulo. Aucune des 
mutations n'affecte la localisation membranaire de l’ArgRS mt. En parallèle, des 
fibroblastes (hétérozygotes composites) issus d'un patient atteint de PCH6 ont été 
cultivés. Là encore, aucune délocalisation de l'ArgRS mt n'est observée. 
En parallèle, j'ai étudié l'impact de 6 des mutations liées à PCH6 sur la propriété 
d'aminoacylation de l'ArgRS mt in vitro. Pour ce faire, j'ai introduit chacune des 
mutations dans l'enzyme recombinante identifiée soluble (L72_ArgRS) après expression 
en système bactérien (voir ci-dessus). Les protéines sauvage et mutantes ont été 
produites dans E. coli et purifiées par chromatographie d'affinité. Les activités 
enzymatiques des mutants ont été établies, comparées à celle de l'enzyme sauvage. 
Aucun impact significatif n'est observé en dépit du fait que pour cette enzyme, les 
mutations touchent des positions très conservées, et de la gravité de la maladie. Ces deux 
observations étaient en faveur d'un impact fort sur la fonction canonique de l’ArgRS mt, 
or ce n'est pas le cas. Cette découverte soutien la possibilité d’une implication de 
l’ArgRS mt dans une fonction alternative, ce qui pourrait expliquer la tissue spécificité 
du phénotype clinique. 
 
Conclusions et perspectives 
Ce travail de thèse est une contribution importante dans la compréhension de 
propriétés fondamentales des aaRS mt humaines et des pathologies liées. Les 
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observations et résultats obtenus ouvrent de nombreuses perspectives. Celles initiées par 
moi et poursuivies au laboratoire sont indiquées ci-dessous. 
L’analyse de phénotypes cliniques des patients permet une vision plus globale des 
pathologies liées aux aaRS mt, d'identifier des groupes d'aaRS mt qui ont des 
présentations cliniques similaires, et de ce fait, de proposer des hypothèses de travail. 
Par exemple, des mutations dans trois synthétases (mt-AspRS, mt-GluRS et AspRS 
cytosolique) conduisent à une leucodystrophie. Ces trois enzymes ont en commun 
l'aspartate et le glutamate, précurseurs indispensable au N-acetyl L-Aspartate Glutamate 
(NAAG), neurotransmetteur du système nerveux central. Une hypothèse en cours 
d'étude au laboratoire est de rechercher un lien possible entre l’AspRS mt et l'Asp-NAT 
(L-aspartate N-acetyltransferase). Cette enzyme est ancrée à la membrane 
mitochondriale interne, est spécifique du L-aspartate, est présente seulement dans le 
système nerveux central, et catalyse la synthèse de NAA (précurseur du NAAG). Or, le 
taux de NAA est significativement diminué chez les patients atteints de LBSL. Une 
seconde perspective en cours d'étude au laboratoire est la recherche de partenaire(s) 
d'aaRS mt qui soient neurone-spécifique(s). Pour ce faire, des expériences de "cross-
link", initialement effectuées sur cellules HEK 293T ou HELA, sont poursuivies sur des 
cellules neuronales, telles les neuroblastomes SH-SY5Y non différentiées et 
différentiées.  
Concernant l'établissement de propriétés cellulaires des aaRS mt humaines: alors 
que l'AspRS mt avait été identifiée doublement localisée dans la mitochondrie, j'ai 
démontré que l'ArgRS se retrouve uniquement au niveau des membranes et son ancrage 
se fait par des interactions de type hydrophobique. L'observation de localisations 
distinctes pour deux enzymes supposément impliquées dans le même processus 
cellulaire de traduction soulève immédiatement la possibilité que ces enzymes aient des 
propriétés cellulaires distinctes. L'analyse est actuellement étendue à d'autres aaRS mt 
au laboratoire, et il est montré qu'une troisième enzyme, la LysRS, est quant à elle 
présente dans la fraction soluble, uniquement. Ainsi, il sera important de définir la 
localisation à l'intérieur de la mitochondrie pour l'ensemble des aaRS mt, de vérifier les 
profils obtenus dans différents types cellulaires mais aussi dans des conditions 
physiologiques, ou pathophysiologiques distinctes. Il sera intéressant de voir si la 
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catégorisation établie corrèle avec celle des présentations cliniques observées. A plus 
long terme, il sera important de comprendre la raison biologique des différences 
observées: manière de moduler l'activité canonique d'aminoacylation? Révélateur de 
fonction(s) alternative(s), éventuellement tissue-spécifique? Lien avec les différentes 
formes observées en particulier pour l'AspRS mt après l'étape de maturation in 
organello? L'ensemble de ces caractérisations futures permettra de mieux définir les 
propriétés fondamentales des aaRS mt, mais aussi de mieux comprendre comment la 
traduction mitochondriale est intégrée dans l'environnement cellulaire et quelles sont les 
modulations et/ou spécificités tissues-spécifiques. 
L'identification des raisons moléculaires sous-jacentes aux pathologies liées aux 
mutations d'aaRS mt reste un défi important. Toutes les analyses effectuées 
précédemment au laboratoire sur l'impact possible des mutations liées à LBSL n'ont pas 
permis de mettre en évidence d'impact majeur sur les propriétés canoniques de l'AspRS. 
J'ai démontré, par mes travaux, que les mutations liées à PCH6 n'ont pas non plus 
d'impact sur la localisation ou la propriété d'aminoacylation de l'ArgRS mt, alors qu'un 
impact fort était anticipé. Nous avons imaginé comme perspective de ce travail, de 
démontrer l'existence de fonction non canonique, neuronale spécifique de l'AspRS mt 
(dans un premier temps). Pour ce faire, des lignées cellulaires neuronales, dont les 
mutations liées à LBSL sont individuellement introduites par la technique de CrispR-
Cas9 sont en cours de préparation au laboratoire (en collaboration). La démonstration 
d'un effet sévère sur les lignées neuronales et modérée sur des lignées non-neuronales 
sera un argument fort en faveur d'une fonction neurone-spécifique de l'AspRS mt, qui 
sera ensuite recherchée.    
Mon travail de thèse est un apport à l'établissement des propriétés cellulaires des 
aaRS mt humaines et ouvre à de nouvelles voies d’investigation. La compréhension des 
mécanismes moléculaires sous-jacents aux pathologies liées aux mutations dans les 
aaRS mt ainsi que la tissue-spécificité, en particulier neuronale, des maladies liées ne 
sera probablement possible que après une meilleure compréhension de comment la 
traduction mitochondriale est intégrée/modulée dans un contexte cellulaire. 
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Résumé 
Les aminoacyl-ARNt synthétases mitochondriales humaines (aaRS mt) sont des enzymes clés de la traduction 
mitochondriale. Elles catalysent l'aminoacylation des ARNt par les acides aminés correspondent. Des mutations dans leurs 
gènes sont corrélées à des pathologies avec un large spectre de phénotypes cliniques, mais aux mécanismes moléculaires 
sous-jacents encore incompris. L'objectif de ce travail de thèse s'intègre dans les axes scientifiques du laboratoire, mais 
élargit l'intérêt et les connaissance à un système encore peu exploré: l'arginyl-ARNt synthétase mitochondriale (ArgRS 
mt). Des mutations dans la ArgRS sont liées à une hypoplasie Pontocérébelleuse (PCH6), une pathologie 
neurodéveloppementale sévère. Le travail de cette thèse s’articule autour de 3 axes : (I) L’analyse des phénotypes 
cliniques des pathologies liées aux mutations dans les aaRS mt, (II) La caractérisation des propriétés cellulaires de 
l’ArgRS mt, et (III) L'étude de l’impact de mutations « pathologiques » sur diverses propriétés de l’ArgRS mt. Combinés 
avec les travaux précédents, les résultats obtenus sont une contribution importante à l'élargissement des connaissances 
fondamentales des mt aaRSs, et apportent un nouvel éclairage sur le lien entre les mt-aaRSs-mutations et la maladie. 
Mots clés: traduction mitochondriale, mitochondrial aminoacyl-ARNt synthétase, aminoacylation, organisation sous 
mitochondriale, pathologies liées aux mutations. 
 
Abstract 
Human mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs) are housekeeping enzymes involved in the mitochondrial 
translation. They catalyze the aminoacylation of tRNAs with their cognate amino acids. Mutations in their nuclear genes 
are correlated with pathologies with a broad spectrum of clinical phenotypes, but with so far no clear explanations about 
the underlying molecular mechanism(s). The aim of this PhD work follows the long-standing efforts of the host laboratory 
but expand the interest and knowledge to an unexplored system: the human mitochondrial arginyl-tRNA synthetase 
(mt-ArgRS). Mutations in the mt-ArgRS lead to Pontocebellar hypoplasia type 6, a severe neuro-developmental pathology. 
I thus contributed to i) comprehensively analyze the clinical data reported in pathologies related to mutations on mt-aaRSs, 
resulting in a categorization according to the affected anatomical system; ii) decipher some cellular properties of the mt-
ArgRS; and iii) investigate to impact of disease-associated mutations on mt-aaRSs properties. Combined with previous 
works, the present results expand the knowledge of the mt-aaRSs, shedding new light on the link between mt-aaRSs-
mutations and disease. 
Keywords: mitochondrial translation, mt-aaRSs, aminoacylation, sub-mitochondrial localization, pathology-related 
mutations. 
 
